<SEC-DOCUMENT>0000950170-22-017517.txt : 20220816
<SEC-HEADER>0000950170-22-017517.hdr.sgml : 20220816
<ACCEPTANCE-DATETIME>20220816171806
ACCESSION NUMBER:		0000950170-22-017517
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		20
CONFORMED PERIOD OF REPORT:	20220811
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220816
DATE AS OF CHANGE:		20220816

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Terns Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001831363
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39926
		FILM NUMBER:		221171110

	BUSINESS ADDRESS:	
		STREET 1:		1065 EAST HILLSDALE BLVD., SUITE 100
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		650-525-5535 EXT.101

	MAIL ADDRESS:	
		STREET 1:		1065 EAST HILLSDALE BLVD., SUITE 100
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tern-20220811.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2022-08-16T13:14:41.8837+00:00 --><!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:tern="http://www.ternspharma.com/20220811">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_4f161d9e-09a7-4a9c-a234-ce2bf546dbf5" name="dei:EntityCentralIndexKey" contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3">0001831363</ix:nonNumeric><ix:nonNumeric id="F_dcb8bccf-5cea-421b-8344-042291526633" name="dei:AmendmentFlag" contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="tern-20220811.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_68019b1d-3c51-449a-83c6-7131b22f32f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-11</xbrli:startDate><xbrli:endDate>2022-08-11</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <p style="border-top:2.250pt double rgba(0,0,0,1);text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.75pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.2pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4becf423-9090-422a-89a9-f92b4790c9cd" contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.2pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.02986111111111111in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d4e5e682-e254-4061-afae-eab8da2cb54d" contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">August 11, 2022</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:24.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c7320e8d-b88e-49bb-a95f-effbe0d32faf" contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:24.0pt;font-family:Times New Roman;min-width:fit-content;">Terns Pharmaceuticals, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:19.571%;"></td>
    <td style="width:2.94%;"></td>
    <td style="width:19.571%;"></td>
    <td style="width:17.744%;"></td>
    <td style="width:40.173%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_54d5b0d3-97f4-457c-a068-2063e81d9b8e" contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4d5befba-3aaf-4ad3-bb5b-1a3342be99d4" contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">001-39926</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_86db0caa-1aae-4b08-8ded-a3a2e898e683" contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">98-1448275</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(State or Other Jurisdiction<br />of Incorporation)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(IRS Employer<br />Identification No.)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0f0c0007-8b5f-477f-bdd9-72bed300e3d7" contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1065 East Hillsdale Blvd.</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_178c5f46-17e9-486a-bf15-9f4625c6c27c" contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Suite 100</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9876f716-0443-4f98-8f4f-42f5683d7bd6" contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Foster City</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e18e396f-9cff-42f2-a123-8e1e0b09b5d5" contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d773e056-3f29-4b13-8723-c68d5eaf58e6" contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">94404</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.125in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.02986111111111111in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#x2019;s Telephone Number, Including Area Code: (</span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_62bc6b0e-9291-4b94-b52a-05d1a65d74f9" contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">650</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_091cf60c-23ab-4f59-8d18-ee8f93bd0b57" contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">525-5535</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.125in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fc378f46-343e-4361-9ad1-6e9bf8bd4847" contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3" name="dei:EntityInformationFormerLegalOrRegisteredName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">N/A</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:9.35pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.35pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9.0pt;line-height:1.15;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_70f47f6a-c773-4584-a883-a4ba0d0b1bfc" contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;line-height:1.15;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_924c73a6-dac1-487b-aaac-7da200c55289" contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;line-height:1.15;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e70910f9-fb7f-4804-a4a0-e7d56e42a14b" contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;line-height:1.15;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8bb03b9c-36bb-445a-bfe4-4784c9c75648" contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:37.996%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.250pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><br />Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.250pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Trading<br />Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.250pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><br />Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b58799d0-0471-4eb4-9655-eabaec2cf76d" contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1fae9fe8-57a4-47da-a761-832e58b20c71" contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">TERN</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_48f0c865-d1b4-48db-bfbc-ab09246856c7" contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">NASDAQ Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#x202f;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#x202f;240.12b-2 of this chapter).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:10.0pt;"><ix:nonNumeric id="F_899031a1-41e9-472d-9231-ca568cfbec3e" contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10.0pt;"><ix:nonNumeric id="F_551e8403-0b87-495d-bf96-eb53c65ee6c3" contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 8.01      Other Events.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On August 11, 2022, Terns Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) entered into an underwriting agreement (the &#x201c;Underwriting Agreement&#x201d;) with Cowen and Company, LLC, as representative of the several underwriters named in Schedule 1 thereto (collectively, the &#x201c;Underwriters&#x201d;), relating to an underwritten offering (the &#x201c;Offering&#x201d;) of 12,250,000 shares (the &#x201c;Shares&#x201d;) of the Company&#x2019;s common stock, $0.0001 par value per share (the &#x201c;Common Stock&#x201d;), and, in lieu of Common Stock to certain investors, pre-funded warrants (the &#x201c;Pre-Funded Warrants&#x201d;) to purchase 14,630,000 shares of Common Stock (the &#x201c;Warrant Shares&#x201d;). The closing of the Offering took place on August 16, 2022. All of the Shares and Pre-Funded Warrants were sold by the Company. The offering price of the Shares to the public is $2.42 per share, and the offering price of the Pre-Funded Warrants to the public is $2.4199 per share underlying each Pre-Funded Warrant. The Underwriters purchased the Shares from the Company pursuant to the Underwriting Agreement at a price of $2.2748 per share and the Pre-Funded Warrants from the Company pursuant to the Underwriting Agreement at a price of $2.2747 per share underlying each Pre-Funded Warrant. The Offering was made in accordance with applicable Nasdaq rules and priced above the &#x201c;Minimum Price&#x201d; (as defined in the Nasdaq rules).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Each Pre-Funded Warrant has an exercise price per share of Common Stock equal to $0.0001 per share. The exercise price and the number of shares of Common Stock issuable upon exercise of each Pre-Funded Warrant is subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock. Each Pre-Funded Warrant is exercisable from the date of issuance by means of a cashless exercise. Under the Pre-Funded Warrants, the Company may not effect the exercise of any Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any Pre-Funded Warrant that, upon giving effect to such exercise, would cause: (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) to exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to the exercise; or (ii) the combined voting power of the Company&#x2019;s securities beneficially owned by such holder (together with its affiliates) to exceed 4.99% of the combined voting power of all of the Company&#x2019;s securities outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrant, which percentage may be changed at the holder&#x2019;s election to a higher or lower percentage not in excess of 19.99% upon 61 days&#x2019; notice to the Company.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, in certain circumstances, upon a fundamental transaction, a holder of Pre-Funded Warrants will be entitled to receive, upon exercise of the Pre-Funded Warrants, the kind and amount of securities, cash or other property that such holder would have received had they exercised the Pre-Funded Warrants immediately prior to the fundamental transaction; provided, however, that in the event of a fundamental transaction where the consideration consists solely of cash, solely of marketable securities or a combination thereof, each Pre-Funded Warrant will be deemed to be exercised in full in a cashless exercise effective immediately prior to and contingent upon the consummation of such fundamental transaction.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company estimates that the net proceeds from the Offering are approximately $60.7 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Shares and the Pre-Funded Warrants were issued pursuant to a shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March 8, 2022 and declared effective by the SEC on March 14, 2022 (File No. 333-263370). A prospectus supplement relating to the offering has been filed with the SEC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Underwriting Agreement contains customary representations, warranties, covenants, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act, and other obligations of the parties. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties. The foregoing is only a brief description of the terms of the Underwriting Agreement, does not purport to be a complete statement of the rights and obligations of the parties under the Underwriting Agreement and the transactions contemplated thereby, and is qualified in its entirety by reference to the Underwriting Agreement, which is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The foregoing is only a brief description of the terms of the form of Pre-Funded Warrant, does not purport to be a complete statement of the rights and obligations of the parties thereto and the transactions contemplated thereby, and is qualified in its entirety by reference to the form of Pre-Funded Warrant, which is filed as Exhibit 4.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">A copy of the legal opinion of Latham &amp; Watkins LLP relating to the validity of the issuance and sale of the Shares and the Pre-Funded Warrants in the Offering is filed as Exhibit 5.1 to this Current Report on Form 8-K and is filed with reference to, and is hereby incorporated by reference into, the Registration Statement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 8.01      Other Events.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The full text of the press release announcing the pricing of the underwritten offering on August 12, 2022 is attached as Exhibit 99.1 hereto and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01      Financial Statements and Exhibits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(d) Exhibits</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.295%;"></td>
    <td style="width:1.044%;"></td>
    <td style="width:91.661%;"></td>
   </tr>
   <tr style="height:21.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit<br />No.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.000pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:21.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="tern-ex1_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Underwriting Agreement, dated August 11, 2022, between Terns Pharmaceuticals, Inc. and Cowen and Company, LLC, as representative of the several underwriters named therein.</span></a></p></td>
   </tr>
   <tr style="height:13.5pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="tern-ex4_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Form of Pre-Funded Warrant.</span></a></p></td>
   </tr>
   <tr style="height:13.5pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="tern-ex5_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Opinion of Latham &amp; Watkins LLP.</span></a></p></td>
   </tr>
   <tr style="height:11.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">23.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="tern-ex5_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Consent of Latham &amp; Watkins LLP (included in Exhibit 5.1).</span></a></p></td>
   </tr>
   <tr style="height:11.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">99.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="tern-ex99_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Press Release dated August 12, 2022.</span></a></p></td>
   </tr>
   <tr style="height:21.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cover Page Interactive Data File (embedded within the inline XBRL document).</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6.002%;"></td>
    <td style="width:43.998%;"></td>
    <td style="width:3.998%;"></td>
    <td style="width:46.002%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.05;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">TERNS PHARMACEUTICALS, INC.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Date:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">August 16, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">By:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.250pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">/s/ Bryan Yoon</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.7pt;line-height:1.05;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Bryan Yoon<br />Chief Operating Officer &amp; General Counsel</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tern-ex1_1.htm
<DESCRIPTION>EX-1.1
<TEXT>
<html>
 <head>
  <title>EX-1.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 1.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Execution Version</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"><br><br><br>Terns Pharmaceuticals, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">12,250,000 Shares of Common Stock, Par Value $0.0001</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Pre-Funded Warrants to Purchase 14,630,000 Shares of Common Stock</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Underwriting Agreement</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">August 11, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Cowen and Company, LLC</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"><br>As Representatives of the<br>several Underwriters listed<br>in Schedule 1 hereto</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">c/o Cowen and Company, LLC</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">599 Lexington Avenue</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">New York, NY 10022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Ladies and Gentlemen:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Terns Pharmaceuticals, Inc., a Delaware corporation (the &#x201c;Company&#x201d;), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the &#x201c;Underwriters&#x201d;), for whom you are acting as representatives (the &#x201c;Representatives&#x201d;), an aggregate of 12,250,000 shares of common stock, par value $0.0001 per share, of the Company (the &#x201c;Shares&#x201d;) and pre-funded warrants to purchase an aggregate of 14,630,000 shares of common stock of the Company, at an exercise price equal to $0.0001 per share, in the form attached hereto as Exhibit B (the &#x201c;Warrants&#x201d;). The Shares and Warrants are herein referred to as the &#x201c;Securities.&#x201d; The shares of common stock of the Company issuable upon exercise of the Warrants are herein referred to as the &#x201c;Warrant Shares.&#x201d; The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares and the exercise of the Warrants are referred to herein as the &#x201c;Stock&#x201d;.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">To the extent that there are no additional Underwriters listed on Schedule 1 hereto, all references to the Representatives and the Underwriters shall refer just to you, and the terms Representatives and Underwriters shall mean either the singular or plural as</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">the context requires. To the extent only one Representative is listed above, all references to term Representatives shall mean Representative in the singular form.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The Company hereby confirms its agreement with the several Underwriters concerning the purchase and sale of the Securities, as follows:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  The Company has prepared and filed with the Securities and Exchange Commission (the &#x201c;Commission&#x201d;) under the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#x201c;Securities Act&#x201d;), a registration statement on Form S-3 (File No. 333-263370), including a prospectus, relating to the Securities and the Warrant Shares.  Such registration statement, as amended at the time it became effective, including the information, if any, deemed pursuant to Rule 430A, 430B or 430C under the Securities Act to be part of the registration statement at the time of its effectiveness (&#x201c;Rule 430 Information&#x201d;), is referred to herein as the &#x201c;Registration Statement&#x201d;; and as used herein, the term &#x201c;Preliminary Prospectus&#x201d; means each prospectus included in such registration statement (and any amendments thereto) before effectiveness, any prospectus filed with the Commission pursuant to Rule 424(a) under the Securities Act and the prospectus included in the Registration Statement at the time of its effectiveness that omits Rule 430 Information (the &#x201c;Base Prospectus&#x201d;), and the term &#x201c;Prospectus&#x201d; means the Base Prospectus and prospectus supplement relating to the Securities and Warrant Shares in the form first used (or made available upon request of purchasers pursuant to Rule 173 under the Securities Act) in connection with confirmation of sales of the Securities.  If the Company has filed an abbreviated registration statement pursuant to Rule 462(b) under the Securities Act (the &#x201c;Rule 462 Registration Statement&#x201d;), then any reference herein to the term &#x201c;Registration Statement&#x201d; shall be deemed to include such Rule 462 Registration Statement. Any reference in this underwriting agreement (this &#x201c;Agreement&#x201d;) to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form S-3 under the Securities Act, as of the effective date of the Registration Statement or the date of such Preliminary Prospectus or the Prospectus, as the case may be, and any reference to &#x201c;amend&#x201d;, &#x201c;amendment&#x201d; or &#x201c;supplement&#x201d; with respect to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include any documents filed after such date under the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#x201c;Exchange Act&#x201d;) that are deemed to be incorporated by reference therein. Capitalized terms used but not defined herein shall have the meanings given to such terms in the Registration Statement and the Prospectus.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">At or prior to the Applicable Time (as defined below), the Company had prepared the following information (collectively with the pricing information set forth on Annex A, the &#x201c;Pricing Disclosure Package&#x201d;): the Base Prospectus and each &#x201c;free-writing prospectus&#x201d; (as defined pursuant to Rule 405 under the Securities Act) listed on Annex A hereto.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Applicable Time&#x201d; means 6:30 P.M., New York City time, on August 11, 2022.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Purchase of the Securities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The Company agrees to issue and sell the Securities to the several Underwriters as provided in this Agreement, and each Underwriter, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, agrees, severally and not jointly, to purchase at a price per share of $2.2748 (the &#x201c;Share Purchase Price&#x201d;) from the Company the respective number of Shares set forth opposite such Underwriter&#x2019;s name in Schedule 1 hereto, and to purchase at a price of $2.2747 per Warrant (the &#x201c;Warrant Purchase Price&#x201d;) from the Company the respective number of Warrants set forth opposite such Underwriter&#x2019;s name in Schedule 1 hereto.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The Company understands that the Underwriters intend to make a public offering of the Securities, and initially to offer the Securities on the terms set forth in the Pricing Disclosure Package.  The Company acknowledges and agrees that the Underwriters may offer and sell Securities to or through any affiliate of an Underwriter.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Payment for the Securities shall be made by wire transfer in immediately available funds to the account specified by the Company to the Representatives at the offices of Davis Polk &amp; Wardwell LLP, 450 Lexington Avenue, New York, New York 10017 at 10:00 A.M. New York City time on August 16, 2022, or at such other time or place on the same or such other date, not later than the fifth business day thereafter, as the Representatives and the Company may agree upon in writing.  The time and date of such payment for the Securities is referred to herein as the &#x201c;Closing Date.&#x201d;</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Payment for the Securities to be purchased on the Closing Date shall be made against delivery to the Representatives for the respective accounts of the several Underwriters of the Securities with any transfer taxes payable in connection with the sale of such Securities duly paid by the Company. Delivery of the Shares shall be made through the facilities of The Depository Trust Company (&#x201c;DTC&#x201d;) unless the Representatives shall otherwise instruct. The Warrants shall be delivered to the purchasers of the Warrants (or to the Representatives as directed by the Representatives), in definitive form, registered in such names and in such denominations as the Representatives shall request in writing not later than the Closing Date. The Warrants will be made available for inspection by the Representatives on the business day prior to the Closing Date.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, the Company and the Representatives shall instruct the purchasers of the Warrants in the public offering to make payment for the Warrants on the Closing Date to the Company by wire transfer in immediately available funds to the account specified by the Company at a purchase price of $2.4199 per Warrant, in lieu of payment by the Underwriters for such Warrants, and the Company shall deliver such Warrants to such purchasers on the Closing Date in definitive form against such payment, in lieu of the Company&#x2019;s obligation to deliver such Warrants to the Underwriters. The Company shall promptly (but in no event later than the Closing Date) pay $0.145194 per warrant (the &#x201c;Warrant Underwriting Discount&#x201d;) to the Representatives by wire transfer in immediately available funds to the account specified by the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Representatives, provided however, that the Company agrees that the Representatives will be entitled at their discretion to set off  the Warrant Underwriting Discount against the payment for the Shares, and any excess amount will remain due and payable on the Closing Date. In the event the purchasers of the Warrants in the offering fail to make payment to the Company for all or part of the Warrants on the Closing Date, the Underwriters agree to make payment to the Company for such Warrants at a price per Warrant equal to the Warrant Purchase Price; provided, however, that the Representatives may elect, by written notice to the Company, to receive Shares in lieu of all or a portion of such Warrants to be delivered to the Underwriters under this Agreement at a price per Share equal to the Share Purchase Price. The aggregate amount of Shares and Warrants to be delivered to the Representatives hereunder may be reallocated at the discretion of the Representatives no later than the business day prior to the Closing Date, to increase or decrease the number of Shares or Warrants, provided that the aggregate number of Shares and Warrants issued does not exceed 26,880,000.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The Company acknowledges and agrees that the Representatives and the other Underwriters are acting solely in the capacity of an arm&#x2019;s length contractual counterparty to the Company with respect to the offering of Securities contemplated hereby (including in connection with determining the terms of the offering) and not as a financial advisor or a fiduciary to, or an agent of, the Company or any other person.  Additionally, neither the Representatives nor any other Underwriter is advising the Company or any other person as to any legal, tax, investment,  accounting or regulatory matters in any jurisdiction.  The Company shall consult with its own advisors concerning such matters and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and neither the Representatives nor the other Underwriters shall have any responsibility or liability to the Company with respect thereto.  Any review by the Representatives and the other Underwriters of the Company, the transactions contemplated hereby or other matters relating to such transactions will be performed solely for the benefit of the Underwriters and shall not be on behalf of the Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Representations and Warranties of the Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  The Company represents and warrants to each Underwriter that:</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preliminary Prospectus.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  No order preventing or suspending the use of any Preliminary Prospectus, if any, has been issued by the Commission, and each Preliminary Prospectus, if any, included in the Pricing Disclosure Package, at the time of filing thereof, complied in all material respects with the Securities Act, and no Preliminary Prospectus, if any, at the time of filing thereof, contained any untrue statement of a material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in any Preliminary Prospectus, it being </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section 7(b) hereof.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pricing Disclosure Package</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  The Pricing Disclosure Package as of the Applicable Time did not, and as of the Closing Date will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in such Pricing Disclosure Package, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section 7(b) hereof.  No statement of material fact included in the Prospectus has been omitted from the Pricing Disclosure Package and no statement of material fact included in the Pricing Disclosure Package that is required to be included in the Prospectus has been omitted therefrom. </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Issuer Free Writing Prospectus.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Other than the Registration Statement, the Preliminary Prospectus, if any, and the Prospectus, the Company (including its agents and representatives, other than the Underwriters in their capacity as such) has not prepared, made, used, authorized, approved or referred to and will not prepare, make, use, authorize, approve or refer to any &#x201c;written communication&#x201d; (as defined in Rule 405 under the Securities Act) that constitutes an offer to sell or solicitation of an offer to buy the Securities (each such communication by the Company or its agents and representatives (other than a communication referred to in clause (i) below) an &#x201c;Issuer Free Writing Prospectus&#x201d;) other than (i) any document not constituting a prospectus pursuant to Section 2(a)(10)(a) of the Securities Act or Rule 134 under the Securities Act or (ii) the documents listed on Annex A hereto, each electronic road show, each electronic investor presentation and any other written communications approved in writing in advance by the Representatives.  Each such Issuer Free Writing Prospectus complies in all material respects with the Securities Act, has been or will be (within the time period specified in Rule 433) filed in accordance with the Securities Act (to the extent required thereby) and does not conflict with the information contained in the Registration Statement or the Pricing Disclosure Package, and, when taken together with the Preliminary Prospectus, if any, accompanying, or delivered prior to delivery of, or filed prior to the first use of, such Issuer Free Writing Prospectus, did not, and as of the Closing Date will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> that the Company makes no representation or warranty with respect to any statements or omissions made in each such Issuer Free Writing Prospectus or Preliminary Prospectus, if any, in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">5</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Representatives expressly for use in such Issuer Free Writing Prospectus or Preliminary Prospectus, if any, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section 7(b) hereof.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Emerging Growth Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  As of the date hereof, the Company is an &#x201c;emerging growth company,&#x201d; as defined in Section 2(a) of the Securities Act (an &#x201c;Emerging Growth Company&#x201d;).  </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Testing-the-Waters Materials.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The Company (i) has not alone engaged in any Testing-the-Waters Communications (as defined below) other than Testing-the-Waters Communications with the consent of the Representatives (x) with entities that are qualified institutional buyers (&#x201c;QIBs&#x201d;) within the meaning of Rule 144A under the Securities Act or institutions that are accredited investors within the meaning of Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act (&#x201c;IAIs&#x201d;) and otherwise in compliance with the requirements of Section 5(d) of the Securities Act or (y) with entities that the Company reasonably believed to be QIBs or IAIs and otherwise in compliance with the requirements of Rule 163B  under the Securities Act and (ii) has not authorized anyone other than the Representatives to engage in Testing-the-Waters Communications. &#x201c;Testing-the-Waters Communication&#x201d; means any oral or written communication with potential investors undertaken in reliance on either Section 5(d) of, or Rule 163B under, the Securities Act. The Company has not distributed or approved for distribution any Written Testing-the-Waters Communications (as defined below) other than those listed on Annex B hereto. &#x201c;Written Testing-the-Waters Communication&#x201d; means any Testing-the-Waters Communication that is a written communication within the meaning of Rule 405 under the Securities Act.  Any individual Written Testing-the-Waters Communication does not conflict with the information contained in the Registration Statement or the Pricing Disclosure Package, complied in all material respects with the Securities Act, and when taken together with the Pricing Disclosure Package as of the Applicable Time, did not, and as of the Closing Date will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Registration Statement and Prospectus.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  The Registration Statement has been declared effective by the Commission.  No order suspending the effectiveness of the Registration Statement has been issued by the Commission, and no proceeding for that purpose or pursuant to Section 8A of the Securities Act against the Company or related to the offering of the Securities has been initiated, or to the knowledge of the Company, threatened by the Commission; as of the applicable effective date of the Registration Statement and any post-effective amendment thereto, the Registration Statement and any such post-effective amendment complied and will comply in all material respects with the applicable requirements of the Securities Act, and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">therein or necessary in order to make the statements therein not misleading; and as of the date of the Prospectus and any amendment or supplement thereto and as of the Closing Date, the Prospectus will comply in all material respects with the Securities Act and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration Statement and the Prospectus and any amendment or supplement thereto, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section 7(b) hereof.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(g)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Incorporated Documents.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> The documents incorporated by reference in the Registration Statement, the Prospectus and the Pricing Disclosure Package, when they were filed with the Commission conformed in all material respects to the requirements of the Exchange Act, and none of such documents contained any untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; and any further documents so filed and incorporated by reference in the Registration Statement, the Prospectus or the Pricing Disclosure Package, when such documents are filed with the Commission, will conform in all material respects to the requirements of the Exchange Act and will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(h)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Statements.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  The financial statements (including the related notes thereto) of the Company and its consolidated subsidiaries included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus comply in all material respects with the applicable requirements of the Securities Act and the Exchange Act, as applicable, and present fairly in all material respects, the financial position of the Company and its consolidated subsidiaries as of the dates indicated and the results of their operations and the changes in their cash flows for the periods specified; such financial statements have been prepared in conformity with generally accepted accounting principles (&#x201c;GAAP&#x201d;) in the United States applied on a consistent basis throughout the periods covered thereby, except in the case of unaudited interim financial statements, which are subject to normal year-end adjustments and do not contain certain footnotes as permitted by the applicable rules of the Commission, and any supporting schedules included or incorporated by reference in the Registration Statement present fairly in all material respects, the information required to be stated therein; and the other financial information included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus has been derived from the accounting records of the </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">7</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Company and its consolidated subsidiaries and presents fairly in all material respects the information shown thereby.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Material Adverse Change.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  Since the date of the most recent financial statements of the Company included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (i) there has not been any change in the capital stock (other than the issuance of shares of Common Stock upon exercise of stock options and warrants described as outstanding in, and the grant of options and awards under existing equity incentive plans described in, the Registration Statement, the Pricing Disclosure Package and the Prospectus), short-term debt or long-term debt of the Company or any of its subsidiaries, or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock, or any material adverse change, or any development that would reasonably be expected to result in a material adverse change, in or affecting the business, properties, management, financial position, stockholders&#x2019; equity, results of operations or prospects of the Company and its subsidiaries taken as a whole; (ii) neither the Company nor any of its subsidiaries has entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company and its subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent, that is material to the Company and its subsidiaries taken as a whole; and (iii) neither the Company nor any of its subsidiaries has sustained any loss or interference with its business that is material to the Company and its subsidiaries taken as a whole and that is either from fire, explosion, pandemic, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority, except in each case as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(j)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Organization and Good Standing.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  The Company and each of its subsidiaries have been duly organized and are validly existing and in good standing under the laws of their respective jurisdictions of organization, are duly qualified to do business and are in good standing in each jurisdiction in which their respective ownership or lease of property or the conduct of their respective businesses requires such qualification, and have all power and authority necessary to own or hold their respective properties and to conduct the businesses in which they are engaged, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect on the business, properties, management, financial position, stockholders&#x2019; equity, results of operations or prospects of the Company and its subsidiaries taken as a whole or on the performance by the Company of its obligations under this Agreement (a &#x201c;Material Adverse Effect&#x201d;).  The subsidiaries listed in Exhibit 21.1 to the Company&#x2019;s Annual Report on Form 10-K are the only significant subsidiaries of the Company.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">8</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(k)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Capitalization.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  All the outstanding shares of capital stock of the Company have been duly and validly authorized and issued and are fully paid and non-assessable and are not subject to any pre-emptive or similar rights that have not been duly waived or satisfied; except as described in or expressly contemplated by the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no outstanding rights (including, without limitation, pre-emptive rights, that have not been duly waived or satisfied), warrants or options to acquire, or instruments convertible into or exchangeable for, any shares of capital stock or other equity interest in the Company or any of its subsidiaries, or any contract, commitment, agreement, understanding or arrangement of any kind relating to the issuance of any capital stock of the Company or any such subsidiary, any such convertible or exchangeable securities or any such rights, warrants or options; the capital stock of the Company conforms in all material respects to the description thereof contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and all the outstanding shares of capital stock or other equity interests of each subsidiary owned, directly or indirectly, by the Company have been duly and validly authorized and issued, are fully paid and non-assessable (except as otherwise described in the Registration Statement, the Pricing Disclosure Package and the Prospectus,) and are owned directly or indirectly by the Company, free and clear of any lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any third party.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(l)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Options.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">With respect to the stock options (the &#x201c;Stock Options&#x201d;) granted pursuant to the stock-based compensation plans of the Company and its subsidiaries (the &#x201c;Company Stock Plans&#x201d;), (i) each grant of a Stock Option was duly authorized no later than the date on which the grant of such Stock Option was by its terms to be effective (the &#x201c;Grant Date&#x201d;) by all necessary corporate action, including, as applicable, approval by the board of directors of the Company (or a duly constituted and authorized committee thereof) and any required stockholder approval by the necessary number of votes or written consents, and the award agreement governing such grant (if any) was duly executed and delivered by each party thereto, (ii) each such grant was made in accordance with the terms of the applicable Company Stock Plan and all other applicable laws and regulatory rules or requirements, and (iii) each such grant was properly accounted for in accordance with GAAP in the financial statements (including the related notes) of the Company and disclosed in the Company&#x2019;s filings with the Commission in accordance with the Exchange Act and all other applicable laws.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(m)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Due Authorization.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  The Company has full right, power and authority to execute and deliver this Agreement and to perform its obligations hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it of this Agreement and the consummation by it of the transactions contemplated hereby has been duly and validly taken.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">9</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(n)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Underwriting Agreement. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> This Agreement has been duly authorized, executed and delivered by the Company.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(o)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Shares and the Warrants.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(i) The Shares to be issued and sold by the Company hereunder have been duly authorized by the Company and, when issued and delivered and paid for as provided herein, will be duly and validly issued, will be fully paid and nonassessable and will conform to the descriptions thereof in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and the issuance of the Shares is not subject to any preemptive or similar rights; (ii) the Warrants have been duly authorized by the Company and, when executed and delivered by the Company in accordance with this Agreement, will constitute valid and legally binding agreements of the Company enofrceable against the Company in accordance with their terms, except as enforceability may be limited by applicable bankruptcy, insolvency or similar laws affecting creditors&#x2019; rights generally or by equitable principles relating to enforceability; (iii) the Warrant Shares to be issued by the Company upon exercise of the Warrants, as provided therein, have been duly and validly authorized and, when issued and delivered upon exercise as provided under the Warrant, will be duly and validly issued, fully paid and non-assessable and will conform in all material respects to the descriptions thereof in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and (iv) the issuance of the Securities and the Warrant Shares is not subject to any preemptive or similar rights. </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(p)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Description of the Underwriting Agreement.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  This Agreement conforms in all material respects to the description thereof contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(q)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Violation or Default.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  Neither the Company nor any of its subsidiaries is (i) in violation of its charter or by-laws or similar organizational documents; (ii) in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any property or asset of the Company or any of its subsidiaries is subject; or (iii) in violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (ii) and (iii) above, for any such default or violation that would not, individually or in the aggregate, have a Material Adverse Effect.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(r)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Conflicts.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The execution, delivery and performance by the Company of this Agreement and the Warrants, the issuance and sale of the Securities and the Warrant Shares and the consummation of the transactions contemplated by this Agreement and the Warrants or the Pricing Disclosure Package and the Prospectus will not (i) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, result </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">10</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">in the termination, modification or acceleration of, or result in the creation or imposition of any lien, charge or encumbrance upon any property, right or asset of the Company or any of its subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any property, right or asset of the Company or any of its subsidiaries is subject, (ii) result in any violation of the provisions of the charter or by-laws or similar organizational documents of the Company or any of its subsidiaries or (iii) result in the violation of any law or statute or any judgment, order, rule  or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (i) and (iii) above, for any such conflict, breach, violation, default, lien, charge or encumbrance that would not, individually or in the aggregate, have a Material Adverse Effect.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(s)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Consents Required.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  No consent, approval, authorization, order, registration or qualification of or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Securities and the consummation of the transactions contemplated by this Agreement, except for the registration of the Securities under the Securities Act and such consents, approvals, authorizations, orders and registrations or qualifications as may be required by the Financial Industry Regulatory Authority, Inc. (&#x201c;FINRA&#x201d;) and under applicable state securities laws in connection with the purchase and distribution of the Securities by the Underwriters.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(t)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Legal Proceedings.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no legal, governmental or regulatory investigations, actions, demands, claims, suits, arbitrations, inquiries or proceedings (&#x201c;Actions&#x201d;) pending to which the Company or any of its subsidiaries is or, may reasonably be expected to become a party or to which any property of the Company or any of its subsidiaries is or may be the subject that, individually or in the aggregate, if determined adversely to the Company or any of its subsidiaries, would reasonably be expected to have a Material Adverse Effect; to the knowledge of the Company, no such Actions are threatened or contemplated by any governmental or regulatory authority or threatened by others; and (i) there are no current or pending Actions that are required under the Securities Act to be described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so described in the Registration Statement, the Pricing Disclosure Package and the Prospectus and (ii) there are no statutes, regulations or contracts or other documents that are required under the Securities Act to be filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package and the Prospectus.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">11</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(u)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Independent Accountants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  Ernst &amp; Young LLP, who have certified certain financial statements of the Company and its subsidiaries, is an independent registered public accounting firm with respect to the Company and its subsidiaries within the applicable rules and regulations adopted by the Commission and the Public Company Accounting Oversight Board (United States) and as required by the Securities Act.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(v)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Title to Real and Personal Property</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  The Company and its subsidiaries have good and marketable title in fee simple (in the case of real property) to, or have valid rights to lease or otherwise use, all items of real and personal property that are material to the respective businesses of the Company and its subsidiaries, in each case free and clear of all liens, encumbrances, claims and defects and imperfections of title except those that (i) do not materially interfere with the use made and proposed to be made of such property by the Company and its subsidiaries or (ii) would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(w)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual Property.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  Except as disclosed in the Pricing Disclosure Package and the final Prospectus, (i) the Company and its subsidiaries own or have the right to use all patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, domain names and other source indicators, copyrights and copyrightable works, know-how, trade secrets, systems, procedures, proprietary or confidential information and all other worldwide intellectual property, industrial property and proprietary rights (collectively, &#x201c;Intellectual Property&#x201d;) used, or as contemplated to be used, in the Registration Statement, in the conduct of their respective businesses; (ii) the Intellectual Property owned by the Company and its subsidiaries and, to the Company&#x2019;s knowledge, the Intellectual Property licensed to the Company and its subsidiaries, are valid, subsisting and enforceable, and there is no pending or, to the Company&#x2019;s knowledge, threatened action, suit, proceeding or claim by others challenging the validity, scope or enforceability of any such Intellectual Property; (iii) to the knowledge of the Company, Company&#x2019;s and its subsidiaries&#x2019; conduct of their respective businesses does not infringe, misappropriate or otherwise violate, and has not infringed, misappropriated or otherwise violated, any valid Intellectual Property of any person; (iv) the Company and its subsidiaries have not received any notice of any claim challenging the Company&#x2019;s rights in or to its Intellectual Property and there are no actual or, to the knowledge of the Company, threatened claims alleging that the Company or any of its subsidiaries infringe, misappropriate or otherwise violate any third party Intellectual Property; (v) to the knowledge of the Company, the Intellectual Property of the Company and its subsidiaries is not being, and has not been, infringed, misappropriated or otherwise violated by any person; (vi) to the knowledge of the Company, all employees or contractors engaged in the development of Intellectual Property owned by the Company or its subsidiaries, on behalf of the Company or any subsidiary of the Company have executed an invention assignment agreement or other agreement whereby such employees or contractors assign all of their right, title and interest in and to such Intellectual Property to the Company or the </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">12</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">applicable subsidiary, and to the Company&#x2019;s knowledge no such agreement has been breached or violated; and (vii) to the knowledge of the Company, the Company and its subsidiaries use, and have used, commercially reasonable efforts to appropriately maintain all information intended by the Company to be maintained as a trade secret</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(x)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Undisclosed Relationships</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  No relationship, direct or indirect, exists between or among the Company or any of its subsidiaries, on the one hand, and the directors, officers, stockholders, customers, suppliers or other affiliates of the Company or any of its subsidiaries, on the other, that is required by the Securities Act to be described in each of the Registration Statement and the Prospectus and that is not so described in such documents and in the Pricing Disclosure Package.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(y)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investment Company Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  The Company is not and, after giving effect to the offering and sale of the Securities and the application of the proceeds thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not be required to register as an &#x201c;investment company&#x201d; or an entity &#x201c;controlled&#x201d; by an &#x201c;investment company&#x201d; within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#x201c;Investment Company Act&#x201d;).</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(z)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Taxes.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  The Company and its subsidiaries have paid all federal, state, local and foreign taxes and filed all tax returns required to be paid or filed through the date hereof except where the failure to pay such taxes or file such tax returns would not, individually or in the aggregate, have a Material Adverse Effect; and except as otherwise disclosed in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, there is no material tax deficiency that has been, or could reasonably be expected to be, asserted against the Company or any of its subsidiaries or any of their respective properties or assets.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(aa)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Licenses and Permits.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  The Company and its subsidiaries possess all licenses, sub-licenses, certificates, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, except where the failure to possess or make the same would not, individually or in the aggregate, have a Material Adverse Effect; and except as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor any of its subsidiaries has received notice of any revocation or modification of any such license, sub-license, certificate, permit or authorization or has any reason to believe that any such license, sub-license, certificate, permit or authorization will not be renewed in the ordinary course, except for such revocations, modifications, or non-renewals, that would not, whether individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">13</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(bb)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Labor Disputes.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  No labor disturbance by or dispute with employees of the Company or any of its subsidiaries exists or, to the knowledge of the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees of any of its or its subsidiaries&#x2019; principal suppliers, contractors or customers, except as would not be reasonably expected to have a Material Adverse Effect.  Neither the Company nor any of its subsidiaries has received any notice of cancellation or termination with respect to any collective bargaining agreement to which it is a party.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(cc)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Certain Environmental Matters</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  (i) The Company and its subsidiaries (x) are in compliance with all, and have not violated any, applicable federal, state, local and foreign laws (including common law), rules, regulations, requirements, decisions, judgments, decrees, orders and other legally enforceable requirements relating to pollution or the protection of human health or safety, the environment, natural resources, hazardous or toxic substances or wastes, pollutants or contaminants (collectively, &#x201c;Environmental Laws&#x201d;); (y) have received and are in compliance with all, and have not violated any, permits, licenses, certificates or other authorizations or approvals required of them under any Environmental Laws to conduct their respective businesses; and (z) have not received notice of any actual or potential liability or obligation under or relating to, or any actual or potential violation of, any Environmental Laws, including for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, and have no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii) there are no costs or liabilities associated with Environmental Laws of or relating to the Company or its subsidiaries, except in the case of each of (i) and (ii) above, for any such matter as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and (iii) except as described in each of the Pricing Disclosure Package and the Prospectus, (x) there is no proceeding that is pending, or that is known by the Company to be contemplated, against the Company or any of its subsidiaries under any Environmental Laws in which a governmental entity is also a party, other than such proceeding regarding which the Company reasonably believes no monetary sanctions of $100,000 or more will be imposed, (y) the Company and its subsidiaries are not aware of any facts or issues regarding compliance with Environmental Laws, or liabilities or other obligations under Environmental Laws or concerning hazardous or toxic substances or wastes, pollutants or contaminants, that would reasonably be expected to have a material effect on the capital expenditures, earnings or competitive position of the Company and its subsidiaries, and (z) none of the Company or its subsidiaries anticipates material capital expenditures relating to any Environmental Laws.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(dd)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compliance with ERISA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  (i) Each employee benefit plan, within the meaning of Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (&#x201c;ERISA&#x201d;), for which the Company or any member of its &#x201c;Controlled Group&#x201d; (defined as any entity, whether or not incorporated, that is </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">14</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">under common control with the Company within the meaning of Section 4001(a)(14) of ERISA or any entity that would be regarded as a single employer with the Company under Section 414(b),(c),(m) or (o) of the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;) would have any liability (each, a &#x201c;Plan&#x201d;) has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code; (ii) no prohibited transaction, within the meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred with respect to any Plan, excluding transactions effected pursuant to a statutory or administrative exemption; (iii) for each Plan that is subject to the funding rules of Section 412 of the Code or Section 302 of ERISA, no Plan has failed (whether or not waived), or is reasonably expected to fail, to satisfy the minimum funding standards (within the meaning of Section 302 of ERISA or Section 412 of the Code) applicable to such Plan; (iv) no Plan is, or is reasonably expected to be, in &#x201c;at risk status&#x201d; (within the meaning of Section 303(i) of ERISA) and no Plan that is a &#x201c;multiemployer plan&#x201d; within the meaning of Section 4001(a)(3) of ERISA is in &#x201c;endangered status&#x201d; or &#x201c;critical status&#x201d; (within the meaning of Sections 304 and 305 of ERISA) (v) the fair market value of the assets of each Plan exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan); (vi) no &#x201c;reportable event&#x201d; (within the meaning of Section 4043(c) of ERISA and the regulations promulgated thereunder) has occurred or is reasonably expected to occur; (vii) each Plan that is intended to be qualified under Section 401(a) of the Code is so qualified, and nothing has occurred, whether by action or by failure to act, which would cause the loss of such qualification; (viii) neither the Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan or premiums to the Pension Benefit Guaranty Corporation, in the ordinary course and without default) in respect of a Plan (including a &#x201c;multiemployer plan&#x201d; within the meaning of Section 4001(a)(3) of ERISA); and (ix) none of the following events has occurred or is reasonably likely to occur: (A) a material increase in the aggregate amount of contributions required to be made to all Plans by the Company or its Controlled Group affiliates in the current fiscal year of the Company and its Controlled Group affiliates compared to the amount of such contributions made in the Company&#x2019;s and its Controlled Group affiliates&#x2019; most recently completed fiscal year; or (B) a material increase in the Company and its subsidiaries&#x2019; &#x201c;accumulated post-retirement benefit obligations&#x201d; (within the meaning of Accounting Standards Codification Topic 715-60) compared to the amount of such obligations in the Company and its subsidiaries&#x2019; most recently completed fiscal year, except in each case with respect to the events or conditions set forth in (i) through (ix) hereof, as would not, individually or in the aggregate, be reasonably expected to have a Material Adverse Effect.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(ee)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disclosure Controls</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  The Company and its subsidiaries, on a consolidated basis, maintain an effective system of &#x201c;disclosure controls and procedures&#x201d; (as defined in Rule 13a-15(e) of the Exchange Act) that complies with the requirements of the Exchange Act and that has been designed to ensure </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">15</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission&#x2019;s rules and forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company&#x2019;s management as appropriate to allow timely decisions regarding required disclosure. The Company and its subsidiaries, on a consolidated basis, have carried out evaluations of the effectiveness of their disclosure controls and procedures as required by Rule 13a-15 of the Exchange Act.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(ff)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Controls.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  The Company and its subsidiaries maintain systems of &#x201c;internal control over financial reporting&#x201d; (as defined in Rule 13a-15(f) of the Exchange Act) that comply with the applicable requirements of the Exchange Act and have been designed by, or under the supervision of, their respective principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP.  The Company and its subsidiaries maintain internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management&#x2019;s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management&#x2019;s general or specific authorization; (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v) interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement, the Prospectus and the Pricing Disclosure Package fairly presents the information called for in all material respects and is prepared in accordance with the Commission&#x2019;s rules and guidelines applicable thereto. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no material weaknesses in the Company&#x2019;s internal controls.  The Company&#x2019;s auditors and the Audit Committee of the Board of Directors of the Company have been advised of:  (i) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which have adversely affected or are reasonably likely to adversely affect the Company&#x2019;s ability to record, process, summarize and report financial information; and (ii) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#x2019;s internal controls over financial reporting.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(gg)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">eXtensible Business Reporting Language</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#x2019;s rules and guidelines applicable thereto.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">16</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(hh)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Insurance.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The Company and its subsidiaries have insurance covering their respective properties, operations, personnel and businesses, including business interruption insurance, which insurance is in amounts and insures against such losses and risks as the Company reasonably believes are adequate to protect the Company and its subsidiaries and their respective businesses; and neither the Company nor any of its subsidiaries has (i) received notice from any insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in order to continue such insurance or (ii) any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue its business.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cybersecurity; Data Protection. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(i)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">the Company and its subsidiaries&#x2019; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">IT Systems</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) are adequate for, and operate and perform as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants; (ii) the Company and its subsidiaries have implemented and maintained commercially reasonable controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data (including all personal, personally identifiable, sensitive, confidential or regulated data (&#x201c;Personal Data&#x201d;)) used in connection with their businesses, and there have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same; and (iii) the Company and its subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Data Security Obligations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The Company has not received any written notification of or written complaint regarding, and is unaware of any other facts that, individually or in the aggregate, would reasonably indicate material non-compliance with any Data Security Obligation, and there is no action, suit or proceeding by or before any court or governmental agency, authority or body pending or, to the knowledge of the Company, threatened alleging non-compliance with any Data Security Obligation.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(jj)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Unlawful Payments.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  Neither the Company nor any of its subsidiaries nor any director, officer or employee of the Company or any of its subsidiaries nor, to the knowledge of the Company, any agent, affiliate or other </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">17</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">person associated with or acting on behalf of the Company or any of its subsidiaries has (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii) made or taken an act in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office; (iii) violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or anti-corruption law; or (iv) made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper payment or benefit.  The Company and its subsidiaries have instituted, maintain and enforce, and will continue to maintain and enforce policies and procedures designed to promote and ensure compliance with all applicable anti-bribery and anti-corruption laws.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(kk)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compliance with Anti-Money Laundering Laws</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions where the Company or any of its subsidiaries conducts business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced by any governmental agency (collectively, the &#x201c;Anti-Money Laundering Laws&#x201d;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(ll)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Conflicts with Sanctions Laws.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Neither the Company nor any of its subsidiaries, directors, officers, or employees, nor, to the knowledge of the Company, any agent,  affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries is currently the subject or the target of any sanctions administered or enforced by the U.S. government, (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury (&#x201c;OFAC&#x201d;) or the U.S. Department of State and including, without limitation, the designation as a &#x201c;specially designated national&#x201d; or &#x201c;blocked person&#x201d;), the United Nations Security Council (&#x201c;UNSC&#x201d;), the European Union, Her Majesty&#x2019;s Treasury (&#x201c;HMT&#x201d;) or other relevant sanctions authority (collectively, &#x201c;Sanctions&#x201d;), nor is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or target of Sanctions, including, without limitation, the so-called Donetsk People&#x2019;s Republic, </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">18</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">the so-called Luhansk People&#x2019;s Republic, the Crimea region of Ukraine, Cuba, Iran, North Korea and Syria (each, a &#x201c;Sanctioned Country&#x201d;); and the Company will not directly or indirectly use the proceeds of the offering of the Securities hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i) to fund or facilitate any activities of or business with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions, (ii) to fund or facilitate any activities of or business in any Sanctioned Country or (iii) in any other manner that will result in a violation by any person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions.  Since the Company&#x2019;s inception, the Company and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(mm)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Restrictions on Subsidiaries</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  No subsidiary of the Company is currently prohibited, directly or indirectly, under any agreement or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution on such subsidiary&#x2019;s capital stock or similar ownership interest, from repaying to the Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary&#x2019;s properties or assets to the Company or any other subsidiary of the Company.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(nn)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Broker&#x2019;s Fees.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  Neither the Company nor any of its subsidiaries is a party to any contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against any of them or any Underwriter for a brokerage commission, finder&#x2019;s fee or like payment in connection with the offering and sale of the Securities.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(oo)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Registration Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  No person has the right to require the Company or any of its subsidiaries to register any securities for sale under the Securities Act by reason of the filing of the Registration Statement with the Commission or the issuance and sale of the Securities, except for such rights as have been duly waived.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(pp)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Stabilization.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  Neither the Company nor any of its subsidiaries or, to the Company&#x2019;s knowledge, other affiliates has taken, directly or indirectly, without giving effect to activities by the Underwriters, any action designed to or that would reasonably be expected to cause or result in any stabilization or manipulation of the price of the Securities.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(qq)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Margin Rules</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  Neither the issuance, sale and delivery of the Securities nor the application of the proceeds thereof by the Company as described in each of the Registration Statement, the Pricing Disclosure Package </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">19</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">and the Prospectus will violate Regulation T, U or X of the Board of Governors of the Federal Reserve System or any other regulation of such Board of Governors.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(rr)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Forward-Looking Statements.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act) included or incorporated by reference in any of the Registration Statement, the Pricing Disclosure Package or the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(ss)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Statistical and Market Data.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  Nothing has come to the attention of the Company that has caused the Company to believe that the statistical and market-related data included or incorporated by reference in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus is not based on or derived from sources that are reliable and accurate in all material respects.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(tt)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sarbanes-Oxley Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  There is and has been no failure on the part of the Company or any of the Company&#x2019;s directors or officers, in their capacities as such, to comply with any applicable provision of the Sarbanes-Oxley Act of 2002, as amended and the rules and regulations promulgated in connection therewith (the &#x201c;Sarbanes-Oxley Act&#x201d;), including Section 402 related to loans and Sections 302 and 906 related to certifications.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(uu)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Status under the Securities Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  At the time of filing the Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that the Company or any offering participant made a </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">bona fide</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> offer (within the meaning of Rule 164(h)(2) under the Securities Act) of the Securities and at the date hereof, the Company was not and is not an &#x201c;ineligible issuer,&#x201d; as defined in Rule 405 under the Securities Act.  </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(vv)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Ratings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  There are (and prior to the Closing Date, will be) no debt securities, convertible securities or preferred stock issued or guaranteed by the Company or any of its subsidiaries that are rated by a &#x201c;nationally recognized statistical rating organization&#x201d;, as such term is defined in Section 3(a)(62) under the Exchange Act.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(ww)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Regulatory Matters; Products and Product Candidates</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company (collectively with its subsidiaries) and except, in each case, as would not, individually or in the aggregate, have a Material Adverse Effect: (i) has operated and currently operates its business in compliance with all Health Care Laws (as defined below) applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, storage, import, export or disposal of any of the Company&#x2019;s or its subsidiaries&#x2019; product candidates or any product manufactured or distributed by the Company; (ii) has not received any FDA Form 483, written notice of adverse finding, warning letter, </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">20</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">untitled letter or other correspondence or written notice from any court or arbitrator or governmental or regulatory authority alleging or asserting non-compliance with (A) any Health Care Laws or (B) any licenses, certificates, approvals, clearances, exemptions, authorizations, permits and supplements or amendments thereto required by any such Health Care Laws (&#x201c;Regulatory Authorizations&#x201d;); (iii) possesses all Regulatory Authorizations required to conduct its business as currently conducted, and such Regulatory Authorizations are valid and in full force and effect and the Company is not in violation of any term of any such Regulatory Authorizations; (iv) has not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the Food and Drug Administration (&#x201c;FDA&#x201d;), the Department of Health and Human Services or any comparable foreign or other regulatory authority to which they are subject (collectively, the &#x201c;Applicable Regulatory Authorities&#x201d;) alleging that any product of the Company is in violation of any Health Care Laws or Regulatory Authorizations and has no knowledge that the Applicable Regulatory Authorities or any other third party is threatening any such claim, litigation, arbitration, action, suit, investigation or proceeding; (v) has not received written notice that any of the Applicable Regulatory Authorities has taken, is taking or intends to take action to limit, suspend, or revoke any Regulatory Authorizations and has no knowledge that any of the Applicable Regulatory Authorities is considering such action; (vi) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws or Regulatory Authorizations and, to the knowledge of the Company, that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and correct on the date filed (or were materially corrected or supplemented by a subsequent submission); (vii) is not a party to and does not have any ongoing reporting obligations pursuant to any corporate integrity agreements, deferred or non-prosecution agreements, monitoring agreements, consent decrees, settlement orders, plans of correction or similar agreements with or imposed by any Applicable Regulatory Authority; and (viii) along with its employees, officers and directors, has not been excluded, suspended or debarred from participation in any government health care program or human clinical research and, to the knowledge of the Company, is not subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion.</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The term &#x201c;Health Care Laws&#x201d; means Title XVIII of the Social Security Act, 42 U.S.C. &#167;&#167; 1395-1395hhh (the Medicare statute); Title XIX of the Social Security Act, 42 U.S.C. &#167;&#167; 1396-1396v (the Medicaid statute); the Federal Anti-Kickback Statute, 42 U.S.C. &#167; 1320a-7b(b); the civil False Claims Act, 31 U.S.C. &#167;&#167; 3729 et seq.; the criminal False Claims Act, 42 U.S.C. 1320a-7b(a); any criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286, 287, 1347 and 1349, and the health care fraud criminal provisions under the Health Insurance Portability and Accountability Act of 1996, 42 U.S.C. &#167;&#167; 1320d et seq. (&#x201c;HIPAA&#x201d;); the Civil Monetary Penalties Law, 42 U.S.C. &#167;&#167;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">21</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">1320a-7a and 1320a-7b; the Physician Payments Sunshine Act, 42 U.S.C. &#167; 1320a-7h; the Exclusion Statute, 42 U.S.C. &#167; 1320a-7; HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, 42 U.S.C. &#167;&#167; 17921 et seq.; the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. &#167;&#167; 301 et seq.; the regulations promulgated pursuant to such laws; and any similar federal, state and local laws and regulations.</font></p>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(xx)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preclinical Studies and Clinical Trials</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">. (i) Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the pre-clinical studies and clinical trials conducted by or, to the knowledge of the Company, on behalf of or sponsored by the Company, or in which the Company has participated that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus or the results of which are referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, were, and if still pending are, being conducted in all respects in accordance with all applicable Health Care Laws; (ii) the descriptions in the Registration Statement, the Pricing Disclosure Package and the Prospectus of the results of such studies and trials are, to the knowledge of the Company, accurate and complete in all respects and fairly present the data derived therefrom; (iii) the Company has no knowledge of any other studies or trials not described in the Registration Statement, the Pricing Disclosure Package and the Prospectus the results of which are inconsistent with or which the Company reasonably believes call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and (iv) the Company has not received any written notices or correspondence from the regulatory authorities or any other governmental agency requiring or threatening the termination, modification or suspension of any pre-clinical studies or clinical trials that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus or the results of which are referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus other than ordinary course communications with respect to modifications in connection with the design and implementation of such studies or trials, and, to the Company&#x2019;s knowledge, there are no reasonable grounds for the same.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Further Agreements of the Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  The Company covenants and agrees with each Underwriter that:</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Required Filings.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  The Company will file the final Prospectus with the Commission within the time periods specified by Rule 424(b) and Rule 430A, 430B or 430C under the Securities Act, will file any Issuer Free Writing Prospectus to the extent required by Rule 433 under the Securities Act; and the Company will file promptly all reports and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and for so long as the delivery of a prospectus is required in connection with the offering or sale of the Securities; and the Company will furnish copies of the Prospectus and each Issuer Free Writing Prospectus (to the </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">22</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">extent not previously delivered) to the Underwriters in New York City prior to 10:00 A.M., New York City time, on the business day next succeeding the date of this Agreement in such quantities as the Representatives may reasonably request.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Delivery of Copies.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  The Company will deliver, without charge, (i) to the Representatives, two signed copies of the Registration Statement as originally filed and each amendment thereto, in each case including all exhibits and consents filed therewith and documents incorporated by reference therein; and (ii) to each Underwriter (A) a conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) and (B) during the Prospectus Delivery Period (as defined below), as many copies of the Prospectus (including all amendments and supplements thereto and documents incorporated by reference therein and each Issuer Free Writing Prospectus) as the Representatives may reasonably request.  As used herein, the term &#x201c;Prospectus Delivery Period&#x201d; means such period of time after the first date of the public offering of the Securities as in the opinion of counsel for the Underwriters a prospectus relating to the Securities is required by law to be delivered (or required to be delivered but for Rule 172 under the Securities Act) in connection with sales of the Securities by any Underwriter or dealer.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Amendments or Supplements, Issuer Free Writing Prospectuses.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  Before making, preparing, using, authorizing, approving, referring to or filing any Issuer Free Writing Prospectus, and before filing any amendment or supplement to the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company will furnish to the Representatives and counsel for the Underwriters a copy of the proposed Issuer Free Writing Prospectus, amendment or supplement for review and will not make, prepare, use, authorize, approve, refer to or file any such Issuer Free Writing Prospectus or file any such proposed amendment or supplement to which the Representatives reasonably object.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Notice to the Representatives.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  The Company will advise the Representatives promptly, and confirm such advice in writing (which may be by electronic mail), (i) when the Registration Statement has become effective; (ii) when any amendment to the Registration Statement has been filed or becomes effective; (iii) when any supplement to the Pricing Disclosure Package, the Prospectus, any Issuer Free Writing Prospectus or any Written Testing-the-Waters Communication or any amendment to the Prospectus has been filed or distributed; (iv) of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus or the receipt of any comments from the Commission relating to the Registration Statement or any other request by the Commission for any additional information including, but not limited to, any request for information concerning any Testing-the-Waters Communication; (v) of the issuance by the Commission or any other governmental or regulatory authority of any order suspending the effectiveness of the Registration Statement or preventing or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure Package, the Prospectus or any Written Testing-the-Waters Communication or the initiation or threatening of any </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">23</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">proceeding for that purpose or pursuant to Section 8A of the Securities Act; (vi) of the occurrence of any event or development within the Prospectus Delivery Period as a result of which the Prospectus, any of the Pricing Disclosure Package, any Issuer Free Writing Prospectus or any Written Testing-the-Waters Communication as then amended or supplemented would include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus, the Pricing Disclosure Package,  any such Issuer Free Writing Prospectus or any Written Testing-the-Waters Communication is delivered to a purchaser, not misleading; and (vii) of the receipt by the Company of any notice with respect to any suspension of the qualification of the Securities for offer and sale in any jurisdiction or the initiation or, to the knowledge of the Company, threatening of any proceeding for such purpose; and the Company will use its reasonable best efforts to prevent the issuance of any such order suspending the effectiveness of the Registration Statement, preventing or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure Package or the Prospectus or any Written Testing-the-Waters Communication or suspending any such qualification of the Securities and, if any such order is issued, will obtain as soon as possible the withdrawal thereof.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Ongoing Compliance.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  (1) If during the Prospectus Delivery Period (i) any event or development shall occur or condition shall exist as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, not misleading or (ii) it is necessary to amend or supplement the Prospectus to comply with law, the Company will as promptly as practicable notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c) above, file with the Commission and furnish to the Underwriters and to such dealers as the Representatives may designate such amendments or supplements to the Prospectus (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in the Prospectus as so amended or supplemented (or any document to be filed with the Commission and incorporated by reference therein) will not, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus will comply with law and (2) if at any time prior to the Closing Date (i) any event or development shall occur or condition shall exist as a result of which the Pricing Disclosure Package as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, not misleading or (ii) it is necessary to amend or supplement the Pricing Disclosure Package to comply with law, the Company will as promptly as practicable notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c) above, file with the Commission (to the extent required) and furnish to the Underwriters and to such dealers as the Representatives may designate such amendments or supplements to </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">24</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">the Pricing Disclosure Package (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in the Pricing Disclosure Package as so amended or supplemented will not, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, be misleading or so that the Pricing Disclosure Package will comply with law.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Blue Sky Compliance.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  The Company will qualify the Securities for offer and sale under the securities or Blue Sky laws of such jurisdictions as the Representatives shall reasonably request and will continue such qualifications in effect so long as required for distribution of the Securities; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> that the Company shall not be required to (i) qualify as a foreign corporation or other entity or as a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii) file any general consent to service of process in any such jurisdiction or (iii) subject itself to taxation in any such jurisdiction if it is not otherwise so subject.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(g)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Earning Statement.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The Company will make generally available to its security holders and the Representatives as soon as practicable an earning statement that satisfies the provisions of Section 11(a) of the Securities Act and Rule 158 of the Commission promulgated thereunder covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the &#x201c;effective date&#x201d; (as defined in Rule 158) of the Registration Statement; provided that the Company will be deemed to have furnished such statements to its security holders and the Representatives to the extent they are filed on the Commission&#x2019;s Electronic Data Gathering, Analysis, and Retrieval System (&#x201c;EDGAR&#x201d;).</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(h)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clear Market.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  For a period of 60 days after the date of the Prospectus (the &#x201c;Restricted Period&#x201d;), the Company will not (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the Commission a registration statement under the Securities Act relating to, any shares of Stock or any securities convertible into or exercisable or exchangeable for Stock, or publicly disclose the intention to undertake any of the foregoing, or (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Stock or any such other securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Stock or such other securities, in cash or otherwise, without the prior written consent of Cowen and Company, LLC, other than the Securities to be sold hereunder and the delivery of Warrant Shares upon exercise of the Warrants. </font></div></div>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The restrictions described above do not apply to (i) the issuance of shares of Stock or securities convertible into or exercisable for shares of Stock pursuant to the conversion or exchange of convertible or exchangeable securities</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">25</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">or the exercise of warrants or options (including net exercise) or the settlement of RSUs (including net settlement), in each case outstanding on the date of this Agreement and described in the Prospectus; (ii) grants of stock options, stock awards, restricted stock, RSUs, or other equity awards and the issuance of shares of Stock or securities convertible into or exercisable or exchangeable for shares of Stock (whether upon the exercise of stock options or otherwise) to the Company&#x2019;s employees, officers, directors, advisors, or consultants pursuant to the terms of an equity compensation plan in effect as of the Closing Date and described in the Prospectus, provided that such recipients enter into a lock-up agreement with the Underwriters; (iii) the issuance of up to 10% of the outstanding shares of Stock, or securities convertible into, exercisable for, or which are otherwise exchangeable for, Stock, immediately following the Closing Date, in acquisitions or other similar strategic transactions, provided that such recipients enter into a lock-up agreement with the Underwriters; or (iv) the filing of any registration statement on Form S-8 relating to securities granted or to be granted pursuant to any plan in effect on the date of this Agreement and described in the Prospectus or any assumed benefit plan pursuant to an acquisition or similar strategic transaction.</font></p>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Proceeds.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  The Company will apply the net proceeds from the sale of the Securities as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading &#x201c;Use of Proceeds&#x201d;.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(j)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Stabilization.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  Neither the Company nor its subsidiaries or affiliates will take, directly or indirectly, without giving effect to activities by the Underwriters, any action designed to or that would reasonably be expected to cause or result in any stabilization or manipulation of the price of the Stock.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(k)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exchange Listing.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  The Company will use its reasonable best efforts to list for quotation the Shares and the Warrant Shares on the Nasdaq Global Select Market (the &#x201c;Nasdaq Market&#x201d;).</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(l)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reports.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  So long as the Securities or the Warrant Shares are outstanding, the Company will furnish to the Representatives, as soon as commercially reasonable after the date that they are available, copies of all reports or other communications (financial or other) furnished to holders of the Securities or the Warrant Shares, and copies of any reports and financial statements furnished to or filed with the Commission or any national securities exchange or automatic quotation system; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> the Company will be deemed to have furnished such reports and financial statements to the Representatives to the extent they are filed on EDGAR, or any successor to such system.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(m)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Record Retention</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  The Company will, pursuant to reasonable procedures developed in good faith, retain copies of each Issuer Free Writing Prospectus that is not filed with the Commission in accordance with Rule 433 under the Securities Act.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">26</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(n)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Shelf Renewal</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">. If immediately prior to the third anniversary (the &#x201c;Renewal Deadline&#x201d;) on the initial effective date of the Registration Statement, any of the Securities remain unsold by the Underwriters, the Company will, prior to the Renewal Deadline, file, if it has not already done so and is eligible to do so, a new automatic shelf registration statement relating to the Securities, in a form satisfactory to the Representatives. If the Company is not eligible to file an automatic shelf registration statement, the Company will, prior to the Renewal Deadline, if it has not already done so, file a new shelf registration statement relating to the Securities, in a form satisfactory to the Representatives, and will use its best efforts to cause such registration statement to be declared effective within 180 days after the Renewal Deadline. The Company will take all other action necessary or appropriate to permit the issuance and sale of the Securities to continue as contemplated in the expired registration statement relating to the Securities. References herein to the Registration Statement shall include such new automatic shelf registration statement or such new shelf registration statement, as the case may be.  </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(o)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Emerging Growth Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  The Company will promptly notify the Representatives if the Company ceases to be an Emerging Growth Company at any time prior to the later of (i) completion of the distribution of Securities within the meaning of the Securities Act and (ii) completion of the 60-day Restricted Period referred to in Section 4(h) hereof.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(p)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrant Shares Reserved.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  The Company shall, at all times while any Warrants are outstanding, reserve and keep available out of its authorized but unissued and otherwise unreserved Shares, solely for the purpose of enabling it to issue Warrant Shares upon exercise of such Warrants, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of the then-outstanding Warrants.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Certain Agreements of the Underwriters</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  Each Underwriter hereby represents and agrees that:</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">It has not, and will not use, authorize use of, refer to or participate in the planning for use of, any &#x201c;free writing prospectus&#x201d;, as defined in Rule 405 under the Securities Act (which term includes use of any written information furnished to the Commission by the Company and not incorporated by reference into the Registration Statement and any press release issued by the Company) other than (i) a free writing prospectus that contains no &#x201c;issuer information&#x201d; (as defined in Rule 433(h)(2) under the Securities Act) that was not included (including through incorporation by reference) in the Preliminary Prospectus, if any, or a previously filed Issuer Free Writing Prospectus, (ii) any Issuer Free Writing Prospectus listed on Annex A or prepared pursuant to Section 3(c) or Section 4(c) above (including any electronic road show), or (iii) any free writing prospectus prepared by such Underwriter and approved by the Company in advance in writing (each such free writing prospectus referred to in clauses (i) or (iii), an &#x201c;Underwriter Free Writing Prospectus&#x201d;).</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">27</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">It has not and will not, without the prior written consent of the Company, use any free writing prospectus that contains the final terms of the Securities unless such terms have previously been included in a free writing prospectus filed with the Commission; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> that Underwriters may use a term sheet substantially in the form of Annex C hereto without the consent of the Company; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided further</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> that any Underwriter using such term sheet shall notify the Company, and provide a copy of such term sheet to the Company, prior to, or substantially concurrently with, the first use of such term sheet.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">It is not subject to any pending proceeding under Section 8A of the Securities Act with respect to the offering (and will promptly notify the Company if any such proceeding against it is initiated during the Prospectus Delivery Period).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Conditions of Underwriters&#x2019; Obligations.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  The obligation of each Underwriter to purchase the Securities on the Closing Date as provided herein is subject to the performance by the Company of its covenants and other obligations hereunder and to the following additional conditions:</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Registration Compliance; No Stop Order.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  No order suspending the effectiveness of the Registration Statement shall be in effect, and no proceeding for such purpose or pursuant to Section 8A under the Securities Act shall be pending before or threatened by the Commission; the Prospectus and each Issuer Free Writing Prospectus shall have been timely filed with the Commission under the Securities Act (in the case of an Issuer Free Writing Prospectus, to the extent required by Rule 433 under the Securities Act) and in accordance with Section 4(a) hereof; and all requests by the Commission for additional information shall have been complied with to the reasonable satisfaction of the Representatives.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Representations and Warranties.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  The representations and warranties of the Company contained herein shall be true and correct on the date hereof and on and as of the Closing Date; and the statements of the Company and its officers made in any certificates delivered pursuant to this Agreement shall be true and correct on and as of the Closing Date.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Material Adverse Change.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  No event or condition of a type described in Section 3(i) hereof shall have occurred or shall exist, which event or condition is not described in the Pricing Disclosure Package (excluding any amendment or supplement thereto) and the Prospectus (excluding any amendment or supplement thereto) and the effect of which in the judgment of the Representatives makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Securities on the Closing Date on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Officers&#x2019; Certificate.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  The Representatives shall have received on and as of the Closing Date a certificate of the chief financial officer or chief </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">28</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">accounting officer of the Company and one additional senior executive officer of the Company who is satisfactory to the Representatives on behalf of the Company and not in their individual capacities (i) confirming that such officers have carefully reviewed the Registration Statement, the Pricing Disclosure Package and the Prospectus and, to the knowledge of such officers, the representations set forth in Sections 3(b) and 3(f) hereof are true and correct, (ii) confirming that the other representations and warranties of the Company in this Agreement are true and correct and that the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date and (iii) to the effect set forth in paragraphs (a), (b) and (c) above.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comfort Letters.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  On the date of this Agreement and on the Closing Date Ernst &amp; Young LLP shall have furnished to the Representatives, at the request of the Company, letters, dated the respective dates of delivery thereof and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives, containing statements and information of the type customarily included in accountants&#x2019; &#x201c;comfort letters&#x201d; to underwriters with respect to the financial statements and certain financial information contained or incorporated by reference in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus; provided, that the letter delivered on the Closing Date shall use a &#x201c;cut-off&#x201d; date no more than two business days prior to such Closing Date.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Opinion and 10b-5 Statement of Counsel for the Company.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  Latham &amp; Watkins LLP, counsel for the Company, shall have furnished to the Representatives, at the request of the Company, their written opinion and 10b-5 statement, dated the Closing Date and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(g)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Opinion of Intellectual Property Counsel for the Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  The Representatives shall have received an opinion, on and as of the Closing Date of Cooley LLP, intellectual property counsel for the Company, addressed to the Underwriters and in form and substance satisfactory to the Representatives.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(h)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Opinion and 10b-5 Statement of Counsel for the Underwriters.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  The Representatives shall have received on and as of the Closing Date an opinion and 10b-5 statement, addressed to the Underwriters, of Davis Polk &amp; Wardwell LLP, counsel for the Underwriters, with respect to such matters as the Representatives may reasonably request, and such counsel shall have received such documents and information as they may reasonably request to enable them to pass upon such matters.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Legal Impediment to Issuance and Sale.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  No action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date, prevent the issuance or sale of the Securities; and no injunction or order of any federal, state or foreign court shall </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">29</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">have been issued that would, as of the Closing Date prevent the issuance or sale of the Securities.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(j)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Good Standing</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  The Representatives shall have received on and as of the Closing Date satisfactory evidence of the good standing of the Company and its significant subsidiaries in their respective jurisdictions of organization and their good standing in such other jurisdictions as the Representatives may reasonably request, in each case in writing or any standard form of telecommunication from the appropriate governmental authorities of such jurisdictions. Notwithstanding the above, the Representatives agree and acknowledge that, to the extent requested, satisfactory evidence of good standing may not be readily, or entirely, available with respect to the Company&#x2019;s significant subsidiaries organized in the P.R.C. and the Company shall not be required to provide such evidence unless requested at least 10 business days prior to the Closing Date.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(k)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exchange Listing.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  The Shares to be delivered on the Closing Date and any Warrant Shares to be delivered upon exercise of the Warrants, shall have been approved for listing on the Nasdaq Market, subject to official notice of issuance.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(l)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lock-up Agreements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  The &#x201c;lock-up&#x201d; agreements, each substantially in the form of Exhibit A hereto, between you and certain shareholders, officers and directors of the Company relating to sales and certain other dispositions of shares of Stock or certain other securities, delivered to you on or before the date hereof, shall be in full force and effect on the Closing Date.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(m)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Additional Documents.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  On or prior to the Closing Date, the Company shall have furnished to the Representatives such further certificates and documents as the Representatives may reasonably request.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(n)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Form of Warrant.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  On or prior to the Closing Date, the Representatives shall have received a form of Warrant in form and substance reasonably satisfactory to the Representatives. </font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">All opinions, letters, certificates and evidence mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Underwriters.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Indemnification and Contribution</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Indemnification of the Underwriters.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  The Company agrees to indemnify and hold harmless each Underwriter, its affiliates, directors and officers and each person, if any, who controls such Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, from and against any and all losses, claims, damages and liabilities (including, without limitation, legal fees and other expenses incurred in connection with any suit, action or proceeding or any claim asserted, as such fees and expenses are incurred), joint or several, that arise out of, or are based upon, (i) </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">30</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">any untrue statement or alleged untrue statement of a material fact contained or incorporated by reference in the Registration Statement or caused by any omission or alleged omission to state therein a material fact required to be stated therein or necessary in order to make the statements therein, not misleading, or (ii) any untrue statement or alleged untrue statement of a material fact contained or incorporated by reference in the Prospectus (or any amendment or supplement thereto), any Preliminary Prospectus, any Issuer Free Writing Prospectus, any &#x201c;issuer information&#x201d; filed or required to be filed pursuant to Rule 433(d) under the Securities Act, any Written Testing-the-Waters Communication, any road show as defined in Rule 433(h) under the Securities Act (a &#x201c;road show&#x201d;) or any Pricing Disclosure Package (including any Pricing Disclosure Package that has subsequently been amended), or caused by any omission or alleged omission to state therein a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading, in each case except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in paragraph (b) below.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Indemnification of the Company.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors, its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act to the same extent as the indemnity set forth in paragraph (a) above, but only with respect to any losses, claims, damages or liabilities that arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to such Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration Statement, the Prospectus (or any amendment or supplement thereto), any Preliminary Prospectus, any Issuer Free Writing Prospectus, any Written Testing-the-Waters Communication, any road show or any Pricing Disclosure Package (including any Pricing Disclosure Package that has subsequently been amended), it being understood and agreed upon that the only such information furnished by any Underwriter consists of the following information in the Prospectus furnished on behalf of each Underwriter:  the concession and reallowance figures appearing in the third paragraph under the caption &#x201c;Underwriting&#x201d;, the information contained in the fifteenth, sixteenth and seventeenth paragraphs under the caption &#x201c;Underwriting&#x201d;.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Notice and Procedures.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  If any suit, action, proceeding (including any governmental or regulatory investigation), claim or demand shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to the preceding paragraphs of this Section 7, such person (the &#x201c;Indemnified Person&#x201d;) shall promptly notify the person against whom such indemnification may be sought (the &#x201c;Indemnifying Person&#x201d;) in writing; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have under the preceding </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">31</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">paragraphs of this Section 7 except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">further</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">, that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have to an Indemnified Person otherwise than under the preceding paragraphs of this Section 7.  If any such proceeding shall be brought or asserted against an Indemnified Person and it shall have notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified Person (who shall not, without the consent of the Indemnified Person, be counsel to the Indemnifying Person) to represent the Indemnified Person and any others entitled to indemnification pursuant to this Section that the Indemnifying Person may designate in such proceeding and shall pay the reasonable fees and expenses in such proceeding and shall pay the reasonable fees and expenses of such counsel related to such proceeding, as incurred.  In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless (i) the Indemnifying Person and the Indemnified Person shall have mutually agreed to the contrary; (ii) the Indemnifying Person has failed within a reasonable time to retain counsel reasonably satisfactory to the Indemnified Person; (iii) the Indemnified Person shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those available to the Indemnifying Person; or (iv) the named parties in any such proceeding (including any impleaded parties) include both the Indemnifying Person and the Indemnified Person and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them.  It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding or related proceeding in the same jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to any local counsel) for all Indemnified Persons, and that all such fees and expenses shall be paid or reimbursed as they are incurred.  Any such separate firm for any Underwriter, its affiliates, directors and officers and any control persons of such Underwriter shall be designated in writing by the Representatives and any such separate firm for the Company, its directors, its officers who signed the Registration Statement and any control persons of the Company shall be designated in writing by the Company.  The Indemnifying Person shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent, the Indemnifying Person agrees to indemnify each Indemnified Person from and against any loss or liability by reason of such settlement.  Notwithstanding the foregoing sentence, if at any time an Indemnified Person shall have requested that an Indemnifying Person reimburse the Indemnified Person for fees and expenses of counsel as contemplated by this paragraph, the Indemnifying Person shall be liable for any settlement of any proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by the Indemnifying Person of such request and (ii) the Indemnifying Person shall not have reimbursed the Indemnified Person in accordance with such request prior to the date of such settlement.  No Indemnifying Person shall, without the written consent of the Indemnified Person, effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person is or could have been a party and indemnification could have been sought hereunder by such Indemnified Person, unless such settlement (x) includes an unconditional release of such Indemnified Person, in form</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">32</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">and substance reasonably satisfactory to such Indemnified Person, from all liability on claims that are the subject matter of such proceeding and (y) does not include any statement as to or any admission of fault, culpability or a failure to act by or on behalf of any Indemnified Person.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contribution.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  If the indemnification provided for in paragraphs (a) or (b) above is unavailable to an Indemnified Person or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu of indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or payable by such Indemnified Person as a result of such losses, claims, damages or liabilities (i) in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters on the other, from the offering of the Securities or (ii) if the allocation provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) but also the relative fault of the Company, on the one hand, and the Underwriters on the other, in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations.  The relative benefits received by the Company, on the one hand, and the Underwriters on the other, shall be deemed to be in the same respective proportions as the net proceeds (before deducting expenses) received by the Company from the sale of the Securities and the total underwriting discounts and commissions received by the Underwriters in connection therewith, in each case as set forth in the table on the cover of the Prospectus, bear to the aggregate offering price of the Securities.  The relative fault of the Company, on the one hand, and the Underwriters on the other, shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or by the Underwriters and the parties&#x2019; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Limitation on Liability.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to paragraph (d) above were determined by </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">pro</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">rata</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take account of the equitable considerations referred to in paragraph (d) above.  The amount paid or payable by an Indemnified Person as a result of the losses, claims, damages and liabilities referred to in paragraph (d) above shall be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such Indemnified Person in connection with any such action or claim.  Notwithstanding the provisions of paragraphs (d) and (e), in no event shall an Underwriter be required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the offering of the Securities exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission.  No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.  The Underwriters&#x2019; obligations to contribute pursuant </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">33</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">to paragraphs (d) and (e) are several in proportion to their respective purchase obligations hereunder and not joint.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Non-Exclusive Remedies.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  The remedies provided for in this Section 7 paragraphs (a) through (e) are not exclusive and shall not limit any rights or remedies which may otherwise be available to any Indemnified Person at law or in equity.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Effectiveness of Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  This Agreement shall become effective as of the date first written above.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  This Agreement may be terminated in the absolute discretion of the Representatives, by notice to the Company, if after the execution and delivery of this Agreement and on or prior to the Closing Date (i) trading generally shall have been suspended or materially limited on or by any of the New York Stock Exchange or The Nasdaq Stock Market; (ii) trading of any securities issued or guaranteed by the Company shall have been suspended on any exchange or in any over-the-counter market; (iii) a general moratorium on commercial banking activities shall have been declared by federal or New York State authorities; or (iv) there shall have occurred any outbreak or escalation of hostilities or any change in financial markets or any calamity or crisis, either within or outside the United States, that, in the judgment of the Representatives, is material and adverse and makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Securities on the Closing Date on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">10.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Defaulting Underwriter</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">If, on the Closing Date, any Underwriter defaults on its obligation to purchase the Securities that it has agreed to purchase hereunder on such date, the non-defaulting Underwriters may in their discretion arrange for the purchase of such Securities by other persons satisfactory to the Company on the terms contained in this Agreement.  If, within 36 hours after any such default by any Underwriter, the non-defaulting Underwriters do not arrange for the purchase of such Securities, then the Company shall be entitled to a further period of 36 hours within which to procure other persons satisfactory to the non-defaulting Underwriters to purchase such Securities on such terms.  If other persons become obligated or agree to purchase the Securities of a defaulting Underwriter, either the non&#x2011;defaulting Underwriters or the Company may postpone the Closing Date for up to five full business days in order to effect any changes that in the opinion of counsel for the Company or counsel for the Underwriters may be necessary in the Registration Statement and the Prospectus or in any other document or arrangement, and the Company agrees to promptly prepare any amendment or supplement to the Registration Statement and the Prospectus that effects any such changes.  As used in this Agreement, the term &#x201c;Underwriter&#x201d; includes, for all purposes of this Agreement unless the context otherwise requires, any person not listed in Schedule 1 hereto that, pursuant to this Section 10, purchases Securities that a defaulting Underwriter agreed but failed to purchase.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">34</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">If, after giving effect to any arrangements for the purchase of the Securities of a defaulting Underwriter or Underwriters by the non-defaulting Underwriters and the Company as provided in paragraph (a) above, the aggregate number of Securities that remain unpurchased on the Closing Date does not exceed one-eleventh of the aggregate number of Securities to be purchased on such date, then the Company shall have the right to require each non-defaulting Underwriter to purchase the number of Securities that such Underwriter agreed to purchase hereunder on such date plus such Underwriter&#x2019;s pro rata share (based on the number of Securities that such Underwriter agreed to purchase on such date) of the Securities of such defaulting Underwriter or Underwriters for which such arrangements have not been made.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">If, after giving effect to any arrangements for the purchase of the Securities of a defaulting Underwriter or Underwriters by the non-defaulting Underwriters and the Company as provided in paragraph (a) above, the aggregate number of Securities that remain unpurchased on the Closing Date exceeds one-eleventh of the aggregate amount of Securities to be purchased on such date, or if the Company shall not exercise the right described in paragraph (b) above, then this Agreement shall terminate without liability on the part of the non-defaulting Underwriters.  Any termination of this Agreement pursuant to this Section 10 shall be without liability on the part of the Company, except that the Company will continue to be liable for the payment of expenses as set forth in Section 11 hereof and except that the provisions of Section 7 hereof shall not terminate and shall remain in effect.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Nothing contained herein shall relieve a defaulting Underwriter of any liability it may have to the Company or any non-defaulting Underwriter for damages caused by its default.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Payment of Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company will pay or cause to be paid all costs and expenses incident to the performance of its obligations hereunder, including without limitation, (i) the costs incident to the authorization, issuance, sale, preparation and delivery of the Securities and any taxes payable in that connection; (ii) the costs incident to the preparation, printing and filing under the Securities Act of the Registration Statement, the Preliminary Prospectus, if any, any Issuer Free Writing Prospectus, any Pricing Disclosure Package and the Prospectus (including all exhibits, amendments and supplements thereto) and the distribution thereof; (iii) the fees and expenses of the Company&#x2019;s counsel and independent accountants; (iv) the fees and expenses incurred in connection with the registration or qualification and determination of eligibility for investment of the Securities under the laws of such jurisdictions as the Representatives may designate and the preparation, printing and distribution of a Blue Sky Memorandum (including the related fees and expenses of counsel for the Underwriters); (v) the cost of preparing stock certificates; (vi) the costs and charges of any transfer agent and any registrar; (vii) all expenses and application fees incurred in connection with any filing with, and clearance of the offering by, FINRA; (viii) all expenses incurred by the Company in connection with any &#x201c;road show&#x201d; presentation to potential investors and (x) </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">35</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">all fees and expenses related to the listing of the Shares and the Warrant Shares on the Nasdaq Market; provided that the aggregate amount payable by the Company pursuant to clauses (iv) and (vii) (other than application fees paid by the Company directly to FINRA) shall not exceed $25,000.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">If (i) this Agreement is terminated pursuant to Section 9, (ii) the Company for any reason fails to tender the Securities for delivery to the Underwriters or (iii) the Underwriters decline to purchase the Securities for any reason permitted under this Agreement, the Company agrees to reimburse the Underwriters for all out-of-pocket costs and expenses (including the fees and expenses of their counsel) reasonably incurred by the Underwriters in connection with this Agreement and the offering contemplated hereby. For the avoidance of doubt, it is understood that the Company shall not pay or reimburse any costs, fees or expenses incurred by any Underwriter that defaults on its obligations to purchase the Securities.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">12.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Persons Entitled to Benefit of Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective successors and the officers and directors and any controlling persons referred to herein, and the affiliates of each Underwriter referred to in Section 7 hereof.  Nothing in this Agreement is intended or shall be construed to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein.  No purchaser of Securities from any Underwriter shall be deemed to be a successor merely by reason of such purchase.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">13.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Survival</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  The respective indemnities, rights of contribution, representations, warranties and agreements of the Company and the Underwriters contained in this Agreement or made by or on behalf of the Company or the Underwriters pursuant to this Agreement or any certificate delivered pursuant hereto shall survive the delivery of and payment for the Securities and shall remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company or the Underwriters or the directors, officers, controlling persons or affiliates referred to in Section 7 hereof.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">14.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Certain Defined Terms</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  For purposes of this Agreement, (a) except where otherwise expressly provided, the term &#x201c;affiliate&#x201d; has the meaning set forth in Rule 405 under the Securities Act; (b) the term &#x201c;business day&#x201d; means any day other than a day on which banks are permitted or required to be closed in New York City; and (c) the term &#x201c;subsidiary&#x201d; has the meaning set forth in Rule 405 under the Securities Act; and (d) the term &#x201c;significant subsidiary&#x201d; has the meaning set forth in Rule 1-02 of Regulation S-X under the Exchange Act. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">36</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">15.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Compliance with USA Patriot Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">. In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including the Company, which information may include the name and address of their respective clients, as well as other information that will allow the Underwriters to properly identify their respective clients.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">16.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Miscellaneous</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Notices.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or transmitted and confirmed by any standard form of telecommunication.  Notices to the Underwriters shall be given to the Representatives c/o Cowen and Company, LLC, Attention: Head of Equity Capital Markets (fax: (646) 562-1249), with a copy to the General Counsel (fax: (646) 562-1130).  Notices to the Company shall be given to it at Terns Pharmaceuticals, Inc., 1065 East Hillsdale, Suite 100, Attention: Chief Executive Officer and General Counsel, and a copy (which shall not constitute notice) to Latham &amp; Watkins LLP, 140 Scott Drive, Menlo Park, California 94025, Attention: Brian Cuneo.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Governing Law.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  This Agreement and any claim, controversy or dispute arising under or related to this Agreement shall be governed by and construed in accordance with the laws of the State of New York. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Waiver of Jury Trial.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  Each of the parties hereto hereby waives any right to trial by jury in any suit or proceeding arising out of or relating to this Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recognition of the U.S. Special Resolution Regimes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">. </font></div></div>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(i) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(ii) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">As used in this Section 16(g):</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;BHC Act Affiliate&#x201d; has the meaning assigned to the term &#x201c;affiliate&#x201d; in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">37</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Covered Entity&#x201d; means any of the following:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:16.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(i) a &#x201c;covered entity&#x201d; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b);</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:16.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(ii) a &#x201c;covered bank&#x201d; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:16.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(iii) a &#x201c;covered FSI&#x201d; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Default Right&#x201d; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;U.S. Special Resolution Regime&#x201d; means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Counterparts.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  This Agreement may be signed in counterparts (which may include counterparts delivered by any standard form of telecommunication), each of which shall be an original and all of which together shall constitute one and the same instrument.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The words &#x201c;execution,&#x201d; &#x201c;signed,&#x201d; &#x201c;signature,&#x201d; and words of like import in this Agreement or in any other certificate, agreement or document related to this Agreement, if any, shall include images of manually executed signatures transmitted by facsimile or other electronic format (including, without limitation, &#x201c;pdf,&#x201d; &#x201c;tif&#x201d; or &#x201c;jpg&#x201d;) and other electronic signatures (including, without limitation, DocuSign and AdobeSign). The use of electronic signatures and electronic records (including, without limitation, any contract or other record created, generated, sent, communicated, received, or stored by electronic means) shall be of the same legal effect, validity and enforceability as a manually executed signature or use of a paper-based record-keeping system to the fullest extent permitted by applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act and any other applicable law, including, without limitation, any state law based on the Uniform Electronic Transactions Act or the Uniform Commercial Code.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Amendments or Waivers.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  No amendment or waiver of any provision of this Agreement, nor any consent or approval to any departure therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(g)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Headings.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  The headings herein are included for convenience of reference only and are not intended to be part of, or to affect the meaning or interpretation of, this Agreement.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">38</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">If the foregoing is in accordance with your understanding, please indicate your acceptance of this Agreement by signing in the space provided below.</font></p>
  <p style="margin-left:45.0%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Very truly yours,</font></p>
  <p style="margin-left:45.0%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">TERNS PHARMACEUTICALS, INC.</font></p>
  <p style="margin-left:45.0%;text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">By:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">/s/ Mark Vignola	<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">      Name: Mark Vignola<br>      Title: Chief Financial Officer</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Accepted:  As of the date first written above</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">COWEN AND COMPANY, LLC</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">For themselves and on behalf of the<br>several Underwriters listed<br>in Schedule 1 hereto.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">COWEN AND COMPANY, LLC</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">By:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">/s/ Tanya Joseph		<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">	Name: Tanya Joseph<br>	Title: Managing Director</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">39</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Schedule 1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:35.383%;"></td>
    <td style="width:32.32%;"></td>
    <td style="width:32.297%;"></td>
   </tr>
   <tr style="height:22.3pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Underwriter</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Number of Warrants</font></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Cowen and Company, LLC</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">10,412,500</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">12,435,500</font></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">UBS Securities LLC</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">1,837,500</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">2,194,500</font></p></td>
   </tr>
   <tr style="height:23.05pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Total</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">12,250,000</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">14,630,000</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">40</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Annex A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">a.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Pricing Disclosure Package</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Free Writing Prospectus containing Form of Warrant attached hereto as Exhibit B</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">b.  	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Pricing Information Provided Orally by Underwriters</font></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Total Number of Shares and Warrants Sold: 26,880,000</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Shares: 12,250,000</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Public Offering Price Per Share: $2.4200</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Warrants: 14,630,000</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Public Offering Price Per Warrant: $2.4199</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The number of shares and warrants to be issued may be reallocated among shares or warrants such that the aggregate number of shares and warrants issued does not exceed 26,880,000.</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Exercise Price for the Warrants: $0.0001</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">41</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Annex B</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Written Testing-the-Waters Communications<br><br>None.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">42</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Annex C</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Terns Pharmaceuticals, Inc.<br><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Pricing Term Sheet</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"><br><br>None.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">43</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">FORM OF LOCK-UP AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">August [</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;min-width:fit-content;">&#xf0b7;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Cowen and Company, LLC<br><br>As Representatives of <br>the several Underwriters listed in <br>Schedule 1 to the Underwriting<br>Agreement referred to below</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">c/o Cowen and Company, LLC</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">599 Lexington Avenue</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">New York, NY 10022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Re:	Terns Pharmaceuticals, Inc. --- Public Offering</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Ladies and Gentlemen:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The undersigned understands that you, each as one of several representatives (the &#x201c;Representatives&#x201d;) of the several Underwriters, propose to enter into an underwriting agreement (the &#x201c;Underwriting Agreement&#x201d;) with Terns Pharmaceuticals, Inc., a Delaware corporation (the &#x201c;Company&#x201d;), providing for the public offering (the &#x201c;Public Offering&#x201d;) by the several Underwriters named in Schedule 1 to the Underwriting Agreement (the &#x201c;Underwriters&#x201d;), of common stock, par value $0.0001 per share (&#x201c;Common Stock&#x201d;), of the Company and pre-funded warrants to purchase shares of common stock of the Company (the &#x201c;Securities&#x201d;). Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Underwriting Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">To the extent that there are no additional Underwriters other than you listed on Schedule 1 to the Underwriting Agreement, all references to the Representatives and the Underwriters shall refer to you, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">In consideration of the Underwriters&#x2019; agreement to purchase and make the Public Offering of the Securities, and for other good and valuable consideration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> the</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:14.0pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">receipt of which is hereby acknowledged, the undersigned hereby agrees that, without the prior written consent of the Representatives on behalf of the Underwriters, the undersigned will not, and will not cause any direct or indirect affiliate to, during the period beginning on the date of this letter agreement (this &#x201c;Letter Agreement&#x201d;) and ending at the close of business 60 days after the date of the final prospectus relating to the Public Offering (the &#x201c;Prospectus&#x201d;) (such period, the &#x201c;Restricted Period&#x201d;), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">44</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock (including without limitation, Common Stock or such other securities which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission and securities which may be issued upon exercise of a stock option or warrant) (collectively with the Common Stock, &#x201c;Lock-Up Securities&#x201d;),   (2) enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any of the economic consequences of ownership of the Lock-Up Securities, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Lock-Up Securities, in cash or otherwise, (3) make any demand for or exercise any right with respect to the registration of any Lock-Up Securities, or (4) publicly disclose the intention to do any of the foregoing.  The undersigned acknowledges and agrees that the foregoing precludes the undersigned from engaging in any hedging or other transactions or arrangements (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) designed or intended, or which could reasonably be expected to lead to or result in, a sale or disposition or transfer (whether by the undersigned or any other person) of any economic consequences of ownership, in whole or in part, directly or indirectly, of any Lock-Up Securities, whether any such transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of Lock-Up Securities, in cash or otherwise.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, the undersigned may:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(a)  transfer or dispose of the undersigned&#x2019;s Lock-Up Securities:</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(i) as a bona fide gift or gifts, or for bona fide estate planning purposes,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(ii) by will, other testamentary document or intestacy,</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(iii) to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned, or if the undersigned is a trust, to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust (for purposes of this Letter Agreement, &#x201c;immediate family&#x201d; shall mean any relationship by blood, current or former marriage, domestic partnership or adoption, not more remote than first cousin),</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(iv) to a partnership, limited liability company or other entity of which the undersigned and the immediate family of the undersigned are the legal and beneficial owner of all of the outstanding equity securities or similar interests,</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(v) to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses (i) through (iv) above,</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(vi) if the undersigned is a corporation, partnership, limited liability company, trust or other business entity, (A) to another corporation, partnership, limited liability company, trust or other business entity that is an affiliate (as defined in Rule 405 promulgated under the Securities Act of 1933, as amended) of the undersigned, or to any investment fund or other entity controlling, controlled by, managing or managed by or</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">45</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">under common control with the undersigned or affiliates of the undersigned (including, for the avoidance of doubt, where the undersigned is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), or (B) as part of a distribution to members, partners,  shareholders or other equity holders of the undersigned,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(vii) by operation of law, such as pursuant to a qualified domestic order, divorce settlement, divorce decree, separation agreement or other court order,</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(viii) to the Company from an employee or other service provider of the Company upon death, disability or termination of employment or service, in each case, of such employee or service provider,</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(ix)  as part of a sale of the undersigned&#x2019;s Lock-Up Securities acquired (A) in open market transactions after the closing date for the Public Offering or (B) from the Underwriters in the Public Offering,</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(x) to the Company in connection with the vesting, settlement, or exercise of restricted stock units, options, warrants or other rights to purchase shares of Common Stock (including, in each case, by way of &#x201c;net&#x201d; or &#x201c;cashless&#x201d; exercise), including for the payment of exercise price and tax and remittance payments due as a result of the vesting, settlement, or exercise of such restricted stock units, options, warrants or rights, provided that any such shares of Common Stock received upon such exercise, vesting or settlement shall be subject to the terms of this Letter Agreement, and provided further that any such restricted stock units, options, warrants or rights are held by the undersigned pursuant to an agreement or equity awards granted under a stock incentive plan or other equity award plan, each such agreement or plan which is described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, or filed as an exhibit to the Registration Statement, or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(xi) pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction that is approved by the Board of Directors of the Company and made to all holders of the Company&#x2019;s capital stock involving a Change of Control (as defined below) of the Company (for purposes hereof, &#x201c;Change of Control&#x201d; shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons, of shares of capital stock if, after such transfer, such person or group of affiliated persons would hold more than 50% of the outstanding voting securities of the Company (or the surviving entity)); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> that in the event that such tender offer, merger, consolidation or other similar transaction is not completed, the undersigned&#x2019;s Lock-Up Securities shall remain subject to the provisions of this Letter Agreement;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> that (A) in the case of any transfer, distribution or other disposition pursuant to clause (a)(i), (ii), (iii), (iv), (v), (vi) and (vii), such transfer shall not involve a disposition for value and each donee, devisee, transferee or distributee shall execute and deliver to the Representatives a lock-up letter in the form of this Letter Agreement, (B) in the case of any transfer, distribution or disposition pursuant to clauses (a)(i), (ii), (iii), (iv), (v),</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">46</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(vi), and (x), no filing by any party (donor, donee, devisee, transferor, transferee, distributer or distributee) under the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), or other public announcement shall be required or shall be made voluntarily in connection with such transfer or distribution (other than a filing on a Form 5 made after the expiration of the Restricted Period referred to above) and (C) in the case of any transfer or distribution pursuant to clauses (a)(vii) and (viii) it shall be a condition to such transfer that no public filing, report or announcement shall be voluntarily made and if any filing under Section 16(a) of the Exchange Act, or other public filing, report or announcement reporting a reduction in beneficial ownership of shares of Common Stock in connection with such transfer or distribution shall be legally required during the Restricted Period, such filing, report or announcement shall clearly indicate in the footnotes thereto the nature and conditions of such transfer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(b)  exercise outstanding options, settle restricted stock units or other equity awards or exercise warrants pursuant to plans described in the Registration Statement, the Pricing Disclosure Package and the Prospectus; provided that any Lock-up Securities received upon such exercise, vesting or settlement shall be subject to the terms of this Letter Agreement;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(c) convert outstanding preferred stock, warrants to acquire preferred stock or convertible securities into shares of Common Stock or warrants to acquire shares of Common Stock; provided that any such shares of Common Stock or warrants received upon such conversion shall be subject to the terms of this Letter Agreement;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(d) establish or amend existing trading plans pursuant to Rule 10b5-1 under the Exchange Act for the transfer or disposition of shares of Lock-Up Securities; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> that (1) such plans do not provide for the transfer or disposition of Lock-Up Securities during the Restricted Period and (2) no filing by any party under the Exchange Act or other public announcement shall be required or made voluntarily in connection with such trading plan during the Restricted Period in contravention of this Lock-Up Agreement; and</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(e) sell Lock-Up Securities under existing trading plans pursuant to Rule 10b5-1 under the Exchange Act; provided that any filing, report or announcement shall clearly indicate in the footnotes thereto the nature and conditions of such transfer.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">If the undersigned is not a natural person, the undersigned represents and warrants that no single natural person, entity or &#x201c;group&#x201d; (within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;)) beneficially owns, directly or indirectly, 50% or more of the common equity interests, or 50% or more of the voting power, in the undersigned.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">In furtherance of the foregoing, the Company, and any duly appointed transfer agent for the registration or transfer of the securities described herein, are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this Letter Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">47</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Letter Agreement.  All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The undersigned acknowledges and agrees that the Underwriters have not provided any recommendation or investment advice nor have the Underwriters solicited any action from the undersigned with respect to the Public Offering of the Securities and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to the extent deemed appropriate. The undersigned further acknowledges and agrees that, although the Representatives may be required or choose to provide certain Regulation Best Interest and Form CRS disclosures to you in connection with the Public Offering, the Representatives and the other Underwriters are not making a recommendation to you to enter into this Letter Agreement, and nothing set forth in such disclosures is intended to suggest that the Representatives or any Underwriter is making such a recommendation.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The undersigned understands that, if either (i) the Representatives, on the one hand, or the Company, on the other hand, informs the other, prior to the execution of the Underwriting Agreement, that it has determined not to proceed with the Public Offering, (ii) the Registration Statement is withdrawn, prior to the execution of the Underwriting Agreement, (iii) the Underwriting Agreement does not become effective by August 31, 2022, (iv) the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Common Stock to be sold thereunder, or (v) the Restricted Period has expired, this Letter Agreement shall automatically terminate and be of no further force and effect and the undersigned shall be released from all obligations under this Letter Agreement.  The undersigned understands that the Underwriters are entering into the Underwriting Agreement and proceeding with the Public Offering in reliance upon this Letter Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">48</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">This Letter Agreement and any claim, controversy or dispute arising under or related to this Letter Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to conflict of law principles thereof.</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Very truly yours,</font></p>
  <p style="margin-left:40.0%;text-indent:11.111%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="margin-left:40.0%;text-indent:11.111%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="margin-left:40.0%;text-indent:11.111%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="margin-left:40.0%;text-indent:11.111%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">By: ______________________</font></p>
  <p style="margin-left:40.0%;text-indent:11.111%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Name:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:40.0%;text-indent:11.111%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Title:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">49</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">TERNS PHARMACEUTICALS, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">WARRANT TO PURCHASE COMMON STOCK</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares: [_________]</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">(subject to adjustment)</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:51.001%;"></td>
    <td style="width:0.996%;"></td>
    <td style="width:48.003%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Warrant No. [___]						 Original Issue Date: August [___], 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	Terns Pharmaceuticals, Inc., a Delaware corporation (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [___________] or its registered assigns (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Holder</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) is entitled, subject to the terms set forth below, to purchase from the Company up to a total of [______] shares of common stock, $0.0001 par value per share (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Common Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), of the Company (each such share, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Warrant Share</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; and all such shares, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Warrant Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) at an exercise price per share equal to $0.0001 per share (as adjusted from time to time as provided in Section 9 herein, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Exercise Price</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) upon surrender of this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Warrant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) at any time and from time to time on or after the date hereof (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Original Issue Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), subject to the following terms and conditions:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	1. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Definitions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. For purposes of this Warrant, the following terms shall have the following meanings:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(a) &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Affiliate</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any Person directly or indirectly controlled by, controlling or under common control with, a Holder, as such terms are used in and construed under Rule 405 under the Securities Act, but only for so long as such control shall continue.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(b) &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Commission</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the United States Securities and Exchange Commission.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(c) &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Closing Sale Price</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, for any security as of any date, the last trade price for such security on the Principal Trading Market for such security, as reported by Bloomberg L.P., or, if such Principal Trading Market begins to operate on an extended hours basis and does not designate the last trade price, then the last trade price of such security prior to 4:00 P.M., New York City time, as reported by Bloomberg L.P., or if the security is not listed for trading on a national securities exchange or other trading market on the relevant date, the last quoted bid price for the security in the over-the-counter market on the relevant date as reported by OTC Markets Group Inc. (or a similar organization or agency succeeding to its functions of reporting prices). If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then the Board of Directors of the Company shall use its good faith judgment to determine the fair market value. The Board of Directors&#x2019; determination shall be binding upon all parties absent demonstrable error. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(d) &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Marketable Securities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means securities meeting all of the following requirements: (i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Exchange Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and is then current in its filing of all required reports and other information under the Securities Act and the Exchange Act; (ii) the class and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">50</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">series of shares or other security of the issuer that would be received by Holder in connection with the Fundamental Transaction (as defined below) were Holder to exercise this Warrant on or prior to the closing thereof is then traded or quoted on a nationally recognized securities exchange, inter-dealer quotation system or over-the-counter market, and (iii) following the closing of such Fundamental Transaction, the Holder would not be restricted from publicly re-selling all of the issuer&#x2019;s shares and/or other securities that would be received by the Holder in such Fundamental Transaction were the Holder to exercise or convert this Warrant in full on or prior to the closing of such Fundamental Transaction.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(e) &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Principal Trading Market</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the national securities exchange or other trading market on which the Common Stock is primarily listed on and quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Global Select Market.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(f) &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Company&#x2019;s Registration Statement on Form S-3 (File No. 333-263370), that became effective on March 14, 2022.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(g) &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Securities Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Securities Act of 1933, as amended.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(h) &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Trading Day</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any weekday on which the Principal Trading Market is open for trading. If the Common Stock is not listed or admitted for trading, &#x201c;Trading Day&#x201d; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in New York City are authorized or required by law or other governmental action to close.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(i) &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Transfer Agent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Computershare Trust Company, N.A., the Company&#x2019;s transfer agent and registrar for the Common Stock, and any successor appointed in such capacity.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	2. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Issuance of Securities; Registration of Warrants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. The Warrant, as initially issued by the Company, is offered and sold pursuant to the Registration Statement. As of the Original Issue Date, the Warrant Shares are issuable under the Registration Statement. Accordingly, the Warrant and, assuming issuance pursuant to the Registration Statement or an exchange meeting the requirements of Section 3(a)(9) of the Exchange Act as in effect on the Original Issue Date, the Warrant Shares, are not &#x201c;restricted securities&#x201d; under Rule 144 promulgated under the Securities Act. The Company shall register ownership of this Warrant, upon records to be maintained by the Company for that purpose (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Warrant Register</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), in the name of the record Holder (which shall include the initial Holder or, as the case may be, any assignee to which this Warrant is assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	3. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Registration of Transfers</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. Subject to compliance with all applicable securities laws, the Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer taxes (if any). Upon any such registration or transfer, a new warrant to purchase Common Stock in substantially the form of this Warrant (any such new warrant, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">New Warrant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue and deliver at the Company&#x2019;s own expense any New Warrant under this Section 3. Until due presentment for registration of transfer, the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">51</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Company may treat the registered Holder hereof as the owner and holder for all purposes, and the Company shall not be affected by any notice to the contrary.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	4. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exercise and Duration of Warrants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(a) All or any part of this Warrant shall be exercisable by the registered Holder in the manner set forth in Section 10 at any time and from time to time on or after the Original Issue Date.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(b) The Holder may exercise this Warrant by delivering to the Company an exercise notice, in the form attached as Schedule 1 hereto (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Exercise Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), completed and duly signed. The date on which such exercise notice is delivered to the Company (as determined in accordance with the notice provisions hereof) is an </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Exercise Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">.&#x201d; The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares, if any. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	5. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Delivery of Warrant Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(a) Upon exercise of this Warrant, the Company shall promptly (but in no event later than three (3) Trading Days after the Exercise Date), upon the request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to such exercise to the Holder&#x2019;s or its designee&#x2019;s balance account with The Depository Trust Company (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">DTC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) through its Deposit Withdrawal Agent Commission system, or if the Transfer Agent is not participating in the Fast Automated Securities Transfer Program or if the certificates are required to bear a legend regarding restriction on transferability, issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Company&#x2019;s share register in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise. The Holder, or any natural person or legal entity (each, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Person</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) so designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective of the date such Warrant Shares are credited to the Holder&#x2019;s DTC account or the date of delivery of the certificates evidencing such Warrant Shares, as the case may be.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(b) If by the close of the third (3rd) Trading Day after the Exercise Date, the Company fails to deliver to the Holder a certificate representing the required number of Warrant Shares in the manner required pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Section 5(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> or fails to credit the Holder&#x2019;s DTC account for such number of Warrant Shares to which the Holder is entitled, and if after such third (3rd) Trading Day and prior to the receipt of such Warrant Shares, the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Buy-In</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), then the Company shall, within three (3) Trading Days after the Holder&#x2019;s request promptly honor its obligation to deliver to the Holder a certificate or certificates representing such Warrant Shares and pay cash to the Holder in an amount equal to the excess (if any) of Holder&#x2019;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased in the Buy-In less the product of (A) the number of shares of Common Stock purchased in the Buy-In, times (B) the Closing Sale Price of a share of Common Stock on the Exercise Date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">52</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(c) To the extent permitted by law and subject to Section 5(b), the Company&#x2019;s obligations to issue and deliver Warrant Shares in accordance with and subject to the terms hereof (including the limitations set forth in Section 11 below) are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Subject to Section 5(b), nothing herein shall limit the Holder&#x2019;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#x2019;s failure to timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	6. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Charges, Taxes and Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. Issuance and delivery of certificates for shares of Common Stock upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp duties) in respect of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares or the Warrants in a name other than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	7. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Replacement of Warrant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case) and, in each case, a customary and reasonable indemnity and surety bond, if requested by the Company. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company&#x2019;s obligation to issue the New Warrant.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	8. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reservation of Warrant Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. The Company covenants that it will, at all times while this Warrant is outstanding, reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into account the adjustments and restrictions of Section 9). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and non-assessable. The Company will take all such action as may be reasonably necessary to assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed. The Company further covenants that it will not, without the prior written consent of the Holder, take any actions to increase the par value of the Common Stock at any time while this Warrant is outstanding.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">53</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	9. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Certain Adjustments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Number of Warrant Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) are subject to adjustment from time to time as set forth in this Section 9.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Stock Dividends and Splits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. If the Company, at any time while this Warrant is outstanding, (i) pays a stock dividend on its Common Stock that is payable in shares of Common Stock, (ii) subdivides its outstanding shares of Common Stock into a larger number of shares of Common Stock, (iii) combines its outstanding shares of Common Stock into a smaller number of shares of Common Stock or (iv) issues by reclassification of shares of capital stock any additional shares of Common Stock of the Company, then in each such case the Number of Warrant Shares shall be multiplied by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately after such event and the denominator of which shall be the number of shares of Common Stock outstanding immediately before such event. Any adjustment made pursuant to clause (i) of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution, provided, however, that if such record date shall have been fixed and such dividend is not fully paid on the date fixed therefor, the Number of Warrant Shares shall be recomputed accordingly as of the close of business on such record date and thereafter the Number of Warrant Shares shall be adjusted pursuant to this paragraph as of the time of actual payment of such dividends. Any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately after the effective date of such subdivision or combination.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Pro Rata Distributions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. If the Company, at any time while this Warrant is outstanding, distributes to all holders of Common Stock for no consideration (i) evidences of its indebtedness, (ii) any security (other than a distribution of Common Stock covered by the preceding paragraph), (iii) rights or warrants to subscribe for or purchase any security (including Common Stock), or (iv) cash or any other asset (in each case, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Distribution</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), other than a reclassification as to which Section 9(c) applies, then in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the ownership limitation set forth in Section 11(a) hereof) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Common Stock are to be determined for the participation in such Distribution;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">, to the extent that the Holder&#x2019;s right to participate in any such Distribution would result in the Holder exceeding the ownership limitation set forth in Section 11(a) hereof, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as the delivery to such Holder of such portion would not result in the Holder exceeding the ownership limitation set forth in Section 11(a) hereof.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(c) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Fundamental Transactions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. If, at any time while this Warrant is outstanding (i) the Company effects any merger or consolidation of the Company with or into another Person, in which the Company is not the surviving entity, (ii) the Company effects any sale to another Person of all or substantially all of its assets in one transaction or a series of related transactions, (iii) pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders of capital stock tender shares representing more than 50% of the voting power of the capital stock of the Company and the Company or such other Person, as applicable, accepts such tender for payment, (iv) the Company consummates a stock purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the voting power of the capital stock of the Company (except for any such transaction in which the stockholders of the Company immediately prior to such transaction</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">54</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">maintain, in substantially the same proportions, the voting power of such Person immediately after the transaction) or (v) the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by Section 9(a) above) (in any such case, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Fundamental Transaction</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), then following such Fundamental Transaction the Holder shall have the right to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the Number of Warrant Shares (in the case of clause (iii) above, assuming it had tendered, and the offeror had accepted, such Warrant Shares) (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Alternate Consideration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The Company shall not effect any Fundamental Transaction in which the Company is not the surviving entity or the Alternate Consideration includes securities of another Person unless (i) the Alternate Consideration is solely cash and the Company provides for the simultaneous &#x201c;cashless exercise&#x201d; of this Warrant pursuant to Section 10 below or (ii) prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity or other Person (including any purchaser of assets of the Company) shall assume the obligation to deliver to the Holder such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under this Warrant. The provisions of this paragraph (c) shall similarly apply to subsequent transactions analogous of a Fundamental Transaction type. Notwithstanding the foregoing, in the event of a Fundamental Transaction where the consideration payable to holders of Common Stock consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities, then this Warrant shall automatically be deemed to be exercised in full in a &#x201c;cashless exercise&#x201d; pursuant to Section 10 below effective immediately prior to and contingent upon the consummation of such Fundamental Transaction. 		</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(d) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Exercise Price</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. Simultaneously with any adjustment to the Number of Warrant Shares pursuant to Section 9 the Exercise Price shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the increased or decreased Number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment. Notwithstanding the foregoing, in no event may the Exercise Price be adjusted below the par value of the Common Stock then in effect.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(e) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Calculations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. All calculations under this Section 9 shall be made to the nearest one-hundredth of one cent or the nearest whole share, as applicable.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(f) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Notice of Adjustments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. Upon the occurrence of each adjustment pursuant to this Section 9, the Company at its expense will, at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Company&#x2019;s transfer agent.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(g) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Notice of Corporate Events</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. If, while this Warrant is outstanding, the Company (i) declares a dividend or any other distribution of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the Company or any subsidiary, (ii) authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii) authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company, then, except if such notice and the contents thereof shall be deemed to constitute material non-public information, the Company shall</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">55</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">deliver to the Holder a notice of such transaction at least ten (10) days prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction; provided, however, that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action required to be described in such notice. In addition, if while this Warrant is outstanding, the Company authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction contemplated by Section 9(c), other than a Fundamental Transaction under clause (iii) of Section 9(c), then, except if such notice and the contents thereof shall be deemed to constitute material non-public information, the Company shall deliver to the Holder a notice of such Fundamental Transaction at least ten (10) days prior to the date such Fundamental Transaction is consummated.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	10. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cashless Exercise</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. Notwithstanding anything contained herein to the contrary, this Warrant may only be exercised through a &#x201c;cashless exercise.&#x201d; Upon exercise, the Company shall issue to the Holder the number of Warrant Shares in an exchange of securities effected pursuant to Section 3(a)(9) of the Securities Act as determined as follows:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:8.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		X = Y [(A-B)/A]</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:8.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">where:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:8.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;X&#x201d; equals the number of Warrant Shares to be issued to the Holder;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:8.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Y&#x201d; equals the total number of Warrant Shares with respect to which this Warrant is then being exercised;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:8.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;A&#x201d; equals the Closing Sale Price per share of Common Stock as of the Trading Day on the date immediately preceding the Exercise Date; and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:8.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;B&#x201d; equals the Exercise Price per Warrant Share then in effect on the Exercise Date.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued in such a &#x201c;cashless exercise&#x201d; transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally issued (provided that the Commission continues to take the position that such treatment is proper at the time of such exercise).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	In no event will the exercise of this Warrant be settled in cash.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	11. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Limitations on Exercise</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(a) Notwithstanding anything to the contrary contained herein, the Company shall not effect any exercise of this Warrant, and the Holder shall not be entitled to exercise this Warrant for a number of Warrant Shares in excess of that number of Warrant Shares which, upon giving effect or immediately prior to such exercise, would cause (i) the aggregate number of shares of Common Stock beneficially owned by the Holder, its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#x2019;s for purposes of Section 13(d) of the Exchange Act to exceed 4.99% (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Maximum Percentage</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of the total number of issued and outstanding shares of Common Stock of the Company following such exercise, or (ii) the combined voting power of the securities of the Company beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#x2019;s for purposes of Section 13(d) of the Exchange Act to exceed 4.99% of the combined voting power of all of the securities of the Company then</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">56</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">outstanding following such exercise. For purposes of this Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x) the Company&#x2019;s most recent Form 10-Q or Form 10-K, as the case may be, filed with the Commission prior to the date hereof, (y) a more recent public announcement by the Company or (z) any other notice by the Company or its transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written request of the Holder, the Company shall within three (3) Trading Days confirm in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder since the date as of which such number of outstanding shares of Common Stock was reported. By written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other percentage specified not in excess of 19.99% specified in such notice; provided that any such increase will not be effective until the sixty-first (61st) day after such notice is delivered to the Company. For purposes of this Section 11(a), the aggregate number of shares of Common Stock or voting securities beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#x2019;s for purposes of Section 13(d) of the Exchange Act shall include the shares of Common Stock issuable upon the exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (x) exercise of the remaining unexercised and non-cancelled portion of this Warrant by the Holder and (y) exercise or conversion of the unexercised, non-converted or non-cancelled portion of any other securities of the Company that do not have voting power (including without limitation any securities of the Company which would entitle the holder thereof to acquire at any time Common Stock, including without limitation any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock), is subject to a limitation on conversion or exercise analogous to the limitation contained herein and is beneficially owned by the Holder or any of its Affiliates and other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#x2019;s for purposes of Section 13(d) of the Exchange Act.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(b) This Section 11 shall not restrict the number of shares of Common Stock which a Holder may receive or beneficially own in order to determine the amount of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction as contemplated in Section 9(c) of this Warrant.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	12. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Fractional Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash the fair market value (based on the Closing Sale Price) for any such fractional shares.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	13. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Notices</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. Any and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via confirmed e-mail prior to 5:30 P.M., New York City time, on a Trading Day, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered via confirmed e-mail on a day that is not a Trading Day or later than 5:30 P.M., New York City time, on any Trading Day, (iii) the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service specifying next business day delivery, or (iv) upon actual receipt by the Person to whom such notice is required to be given, if by hand delivery. The addresses and e-mail addresses for such communications shall be:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">If to the Company:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Terns Pharmaceuticals, Inc.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">57</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">1065 East Hillsdale Blvd.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Suite 100</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Foster City, California 94404</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Attention: General Counsel</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Telephone: [     ]</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Email: [     ]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">If to the Holder, to its address or e-mail address set forth herein or on the books and records of the Company.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	Or, in each of the above instances, to such other address or e-mail address as the recipient party has specified by written notice given to each other party at least five (5) days prior to the effectiveness of such change.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	14. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrant Agent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. The Company shall initially serve as warrant agent under this Warrant. Upon ten (10) days&#x2019; notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder&#x2019;s last address as shown on the Warrant Register.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	15. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Miscellaneous</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">No Rights as a Stockholder</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. The Holder, solely in such Person&#x2019;s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person&#x2019;s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Authorized Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and non-assessable Warrant Shares upon the exercise of this Warrant, and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">58</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> 		(c) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Successors and Assigns</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. Subject to compliance with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company without the written consent of the Holder, except to a successor in the event of a Fundamental Transaction. This Warrant shall be binding on and inure to the benefit of the Company and the Holder and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(d) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Amendment and Waiver</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. Except as otherwise provided herein, this Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(e) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Acceptance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(f) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Governing Law; Jurisdiction</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(g) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Headings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(h) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Severability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">59</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">60</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of the date first indicated above.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="margin-left:40.0%;text-indent:11.111%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">TERNS PHARMACEUTICALS, INC.</font></p>
  <p style="margin-left:40.0%;text-indent:11.111%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">By:________________________________<br>            Name:<br>            Title:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Signature Page to Warrant Agreement</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">SCHEDULE 1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">FORM OF EXERCISE NOTICE</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">[To be executed by the Holder to purchase shares of Common Stock under the Warrant]</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Ladies and Gentlemen:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(1) The undersigned is the Holder of Warrant No. ___ (the &#x201c;Warrant&#x201d;) issued by Terns Pharmaceuticals, Inc., a Delaware corporation (the &#x201c;Company&#x201d;). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(2) The undersigned hereby exercises its right to purchase ___________ Warrant Shares pursuant to the Warrant.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(3) The Holder intends that payment of the Exercise Price shall be made as a &#x201c;Cashless Exercise&#x201d; under Section 10 of the Warrant.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(4) Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in accordance with the terms of the Warrant. The Warrant Shares shall be delivered to the following DWAC Account Number:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(5) By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under Section 11(a) of the Warrant to which this notice relates.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:33.029%;"></td>
    <td style="width:0.994%;"></td>
    <td style="width:65.977%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Dated:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Name of Holder:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(Signature must conform in all respects to name of Holder as specified on the face of the Warrant)</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">62</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>tern-ex4_1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<html>
 <head>
  <title>EX-4.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 4.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">TERNS PHARMACEUTICALS, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">WARRANT TO PURCHASE COMMON STOCK</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares: [_________]</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">(subject to adjustment)</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:51.001%;"></td>
    <td style="width:0.996%;"></td>
    <td style="width:48.003%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Warrant No. [___]						 Original Issue Date: August [___], 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	Terns Pharmaceuticals, Inc., a Delaware corporation (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [___________] or its registered assigns (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Holder</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) is entitled, subject to the terms set forth below, to purchase from the Company up to a total of [______] shares of common stock, $0.0001 par value per share (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Common Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), of the Company (each such share, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Warrant Share</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; and all such shares, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Warrant Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) at an exercise price per share equal to $0.0001 per share (as adjusted from time to time as provided in Section 9 herein, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Exercise Price</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) upon surrender of this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Warrant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) at any time and from time to time on or after the date hereof (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Original Issue Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), subject to the following terms and conditions:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	1. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Definitions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. For purposes of this Warrant, the following terms shall have the following meanings:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(a) &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Affiliate</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any Person directly or indirectly controlled by, controlling or under common control with, a Holder, as such terms are used in and construed under Rule 405 under the Securities Act, but only for so long as such control shall continue.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(b) &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Commission</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the United States Securities and Exchange Commission.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(c) &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Closing Sale Price</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, for any security as of any date, the last trade price for such security on the Principal Trading Market for such security, as reported by Bloomberg L.P., or, if such Principal Trading Market begins to operate on an extended hours basis and does not designate the last trade price, then the last trade price of such security prior to 4:00 P.M., New York City time, as reported by Bloomberg L.P., or if the security is not listed for trading on a national securities exchange or other trading market on the relevant date, the last quoted bid price for the security in the over-the-counter market on the relevant date as reported by OTC Markets Group Inc. (or a similar organization or agency succeeding to its functions of reporting prices). If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then the Board of Directors of the Company shall use its good faith judgment to determine the fair market value. The Board of Directors&#x2019; determination shall be binding upon all parties absent demonstrable error. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(d) &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Marketable Securities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means securities meeting all of the following requirements: (i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Exchange Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and is then current in its filing of all required reports and other information under the Securities Act and the Exchange Act; (ii) the class and series of shares or other security of the issuer that would be received by Holder in connection with the Fundamental Transaction (as defined below) were Holder to exercise this Warrant on or prior to the closing thereof is then traded or quoted on a nationally recognized securities exchange, inter-dealer</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">quotation system or over-the-counter market, and (iii) following the closing of such Fundamental Transaction, the Holder would not be restricted from publicly re-selling all of the issuer&#x2019;s shares and/or other securities that would be received by the Holder in such Fundamental Transaction were the Holder to exercise or convert this Warrant in full on or prior to the closing of such Fundamental Transaction.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(e) &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Principal Trading Market</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the national securities exchange or other trading market on which the Common Stock is primarily listed on and quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Global Select Market.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(f) &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Company&#x2019;s Registration Statement on Form S-3 (File No. 333-263370), that became effective on March 14, 2022.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(g) &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Securities Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Securities Act of 1933, as amended.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(h) &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Trading Day</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any weekday on which the Principal Trading Market is open for trading. If the Common Stock is not listed or admitted for trading, &#x201c;Trading Day&#x201d; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in New York City are authorized or required by law or other governmental action to close.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(i) &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Transfer Agent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Computershare Trust Company, N.A., the Company&#x2019;s transfer agent and registrar for the Common Stock, and any successor appointed in such capacity.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	2. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Issuance of Securities; Registration of Warrants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. The Warrant, as initially issued by the Company, is offered and sold pursuant to the Registration Statement. As of the Original Issue Date, the Warrant Shares are issuable under the Registration Statement. Accordingly, the Warrant and, assuming issuance pursuant to the Registration Statement or an exchange meeting the requirements of Section 3(a)(9) of the Exchange Act as in effect on the Original Issue Date, the Warrant Shares, are not &#x201c;restricted securities&#x201d; under Rule 144 promulgated under the Securities Act. The Company shall register ownership of this Warrant, upon records to be maintained by the Company for that purpose (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Warrant Register</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), in the name of the record Holder (which shall include the initial Holder or, as the case may be, any assignee to which this Warrant is assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	3. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Registration of Transfers</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. Subject to compliance with all applicable securities laws, the Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer taxes (if any). Upon any such registration or transfer, a new warrant to purchase Common Stock in substantially the form of this Warrant (any such new warrant, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">New Warrant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue and deliver at the Company&#x2019;s own expense any New Warrant under this Section 3. Until due presentment for registration of transfer, the Company may treat the registered Holder hereof as the owner and holder for all purposes, and the Company shall not be affected by any notice to the contrary.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	4. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exercise and Duration of Warrants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(a) All or any part of this Warrant shall be exercisable by the registered Holder in the manner set forth in Section 10 at any time and from time to time on or after the Original Issue Date.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(b) The Holder may exercise this Warrant by delivering to the Company an exercise notice, in the form attached as Schedule 1 hereto (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Exercise Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), completed and duly signed. The date on which such exercise notice is delivered to the Company (as determined in accordance with the notice provisions hereof) is an </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Exercise Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">.&#x201d; The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares, if any. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	5. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Delivery of Warrant Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(a) Upon exercise of this Warrant, the Company shall promptly (but in no event later than three (3) Trading Days after the Exercise Date), upon the request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to such exercise to the Holder&#x2019;s or its designee&#x2019;s balance account with The Depository Trust Company (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">DTC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) through its Deposit Withdrawal Agent Commission system, or if the Transfer Agent is not participating in the Fast Automated Securities Transfer Program or if the certificates are required to bear a legend regarding restriction on transferability, issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Company&#x2019;s share register in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise. The Holder, or any natural person or legal entity (each, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Person</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) so designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective of the date such Warrant Shares are credited to the Holder&#x2019;s DTC account or the date of delivery of the certificates evidencing such Warrant Shares, as the case may be.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(b) If by the close of the third (3rd) Trading Day after the Exercise Date, the Company fails to deliver to the Holder a certificate representing the required number of Warrant Shares in the manner required pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Section 5(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> or fails to credit the Holder&#x2019;s DTC account for such number of Warrant Shares to which the Holder is entitled, and if after such third (3rd) Trading Day and prior to the receipt of such Warrant Shares, the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Buy-In</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), then the Company shall, within three (3) Trading Days after the Holder&#x2019;s request promptly honor its obligation to deliver to the Holder a certificate or certificates representing such Warrant Shares and pay cash to the Holder in an amount equal to the excess (if any) of Holder&#x2019;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased in the Buy-In less the product of (A) the number of shares of Common Stock purchased in the Buy-In, times (B) the Closing Sale Price of a share of Common Stock on the Exercise Date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(c) To the extent permitted by law and subject to Section 5(b), the Company&#x2019;s obligations to issue and deliver Warrant Shares in accordance with and subject to the terms hereof (including the limitations set forth in Section 11 below) are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Subject to Section 5(b), nothing herein shall limit the Holder&#x2019;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#x2019;s failure to timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	6. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Charges, Taxes and Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. Issuance and delivery of certificates for shares of Common Stock upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp duties) in respect of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares or the Warrants in a name other than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	7. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Replacement of Warrant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case) and, in each case, a customary and reasonable indemnity and surety bond, if requested by the Company. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company&#x2019;s obligation to issue the New Warrant.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	8. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reservation of Warrant Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. The Company covenants that it will, at all times while this Warrant is outstanding, reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into account the adjustments and restrictions of Section 9). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and non-assessable. The Company will take all such action as may be reasonably necessary to assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed. The Company further covenants that it will not, without the prior written consent of the Holder, take any actions to increase the par value of the Common Stock at any time while this Warrant is outstanding.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	9. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Certain Adjustments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Number of Warrant Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) are subject to adjustment from time to time as set forth in this Section 9.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Stock Dividends and Splits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. If the Company, at any time while this Warrant is outstanding, (i) pays a stock dividend on its Common Stock that is payable in shares of Common Stock, (ii) subdivides</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">its outstanding shares of Common Stock into a larger number of shares of Common Stock, (iii) combines its outstanding shares of Common Stock into a smaller number of shares of Common Stock or (iv) issues by reclassification of shares of capital stock any additional shares of Common Stock of the Company, then in each such case the Number of Warrant Shares shall be multiplied by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately after such event and the denominator of which shall be the number of shares of Common Stock outstanding immediately before such event. Any adjustment made pursuant to clause (i) of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution, provided, however, that if such record date shall have been fixed and such dividend is not fully paid on the date fixed therefor, the Number of Warrant Shares shall be recomputed accordingly as of the close of business on such record date and thereafter the Number of Warrant Shares shall be adjusted pursuant to this paragraph as of the time of actual payment of such dividends. Any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately after the effective date of such subdivision or combination.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Pro Rata Distributions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. If the Company, at any time while this Warrant is outstanding, distributes to all holders of Common Stock for no consideration (i) evidences of its indebtedness, (ii) any security (other than a distribution of Common Stock covered by the preceding paragraph), (iii) rights or warrants to subscribe for or purchase any security (including Common Stock), or (iv) cash or any other asset (in each case, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Distribution</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), other than a reclassification as to which Section 9(c) applies, then in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the ownership limitation set forth in Section 11(a) hereof) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Common Stock are to be determined for the participation in such Distribution;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">, to the extent that the Holder&#x2019;s right to participate in any such Distribution would result in the Holder exceeding the ownership limitation set forth in Section 11(a) hereof, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as the delivery to such Holder of such portion would not result in the Holder exceeding the ownership limitation set forth in Section 11(a) hereof.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(c) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Fundamental Transactions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. If, at any time while this Warrant is outstanding (i) the Company effects any merger or consolidation of the Company with or into another Person, in which the Company is not the surviving entity, (ii) the Company effects any sale to another Person of all or substantially all of its assets in one transaction or a series of related transactions, (iii) pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders of capital stock tender shares representing more than 50% of the voting power of the capital stock of the Company and the Company or such other Person, as applicable, accepts such tender for payment, (iv) the Company consummates a stock purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the voting power of the capital stock of the Company (except for any such transaction in which the stockholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such Person immediately after the transaction) or (v) the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by Section 9(a) above) (in any such case, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Fundamental Transaction</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), then following such Fundamental Transaction the Holder shall have the right to receive, upon exercise of this Warrant,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">5</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the Number of Warrant Shares (in the case of clause (iii) above, assuming it had tendered, and the offeror had accepted, such Warrant Shares) (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Alternate Consideration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The Company shall not effect any Fundamental Transaction in which the Company is not the surviving entity or the Alternate Consideration includes securities of another Person unless (i) the Alternate Consideration is solely cash and the Company provides for the simultaneous &#x201c;cashless exercise&#x201d; of this Warrant pursuant to Section 10 below or (ii) prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity or other Person (including any purchaser of assets of the Company) shall assume the obligation to deliver to the Holder such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under this Warrant. The provisions of this paragraph (c) shall similarly apply to subsequent transactions analogous of a Fundamental Transaction type. Notwithstanding the foregoing, in the event of a Fundamental Transaction where the consideration payable to holders of Common Stock consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities, then this Warrant shall automatically be deemed to be exercised in full in a &#x201c;cashless exercise&#x201d; pursuant to Section 10 below effective immediately prior to and contingent upon the consummation of such Fundamental Transaction. 		</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(d) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Exercise Price</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. Simultaneously with any adjustment to the Number of Warrant Shares pursuant to Section 9 the Exercise Price shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the increased or decreased Number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment. Notwithstanding the foregoing, in no event may the Exercise Price be adjusted below the par value of the Common Stock then in effect.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(e) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Calculations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. All calculations under this Section 9 shall be made to the nearest one-hundredth of one cent or the nearest whole share, as applicable.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(f) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Notice of Adjustments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. Upon the occurrence of each adjustment pursuant to this Section 9, the Company at its expense will, at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Company&#x2019;s transfer agent.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(g) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Notice of Corporate Events</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. If, while this Warrant is outstanding, the Company (i) declares a dividend or any other distribution of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the Company or any subsidiary, (ii) authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii) authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company, then, except if such notice and the contents thereof shall be deemed to constitute material non-public information, the Company shall deliver to the Holder a notice of such transaction at least ten (10) days prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction; provided, however, that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action required to be described in such notice. In addition, if while this Warrant is outstanding, the Company authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction contemplated by Section</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">9(c), other than a Fundamental Transaction under clause (iii) of Section 9(c), then, except if such notice and the contents thereof shall be deemed to constitute material non-public information, the Company shall deliver to the Holder a notice of such Fundamental Transaction at least ten (10) days prior to the date such Fundamental Transaction is consummated.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	10. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cashless Exercise</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. Notwithstanding anything contained herein to the contrary, this Warrant may only be exercised through a &#x201c;cashless exercise.&#x201d; Upon exercise, the Company shall issue to the Holder the number of Warrant Shares in an exchange of securities effected pursuant to Section 3(a)(9) of the Securities Act as determined as follows:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:8.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		X = Y [(A-B)/A]</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:8.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">where:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:8.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;X&#x201d; equals the number of Warrant Shares to be issued to the Holder;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:8.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Y&#x201d; equals the total number of Warrant Shares with respect to which this Warrant is then being exercised;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:8.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;A&#x201d; equals the Closing Sale Price per share of Common Stock as of the Trading Day on the date immediately preceding the Exercise Date; and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:8.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;B&#x201d; equals the Exercise Price per Warrant Share then in effect on the Exercise Date.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued in such a &#x201c;cashless exercise&#x201d; transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally issued (provided that the Commission continues to take the position that such treatment is proper at the time of such exercise).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	In no event will the exercise of this Warrant be settled in cash.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	11. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Limitations on Exercise</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(a) Notwithstanding anything to the contrary contained herein, the Company shall not effect any exercise of this Warrant, and the Holder shall not be entitled to exercise this Warrant for a number of Warrant Shares in excess of that number of Warrant Shares which, upon giving effect or immediately prior to such exercise, would cause (i) the aggregate number of shares of Common Stock beneficially owned by the Holder, its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#x2019;s for purposes of Section 13(d) of the Exchange Act to exceed 4.99% (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Maximum Percentage</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of the total number of issued and outstanding shares of Common Stock of the Company following such exercise, or (ii) the combined voting power of the securities of the Company beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#x2019;s for purposes of Section 13(d) of the Exchange Act to exceed 4.99% of the combined voting power of all of the securities of the Company then outstanding following such exercise. For purposes of this Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x) the Company&#x2019;s most recent Form 10-Q or Form 10-K, as the case may be, filed with the Commission prior to the date hereof, (y) a more recent public announcement by the Company or (z) any other notice by the Company or its transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written request of the Holder, the Company shall within three</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">7</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">(3) Trading Days confirm in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder since the date as of which such number of outstanding shares of Common Stock was reported. By written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other percentage specified not in excess of 19.99% specified in such notice; provided that any such increase will not be effective until the sixty-first (61st) day after such notice is delivered to the Company. For purposes of this Section 11(a), the aggregate number of shares of Common Stock or voting securities beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#x2019;s for purposes of Section 13(d) of the Exchange Act shall include the shares of Common Stock issuable upon the exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (x) exercise of the remaining unexercised and non-cancelled portion of this Warrant by the Holder and (y) exercise or conversion of the unexercised, non-converted or non-cancelled portion of any other securities of the Company that do not have voting power (including without limitation any securities of the Company which would entitle the holder thereof to acquire at any time Common Stock, including without limitation any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock), is subject to a limitation on conversion or exercise analogous to the limitation contained herein and is beneficially owned by the Holder or any of its Affiliates and other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#x2019;s for purposes of Section 13(d) of the Exchange Act.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(b) This Section 11 shall not restrict the number of shares of Common Stock which a Holder may receive or beneficially own in order to determine the amount of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction as contemplated in Section 9(c) of this Warrant.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	12. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Fractional Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash the fair market value (based on the Closing Sale Price) for any such fractional shares.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	13. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Notices</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. Any and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via confirmed e-mail prior to 5:30 P.M., New York City time, on a Trading Day, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered via confirmed e-mail on a day that is not a Trading Day or later than 5:30 P.M., New York City time, on any Trading Day, (iii) the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service specifying next business day delivery, or (iv) upon actual receipt by the Person to whom such notice is required to be given, if by hand delivery. The addresses and e-mail addresses for such communications shall be:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">If to the Company:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Terns Pharmaceuticals, Inc.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">1065 East Hillsdale Blvd.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Suite 100</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Foster City, California 94404</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Attention: General Counsel</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Telephone: [__]</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Email: [__]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">8</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">If to the Holder, to its address or e-mail address set forth herein or on the books and records of the Company.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	Or, in each of the above instances, to such other address or e-mail address as the recipient party has specified by written notice given to each other party at least five (5) days prior to the effectiveness of such change.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	14. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrant Agent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. The Company shall initially serve as warrant agent under this Warrant. Upon ten (10) days&#x2019; notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder&#x2019;s last address as shown on the Warrant Register.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">	15. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Miscellaneous</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">No Rights as a Stockholder</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. The Holder, solely in such Person&#x2019;s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person&#x2019;s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Authorized Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and non-assessable Warrant Shares upon the exercise of this Warrant, and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> 		(c) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Successors and Assigns</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. Subject to compliance with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company without the written consent of the Holder, except to a successor in the event of a Fundamental Transaction. This</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">9</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Warrant shall be binding on and inure to the benefit of the Company and the Holder and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(d) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Amendment and Waiver</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. Except as otherwise provided herein, this Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(e) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Acceptance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(f) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Governing Law; Jurisdiction</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(g) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Headings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">		(h) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Severability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">10</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of the date first indicated above.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="margin-left:40.0%;text-indent:11.111%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">TERNS PHARMACEUTICALS, INC.</font></p>
  <p style="margin-left:40.0%;text-indent:11.111%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">By:________________________________<br>            Name:<br>            Title:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Signature Page to Warrant Agreement</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">SCHEDULE 1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">FORM OF EXERCISE NOTICE</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">[To be executed by the Holder to purchase shares of Common Stock under the Warrant]</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Ladies and Gentlemen:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(1) The undersigned is the Holder of Warrant No. ___ (the &#x201c;Warrant&#x201d;) issued by Terns Pharmaceuticals, Inc., a Delaware corporation (the &#x201c;Company&#x201d;). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(2) The undersigned hereby exercises its right to purchase ___________ Warrant Shares pursuant to the Warrant.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(3) The Holder intends that payment of the Exercise Price shall be made as a &#x201c;Cashless Exercise&#x201d; under Section 10 of the Warrant.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(4) Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in accordance with the terms of the Warrant. The Warrant Shares shall be delivered to the following DWAC Account Number:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(5) By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under Section 11(a) of the Warrant to which this notice relates.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:33.029%;"></td>
    <td style="width:0.994%;"></td>
    <td style="width:65.977%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Dated:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Name of Holder:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(Signature must conform in all respects to name of Holder as specified on the face of the Warrant)</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>tern-ex5_1.htm
<DESCRIPTION>EX-5.1
<TEXT>
<html>
 <head>
  <title>EX-5.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:62.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:50.4pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:11.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Arial;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 5.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img60210087_0.jpg" alt="img60210087_0.jpg" style="width:257px;height:35px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><img src="img60210087_1.jpg" alt="img60210087_1.jpg" style="width:198px;height:312px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">August 16, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Terns Pharmaceuticals, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">1065 East Hillsdale Blvd.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Foster City, California 94404</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">	Re:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement on Form S-3 (No. 333-263370); 12,500,000 shares of common stock, $0.0001 par value per share, and pre-funded warrants to purchase 14,630,000 shares of common stock, $0.0001 par value per share.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">To the addressee set forth above:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">We have acted as special counsel to Terns Pharmaceuticals, Inc., a Delaware corporation (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), in connection with the proposed issuance of 12,500,000 shares of common stock, $0.0001 par value per share (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and pre-funded warrants to purchase 14,630,000 shares of Common Stock (each, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pre-Funded Warrant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; or collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pre-Funded Warrants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The Shares and Pre-Funded Warrants are included in a registration statement on Form S-3 under the Securities Act of 1933, as amended (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), filed with the Securities and Exchange Commission (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Commission</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) on March 8, 2022 (Registration No. 333-263370) (as amended, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Registration Statement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and are being offered pursuant to a base prospectus dated March 14, 2022 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Base Prospectus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and a prospectus supplement dated August 11, 2022 filed with the Commission pursuant to Rule 424(b) under the Act (together with the Base Prospectus, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Prospectus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  The Shares and Pre-Funded Warrants are being sold pursuant to an</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:27.35pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Arial;min-width:fit-content;">August 16, 2022</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Arial;min-width:fit-content;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Arial;min-width:fit-content;">2</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.65pt;line-height:1.15;font-family:Times New Roman;margin-bottom:18.0pt;text-align:left;"><img src="img60210087_2.jpg" alt="img60210087_2.jpg" style="width:163px;height:11px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">underwriting agreement dated August 11, 2022 between the Company and Cowen and Company, LLC, as representative of the several underwriters named in Schedule 1 thereto (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Underwriting Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or the Prospectus, other than as expressly stated herein with respect to the issue of the Shares, Pre-Funded Warrants, and Warrant Shares (as defined below).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DGCL</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and we express no opinion with respect to any other laws.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">When the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers, and have been issued by the Company against payment therefor (not less than par value) in the circumstances contemplated by the Underwriting Agreement, the issue and sale of the Shares will have been duly authorized by all necessary corporate action of the Company, and the Shares will be validly issued, fully paid and nonassessable.  In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL. </font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">When the Pre-Funded Warrants have been duly issued by the Company against payment therefor in the circumstances contemplated by Underwriting Agreement, the issue and sale of the Pre-Funded Warrants will have been duly authorized by all necessary corporate action of the Company, and the Pre-Funded Warrants will be legally valid and binding obligations of the Company, enforceable against the Company in accordance with their terms.</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">When the shares of Common Stock initially issuable upon exercise of the Pre-Funded Warrants (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrant Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the Pre-Funded Warrant holders, and have been issued by the Company against payment therefor (not less than par value) in the circumstances contemplated by the Pre-Funded Warrants, the issue of the Warrant Shares will have been duly authorized by all necessary corporate action of the Company, and the Warrant Shares will have been validly reserved by all necessary corporate action of the Company, and the Warrant Shares will be validly issued, fully paid and nonassessable.  In rendering the foregoing opinion, we have assumed that (i) the Company will comply with all applicable notice requirements regarding </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:27.35pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Arial;min-width:fit-content;">August 16, 2022</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Arial;min-width:fit-content;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Arial;min-width:fit-content;">3</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.65pt;line-height:1.15;font-family:Times New Roman;margin-bottom:18.0pt;text-align:left;"><img src="img60210087_2.jpg" alt="img60210087_2.jpg" style="width:163px;height:11px;">&#160;</p>
  <div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;visibility:hidden;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">uncertificated shares provided in the DGCL and (ii) upon the issue of any of the Warrant Shares, the total number of shares of Common Stock issued and outstanding will not exceed the total number of shares of Common Stock that the Company is then authorized to issue under its Amended and Restated Certificate of Incorporation and by the board of directors of the Company in connection with the offering contemplated by the Registration Statement and the Prospectus.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">With your consent, we have assumed that the status of the Pre-Funded Warrants as legally valid and binding obligations of the Company is not affected by any (i) breaches of, or defaults under, agreements or instruments, (ii) violations of statutes, rules, regulations or court or governmental orders, or (iii) failures to obtain required consents, approvals or authorizations from, or make required registrations, declarations or filings with, governmental authorities.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Our opinions are subject to: (i) the effect of bankruptcy, insolvency, reorganization, preference, fraudulent transfer, moratorium or other similar laws relating to or affecting the rights and remedies of creditors; (ii) (a) the effect of general principles of equity, whether considered in a proceeding in equity or at law (including the possible unavailability of specific performance or injunctive relief), (b) concepts of materiality, reasonableness, good faith and fair dealing, and (c) the discretion of the court before which a proceeding is brought; and (iii) the invalidity under certain circumstances under law or court decisions of provisions providing for the indemnification of or contribution to a party with respect to a liability where such indemnification or contribution is contrary to public policy.  We express no opinion as to (a) any provision for liquidated damages, default interest, late charges, monetary penalties, make-whole premiums or other economic remedies to the extent such provisions are deemed to constitute a penalty; (b) consents to, or restrictions upon, governing law, jurisdiction, venue, arbitration, remedies, or judicial relief; (c) any provision requiring the payment of attorneys&#x2019; fees, where such payment is contrary to law or public policy; (d) other applicable exceptions; and (e) the severability, if invalid, of provisions to the foregoing effect.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act.  We consent to your filing this opinion as an exhibit to the Company&#x2019;s Current Report on Form 8-K dated August 16, 2022 and to the reference to our firm in the Prospectus under the heading &#x201c;Legal Matters.&#x201d;  In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Sincerely,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">/s/ Latham &amp; Watkins LLP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">3</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>tern-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Exhibit 99.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">	</font><img src="img52906712_0.jpg" alt="img52906712_0.jpg" style="width:162px;height:62px;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> 							</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">Terns Announces $65 Million Oversubscribed Offering</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Calibri;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">Foster City, Calif., August 12, 2022 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">&#x2013; Terns Pharmaceuticals, Inc. (&#x201c;Terns&#x201d; or the &#x201c;Company&#x201d;) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Calibri;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">announced that it has agreed to sell, by way of an underwritten public offering, 12,250,000 shares of its common stock at a price of $2.42 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 14,630,000 shares of common stock at a price of $2.4199 per pre-funded warrant, for expected aggregate gross proceeds of approximately $65.0 million, before deducting underwriting discounts and commissions and other offering expenses. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the $0.0001 per share exercise price of such pre-funded warrant. The offering is expected to close on August 16, 2022, subject to customary closing conditions. All of the securities are being offered by Terns.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">The offering was oversubscribed and led by new investors Fairmount and Venrock Healthcare Capital Partners and included participation from existing top-tier healthcare investors.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">Cowen and Company, LLC is acting as lead book-running manager for the offering. UBS Securities LLC is also acting as a bookrunner for the offering.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">Terns intends to use the net proceeds from the offering, together with existing cash and cash equivalents, as follows: (1) to initiate and complete one or more clinical studies in the United States and/or Europe to assess TERN-701 and advance the product candidate into Phase 2 clinical development in chronic myeloid leukemia; (2) to advance the clinical development of TERN-601 in obesity through the completion of Phase 2-enabling studies and initiate a Phase 2 clinical trial of TERN-601 in obesity; (3) to complete the ongoing Phase 2a DUET trial of TERN-501 as monotherapy and in combination with TERN-101 in NASH patients; and (4) for working capital and general corporate purposes.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">The public offering is being made pursuant to a registration statement on Form S-3 previously filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;), which became effective on March 14, 2022.  A prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC&#x2019;s website located at www.sec.gov. Copies of the prospectus supplement and accompanying prospectus relating to this offering, when available, may be obtained from Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at 1-833-297-2926 or by e-mail: PostSaleManualRequests@broadridge.com.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Calibri;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification of these securities under the securities laws of any such state or other jurisdiction.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">About Terns Pharmaceuticals</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and NASH. Terns&#x2019; pipeline includes four clinical stage development programs including an allosteric BCR-ABL inhibitor, a THR-&#x3b2; agonist, an FXR agonist, a VAP-1 inhibitor, and a preclinical small-molecule GLP-1 receptor agonist program.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">Cautionary Note Regarding Forward-Looking Statements</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">This press release contains forward-looking statements about Terns Pharmaceuticals, Inc. (the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;) within the meaning of the federal securities laws, including those related to the completion of the public offering. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#x201c;aim,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;assume,&#x201d; &#x201c;believe,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;design,&#x201d; &#x201c;due,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;goal,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;objective,&#x201d; &#x201c;plan,&#x201d; &#x201c;positioned,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;seek,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;will,&#x201d; &#x201c;would&#x201d; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results and the implementation of the Company&#x2019;s plans to vary materially, including the risks associated with the initiation, cost, timing, progress, results and utility of the Company&#x2019;s current and future research and development activities and preclinical studies and clinical trials. In particular, the impact of the COVID-19 pandemic on the Company&#x2019;s ability to progress with its research, development, manufacturing and regulatory efforts, including the Company&#x2019;s clinical trials for its product candidates, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States and in other countries, and the effectiveness of actions taken globally to contain and treat the disease. These risks are not exhaustive. For a detailed discussion of the risk factors that could affect the Company and the offering, please refer to the risk factors identified in the Company&#x2019;s SEC reports, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2021 and its Quarterly Report on Form 10-Q for the periods ended March 31, 2022 and June 30, 2022, and its prospectus supplement. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">Contacts for Terns</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">Investors</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Calibri;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">Justin Ng</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">investors@ternspharma.com</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Calibri;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">Media</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">Jenna Urban</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">Berry &amp; Company Public Relations</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">media@ternspharma.com</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img52906712_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img52906712_0.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" != /,# 2(  A$! Q$!_\0
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M/$.E^)K(7FCZE9ZK:$X%Q8SI-&3Z;E)%'*UK82DF[)FA1112*"BBB@ HHHH
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MM<Y0.0=JG&W!.*T=9670;R[N8M%U&>PU;P6VCV;:=HTL*_:A+-\A@ )@SO!
M;CGK0!]$-JEFC;6NX%;C@R*#ST[T^2^MH86EDN(HXE.TR,X"@^F?6O"A\);&
M3Q9\*6U#PO;SR)I4L>KS-:AU\V.UA6,2MC!(*D+GTXK MO#O]GWFGW?BGPUJ
M&J^&8M5UII+1;%[@)-).##*T(&64IN"M@@$YXSF@#Z8::-%5FD558@*20 2>
M@%'FH9#&'4R 9*YY ]<5\T^-O"_B'QEH/A;PYX9\+ZGI5AI=E)J*V][>&-K>
MX9F6V!E;=N9!E_+SD!P"5Q71:#XXN-/^(0\2:SH6MQ#4_#MG$ZVVE3R^7<++
M+YB$*IQ@^O8CUH ]Q%W UP;<31F<#<8MPW >N.M35\U:;H-QI_QL6ZM-"U"Y
MN9M=DGN/[0TYU>VB96!GCOD(5X<$;87SCICO7TK0 4444 %%%% !1110 444
M4 -D(6-B>!BO,?V<_!A\'_#.T::'R;[4Y&OYP1R-W"#_ +X"_B37IY&1@C(H
M50JA5   P .U=,:\H4945M)IOY7_ ,SCGAH5,1#$2W@I)?\ ;UK_ )?B+111
M7,=@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img60210087_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img60210087_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  T 8$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KGO&.KW>BZ1%<V;*LC3B,EESP58_T%=#7'_$?_ )%ZW_Z^U_\ 0'H
MZZ)BT2,>I4$TZF0_ZB/_ '1_*GT 4]5OETW2KF\;'[J,L >Y[#\\5ROA#Q5>
MZKJ<EGJ#(2T>^(A-O(Z_H<_A4OC^[=K.STJ#F6[E'RCN!T'XDC\JR_$5I_PC
M.M:+J$ /E1HL3D#KLX/YJ?TH ]%/3CK7"7]_XUTZSEN[@6JPQC+$!3WQT_&N
MZ5@ZAE(*D9!'<5B>,?\ D4[_ /W5_P#0A0!S]AJ'C34K*.[MA:M#)DJ2%'0X
MZ?A78:I<2VFC7=S&0)8H'=21D;@N:SO!O_(I6'^ZW_H;5<U[_D7M1_Z]I/\
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MR3C\OSJ7PEJ\^M:+]INF4S+*R,5&/0CC\:P]84:[X^M=./S06D9:0=LXR?\
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M]$JP1&U6V:3(8ALX"\9SCK0!V%%06/GG3[8W7_'QY2^;C^_@9_7-3T %%%%
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M&LJV?FA92"P=\C(]/SJUJ%C#J=C+9W 8Q2@!MIP>#G^E &7X-_Y%*P_W6_\
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>1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img60210087_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img60210087_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '4 2D# 2(  A$! Q$!_\0
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M3D=N/7FNEGMH+JV>VGB5X77:R$<$57ATJTAE$NV61PI4&>9Y=H/7&\G&>^*
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MHIMO(PB ],M(,[MP()& >W2H[G3K]H=0TU+4M#>77FK<^8H5%8@MD9W9&#C
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHW.[9][ECMQGC[W7VK8HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1Y>[_;^]UYQUH [NBL&RM8;#Q2UM:QK%$U@K,JC&Y@Y&X^IYZ]:WJ "BBB@
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M)K*%84'#Q?Q(XX8-W+9ZD\GK6C0 4444 %%%% !1110 4444 %%%% !1110
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M,0DO+=_*9U+*D88%C@XSST!-:EE:3PZWJEQ(F(IS%Y;9'S;5P?IS0!I4444
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M* "BBB@ HHHH **** "BBB@ HHK U&]F3Q!]E^V7D$ M5D M;82DL78<_(Q
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MRW#+;0AFF9P"K,N[Y5P0V 03DC\:F.O3K;S31V?GP6BI]IE\S:V=H9MBXP<
M@\D4V;P[-]EN;:UOQ#'=0I'-F'<<JNW*_,,9 &0<U(^@2>7<6\-]Y=M=!1<)
MY66) "L4;/R[@ #D&@".3Q'(AO)4LE>SM)$5Y?.PS!@IRJ[><;NA(K?K%E\/
M*]EJ-JEQL6\D5Q\F?+"A1CKS]W]:VJ "BBB@ HHHH **** (YHVEA9$F>%CT
MD0*2/IN!'Z5AV$]R@U*ZN]3N7AL9W4ILB 9%4-SA <\GH1705GQ:2BV^HP2R
M%X[Z1W8 8VAE"D?IUH RAXI6>)T3[,LLEM)+"8+E9BA5=V'&!M/YC@UL6]YL
MT2*]N6SBV$LC8_V<DU632[XV9M)]25X?(:%0MN%)R, L<G./;;4EQI/VC1X-
M.,^(D$:RG9_K$7&5Z\9Q[T 9^F:IJ8^U1WD:S7#6XO+:)?E^0_\ +/('4' Z
M$\]Z6^\1@6(DMHV.ZS^ULZN 4!(  RI!))/4=C5QM!M([ZTN[&*"SD@<[O*A
M $B$8*G&/;![54C\+1Q6&I6J7) O&^4E,B) 254#/.,GG/>@"R^N%%G4VW^D
M)>+:K$9/O;L%6SC@%3G\#6O65)HD<GB&/5?-("I@P[>&< @-G/8,1TK5H **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK(7_D<)?^O!/_ $8U
M &O16#=W-]<7VI1V]X;5+&%64"-6WL06RVX'CC'&._-59-5U#9!?W$D]I920
MPR))%"LL2DKN;S!]\#MD8 XYH ZBBLW7KU['2)7ASY\F(H0JDG>W P!R<<G\
M*YRWOFT?2M7L;.2=/L\7VBT:>%D;:>&X<= WM_%0!VM%<O?ZEJ.E2W-N;O[0
M_P!DCE5Y(U&QVDV'&T#CG.#GIUIFH:CJ6D75U!]L>ZQ;1-$7B0%&>39DXP#[
M9P.F?6@#JZ*Y+4WU/^S;M+J.Y-KF%DDN?)#AO-7*_NS@C'/3UJ:#4=8O)'NK
M6&XD1;ED$/[D1&-6VG)+;PV 3Z9QP10!T]%<];7E_#JT46HS7$)DD=50PHT$
MG+; CK\RG !^;KSQ70T %%%% !14<T$5S"T,\22Q-]Y'4,#]0:YK3[6RL8-;
MO8["V\VTN96B/E+E0L:D '' Z]/6@#J:*Y6ZNKZ"TA6XO#<I?64S,K(J^6PC
MW97 ''.,'/;FH;'4=0DT2:XBE:"2PAB(M-BG=&%#%F)&3N7. ",?6@#L**YV
M75+FXVO;7!2"ZOEM87V#*H%)=AGJ2RL!G/TJ]I=S<&\O[&XF,YM77;,5 9E9
M<@$  9'J.O% &I1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !5*YTJUNKH7,@F6;8(]\5Q)&2N2<?*P[DU=JN;ZV&H"P,H%T8_-$9!Y7)&0
M>G8\4 5IM#T^XV^;%(Q">629WRZYSASG+C_>S3IM%T^>8R/!RP4,JNRHX7[N
MY0=K8]P>.*G6^MGOWLEE!N8T$CH ?E!Z9/3\.M6* (9K2"XF@FECW/ Q:,DG
M"DC&<=#P>]07VDV.HLK74'F,$:,$,5^5NHX(STJ<74)O39A_WXC$I3!^Z20#
MGIU!IXE4S-$ ^Y0"24('/H<8/TH I:CID=W'<2)#"]U) 81Y^XH5SG:0#Z]Q
MR/TJC8>'T6>[EO(8]MQ$L)A$SS J.<EWP2>@ [!16Q'=P2W4ULCYF@"F1<'Y
M=V<<_@:FH SAH>G^6Z-"\F\*&:29W;"G< &)) !YP#BG/HNGR7#3- 27<2,G
MF,(V?^\4SM)X')':K]% %"+1K"&=)HX6!1BZ*9&*(QSDJA.T'D]!WJ_110 4
M444 %016=O")PD8 G<R2@DD,Q !Z^P'%+=74-E;/<7#[(DY9L$XYQVILE_;1
M7T-D\H%Q,I:-,'Y@.O/2@"O#H>G0!PD!PT9B^:1FVH>JKD_*/88HFTV*-1-:
MVT;7,<'D1B21E0I_=;&<CZ@U:@NX;EIEA?<87,;_ "D88#..>O7M4U &=;Z/
M:QZ/;:=(@>.%5P02I##G<".0<\Y%6K2S@L8C';H5#,78EBS,QZDL<DGZTHNH
M3>-:!_WZQB0K@_=)(!STZ@T]9%:5XP'W( 22A Y]#T/3MTH ?114-Q=0VHC,
MS[1)(L2\$Y9C@#B@":BBB@ HHK,_M_3OF)EE$:N8VE-O((U(.#E]NT#/?.*
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M;4I999[+:%T5&2*;YS'\TF#D\YXZ]?SJK,3=6LIF9F,L6F[V)Y.6.3FN]HH
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<B@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img60210087_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img60210087_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "Q"F<# 2(  A$! Q$!_\0
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M*3IK%4B4L;8Y8HV68X;&7'#8P /NA#S1'^T%XW2X$K'370.6\IK8[2,O\O#
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MRW%Q+'#!$A>221@JHH&223P !SFOA#5M2FUG6;[5+A8UGO;B2XD6,$*&=BQ
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M*8_HNN7^'_@ZW\#^$K;28OFN&Q->2!RPDG*@.5R!A> !P. ,\Y)ZB@ HHHH
M**** "BBB@#R/XT?$76O ]QI4&BO&KWEO<"4S6Q95.4".C'@NOS_ "Y(^8;E
M.5KS"?\ :"\;S"4(=-@WN64QVQ.P&/9M&YCP&^?G)W=25^6ND_:7;.H^'5\V
M<XBG/EM'B-<E.5;;RQQR-QP%4X&[+>#T >H2?'[QR^_;<6,>[=C;:CY,^9C&
M2>F]<9S_ *I,YR^_4\/?'3QIJ'BK2[29+2X@N;V.-[:&W56=7=AL4LP .)%
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M=/V:=O\ ;.OYM8V?[/%BX*-NC&YLH#MP W!(+ G8,!L$K]%T %%%% !1110
M4444 %%%% !5>^O[/3+.2\O[N"TM8\;YIY!&BY( RQX&20/QK@_B3\5]-\"V
M[6ENL=]K4B,([=9%*P, I!F ;<H(?<!CYL$9'6OF#Q1XNUKQCJCW^L7LDQ+L
MT4 8B* ' VQIG"C"K[G&22>: /?]?_:*\.:>[1:+I]WJSJX'F,?L\3*5R2I8
M%\@X&"@[\],^::G\?O'-_P"5]FN+'3=F=WV2U#>9G&,^:7Z8[8ZG.>,>7T4
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MXR"10!\L>/\ 7U\4>/-9UB)HV@GN"L#HK*'B0!(VPW()55)SCDG@=*YNBB@
MHHHH *]X_9P\3I!>:GX8N9]OVC%W:(=H!<#$@!^\6*A"!SPC'CG/@]=!X)\3
MW'A'Q;I^KPSSQ0QRJ+I8<$RP%AYB8/!R!QGN <@@$ 'V_1110 4444 %%%%
M!1110 4444 ? %%?7_\ PI+X>?\ 0O?^3MQ_\<H_X4E\//\ H7O_ "=N/_CE
M 'R!17U__P *2^'G_0O?^3MQ_P#'*/\ A27P\_Z%[_R=N/\ XY0!\@45]?\
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MV<K)&HN+B:52NW+ .4RV$4YRA')<X ^;&%7TR@ HHHH **** "BBB@ HHHH
M**** "L/QCKZ^%O!VJZTS1A[6W9HO,5F5I3\L:D+S@N5';KU'6MRO!_VC_$[
MP6>F>&+:?;]HS=W:#<"4!Q&"?NE2P<D<\HIXXR ?/%%%% !1110 5]=_!+7V
MU[X96*RM(T^G.UB[,JJ"$ *!<=0(V09.#D'KU/R)7L'[.VLRV7CF[TK?_H^H
M6A)3*#,D9W*?F(8X4R#"Y/S9(P"5 /I^BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#B_BU?MIOPK\03H9,M;B#Y&4'$CK&?O*PQA^>,XS@J<,/C2OJ/\
M:*F:+X<VJ*(R)=3B1MT:L0/+D;Y21E3E1R,'&1T)!^7* "BBB@ K4\-ZW-X<
M\2Z;K,'F%[.X24HDAC,B@_,FX= RY4\'@G@UET4 ??<$\-U;Q7%O+'-!*@>.
M2-@RNI&001P01SFI*\[^"6OMKWPRL5E:1I].=K%V954$( 4"XZ@1L@R<'(/7
MJ?1* "BBB@ HHHH **** "OACQ5K[^*/%&HZW)!Y#7DID$7FM)L&, ;F.3@
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M 'R!17U__P *2^'G_0O?^3MQ_P#'*/\ A27P\_Z%[_R=N/\ XY0!\@45]?\
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M=.UO1;J[T][.]ANOLS'SHBL9!*+N^<%B =Q9L9/'3 !ZI1110 4444 %%%%
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M #7TO7PQX5\0W'A3Q1IVN6J[Y+24.4R!YB$8=,D'&Y2PSCC.1S7W/0 4444
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MVUGCDR8[9#SF3!!+$=%!'!W'C 8 ],GGAM;>6XN)8X8(D+R22,%5% R22>
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M %N<\_=QWR/+Z^C_ -FO3/*\/:YJWG9^TW:6WE;?N^4F[=G/.?.QC'&WOG@
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M\0W'BKX?Z/K%XN+J:(I,<CYW1FC9^  -Q4M@#C..U '44444 %%%% !1110
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MC['TK2K'0]+M],TRVCMK.W39%$G11_,DG))/))).2: +E%%% !1110 4444
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M7(8DKM#<BN;H **** /IOX!>.5UCP^?"]Y+(VH::A> L&.^VR /F)/*LVW'
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M_H5-#_\ !=#_ /$U)X+C6'P+X>B2:.=$TRV598PP5P(E^8;@#@]>0#Z@5N4
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M0"&(4L1\65]I_$Z)I?AEXB5+>.<BR=MCQK(  ,EL,RC*@;@<Y! (#$!3\64
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M;/Q#H=EJ]@^^UNXEE3)!*YZJV"0&!R",\$$5H4 %%%% !1110 4444 %%%%
M!1110 5P_P 8'MT^%&OFZ3?'Y2 #:6^<R($. R]&VG.>.I##Y3W%</\ &";R
M/A1K[_:9[?,2)O@&6.Z1%VGD?*V=K<_=8\'H0#XXHHHH *^Q_@_Y7_"J- \G
MR-OE/GR-^W=YC[L[^=V<[L?+NSM^7%?'%?8_P?\ *_X51H'D^1M\I\^1OV[O
M,?=G?SNSG=CY=V=ORXH [BBBB@ HHHH **** "BBB@ HHHH *^?/VF8V%QX:
ME,TA1DN5$1"[5(,66'&<G(!R2/E& .<_0=?/'[2Z(-1\.R"SV2-%.&NL+^\
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M_+_>YV5]'U\Z?LTB[_MG7V22068MXA*@1"IDW-L)8G<"!YF  0<G)!"Y^BZ
M"BBB@ HHHH **** .?\ ''AO_A+O!>J:&)/+DNHOW3EL 2*0Z;C@_+N5<X&<
M9QS7Q!7W_7S9\>OA\VFZH?%NF02-9WK_ .G*D:A+>7@!^.<.<Y)'WLY.7 H
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MBEB!D@9P/45\*7]]<:GJ-S?WDGF75U*\TS[0-SL26.!P,DGI0!7HHHH ]0^
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M%#2]]QY-O?;K*7Y-V_>/D7H2,R"/D8]SC-?7] !1110 4444 %%%% !1110
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MSCJS*V #SB+N!QX?7V?\4?#O_"3_  ZU>QCB\RZCB^TVP6'S7\R/Y@J#KN8
MID<_.>O0_&% !1110!]O^!_$G_"7>"]+UPQ^7)=1?O4"X D4E'VC)^7<K8R<
MXQGFN@KP/]FS7U-OK/AR1HPZN+Z!0K;F! 20D],#$6!P?F/7M[Y0 4444 %%
M%% !1110 4444 %>-_M&ZJMKX*T_3%N9(Y[V]#F)=P$L4:G=NQP0&:(X/?!'
M3CV2OGC]I36=^HZ'H:/.OE1/>2IG$;[SL0XSRPV2=1P&X/)H \'HHHH ZSX8
MV2W_ ,3?#L+RR1A;U)MR0M*28SO PO(!*X+=%!+'@&OM.ODSX#:;-??%2SN(
MFC"6%O-<2AB<E2ABPO'7=(IYQP#]#]9T <G\3='FUWX;ZYI]O!)/.]OYD<4;
M$,[(P< 85B3E?NX^;IE<[A\65]_U\4?$;1O[ ^(NO:<$@CC6[:6*. 81(Y/W
MB*!@8PKJ,#@8XXH Y>BBB@#W#]G#Q%]FUS4_#TTN([R(7-N'FP!(G#*J'JS*
MV21SB+N!Q]'U\.>#M?;PMXQTK6E:0):W"M+Y:JS-$?ED4!N,E"P[=>HZU]QT
M %%%% 'S9^T;XAFN?$NG^'XKF-K2TMQ<2QQN21,Y(PXSC(0*5R,@2'LU>)UN
M>,=?;Q3XQU76F:0I=7#-%YBJK+$/EC4A>,A H[].IZUAT %>D?!'PP_B#XBV
MEU)!YECI7^ES,=P <?ZH C^+?A@"1D(W7&#YO7TW^SKH#:?X.OM:E617U2X"
MQY92K1194, .0=[2@Y_NCCN0#V2L/QEIBZSX*UO3VCCD,]E*J!XFD ?:2C;5
M5F)# $;03D# SBMRB@#X HJYJU@VE:S?:<XD#VEQ) WF*H;*L5Y"LP!X[,1Z
M$]:IT %?0_[-%]<2:=XBL&DS:PRP31IM'RNX<,<]>1&GY>YKYXKV#]G.]\CQ
M]>VI3*W&GO@B#>0RNA&7 )1<;LY(4G:#D[: /I^BBB@ HHHH **** "O._B_
M\0)O GAJ$:?Y?]K:@[16Q=21$JCYY,8P2N5 ![L#@@$'T2OCSXQZ^WB#XFZJ
MVZ3R+%_L,*NJJ5$9(<<=09/,()YP1TZ  X>>>:ZN);BXEDFGE<O))(Q9G8G)
M))Y))YS7I'PS^$%]XZ0ZG?3R:?HJ.%64)E[DAOF6//  &1O.0#P V&QC_"WP
M8OCCQK!I\\D:V=NGVN[5MV9(E9047!!RQ8#.1@$GD@ _8\$$-K;Q6]O%'#!$
M@2..-0JHH&  !P !QB@#YX^('P"FL+?^T?"!DN8(+<>?8RL6G=E !:/ PQ89
M8KQR#MSD*/"Z^_Z\K^)GP:L?%Z#4-#6TT[6@Y,C%=D5R&;+&3:"=^23OP2>A
MSP5 /E2OKOX3> M%\)^'TO[.[M-4U"\3$^HV[B2,@'F.)A_ &')ZL1DXP%7Y
M0U72K[0]4N-,U.VDMKRW?9+$_53_ "((P01P001D&NP^&?Q,OO &J%'$ESHM
MPX-U: \@]/,CSP' [=& P>@*@'V'16/X8\3Z7XNT.'5](G\VWDX96X>)QU1Q
MV89'Y@@D$$[% 'Q1\1?#UOX5^(&L:/9MFUAE#PC!^1'59%3DDG:&"Y)YQGO7
MM_[.&K/=>$M3TN2;?]BNQ)&ID8F-)%Z $;57<CD88Y);('!;@/VAO*_X65'Y
M?G[O[/B\SS=^W=N?[F[C;C'W/EW;OXMU=!^S0V-1\1+YLXS% ?+6/,;8+\LV
MWAAG@;AD,QP=N5 /H>BBB@ HHHH **** "OF#]HG1/L/CFTU:.WV0ZE:#?+O
MSYDT9VMQGC"&(= #]<U]/UY'^T+H"ZEX#BUA5C\_2KA6+LS ^5(0C*H'!);R
MCSV4X/8@'RY1110!8L+ZXTS4;:_LY/+NK65)H7V@[74@J<'@X('6OO."9;FW
MBG02!)$#J)(V1@",\JP!4^Q ([U\"5]A_!K56U;X5Z,\MS'//;H]J^W;F,(Y
M5$8#H1'LZ\D$'G.: .\HHK+\2:W#X<\-:EK,_EE+.W>4(\@C$C ?*FX]"S84
M<'DC@T ?('Q-UN'Q#\2-<U&W\OR&N/*C:.02+(L:B,.&'!#!-WX]3UKDZ**
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MSC#],[1C>GJ%>7_'Z39\+YU\S;ONX5QOV[^2<8WKNZ9QA^F=HQO0 ^4****
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M-P H ^/**],\4? SQ?X>1[BTACUBT#L UB&:4+N 4M$1G)SG";L8.3@9/F=
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M^0/@E_R5[0O^WC_TGDKZ_H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[#8V;\8!.<;'Z8SG QC.Y,;U^SZ "BBB@ HHHH **** "BBB@ HHHH *\O\
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MWEDAGB</')&Q5D8'(((Y!!YS7V/\,/&T/C;P=:W3W$;ZI;H(K^,$;ED&0'(
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MC #-ZA0 4444 %%%% !1110 5Y'^T+KZZ;X#BT=6C\_5;A5*,K$^5&0[,I'
M(;RASV8X'<>N5\H?'GQ%_;7Q%EL8I=]KI42VRA)MZ&0_-(P'16R0A'7]WSZ
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M4(^8#<?OG@D@=@"6SX/7T_\ M&6+W'@&RNHXYW^S:@AD*,VQ$9'&YE'R_>V
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MQ\R??7[3KXP^%<GE?%#P\WF>7F["YW[,Y!&,[TZYQC)SG&U\[&^SZ "BBB@
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MR,@GI0!\$45W'Q3\"OX%\6R6\0SIEYNGLF"MA4+']T2V<LG /)R"I.-V!P]
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M D@ .!M.3@9!(.T5VE% 'P!17L'Q^\&_V+XHC\0V<.VQU7_7;%PL=P!\V<*
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M8D#H* "BBB@ HHHH ^ **** /0/@E_R5[0O^WC_TGDKZ_KY ^"7_ "5[0O\
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M[#^#$:Q?"3052:.8%)6W(& !,SDK\P!R"<'MD'!(P2 =Y1110 4444 %%%%
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MN^B::SN\KLQM4)9I5VRD\<EU&&/\0X.: /A2BONM/#6@QNCIHFFJZ/$ZL+5
M5:)=L1''!13A3_".!BHT\)^&XY;66/P_I226F/LSK91@PX8N-AQ\OS$MQW)/
M6@#X8HK['\8?#WP_J'@;6--L-'L;"26+SHWL[-582Q@E#A$+'J5^4%BKL!R:
M^.* "BBB@#Z[^"6NS:Y\,K$7$L<DM@[61*YR%0#8&&T $(RCC=D $G)('HE?
M+G[/6OMIOCR71V:3R-5MV4(JJ1YL8+JS$\@!?-''=AD=Q]1T %%%% !1110
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M110 4444 %%%% 'P!1110!VGPGU6QT/XE:7J>IW,=M9VZ7#RROT4>1)^)).
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M, 6>1@WSGE0P 4=L)E<@G.XL!Z97E_P!1%^%\!1X&9KN8N(F4LIR!AP%!#8
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M"0 ?8?@[0F\,^#M*T:1XWEM+=4E:-5"E^K8PJY&XGDC)ZMDDD[E%% !1110
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MS%./,:3,;8*<*N[AAGD[1D,HR=N%\'H *V/";I'XRT.26\^Q1KJ%N6NLJ/)
MD7+Y<%1CK\P(XY&*QZV/";;/&6AMYL\6-0MSYEO'YDB?O%Y1=K;F'8;6R>,'
MI0!]ST444 %%%% !1110 4444 %?-'[2+N?&6DQF\WQKI^5M<M^[)D?+X(V_
M-@#@Y_=\@#;GZ7KYH_:1;/C+25\V XT_/EK'B1<R/RS;>5..!N."K' W98 \
M7HHHH ] ^"7_ "5[0O\ MX_])Y*^OZ^0/@E_R5[0O^WC_P!)Y*^OZ "BBB@
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M<[9.3UW22'/J['^(YIT >F?$#XSZOXWL/[+@M(],TN1 +BW#B9IF#A@2Y4$
M%5P% [Y)R /,Z** "BBNL^'_ (#OO'WB#^S[=I+>TC0O=7HBWK ,';D97)9A
M@#.>IZ*: /2/V>O!,TVJ2^+[ZWD2WMT:*P9@0))&RKNO/(5<KR""7.#E*^BZ
MIZ5I5CH>EV^F:9;1VUG;ILBB3HH_F23DDGDDDG)-7* "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^
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MPS?#?MQN4+C=Y>,Y/'^M7.>F'SC8^T ^@_@,2?A79@QR+BXF +/(P;YSRH8
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M$"UUC7+#[#:V<4KJ?.BE\UV4QA/D<D<.6SC^''>OH>@ HHHH **** "BBB@
MHHHH *P_&.@+XI\':KHK+&7NK=EB\QF55E'S1L2O. X4]^G0]*W** /@"BO7
M/B/\*/%$OQ!U6YT;1KN\L+ZX-Q%,'1LM(4W@X(V@22$#=CY03R%9AR?_  JO
MQS]E^T?\(S?;/3:-_P#JO-^[G=]WCI][Y/O_ "T <?7I'P1\3OX?^(MI:R3^
M78ZK_HDRG<07/^J( _BWX4$@X#MTSD9<_P )?'EL)2_AJ[/EN4;RV1\D1^9Q
MM8[AMXR,@M\H^;Y:L#X3?$33KA[B'0;N*>R1;D203QEEP208RK99P4)VKEA\
MO'(R ?8=%5[":XN-.MIKRU^R74D2/-;^8)/*<@%DW#AL'(R.N*L4 %%%% !1
M14<\RVUO+.XD*1H781QL[$ 9X502Q]@"3VH ^*/B!J:ZQ\0=?OHY(Y8GO9%B
MDCE:1713M5@Q8Y!50>#@9PH P!S==I=_#'QY)<7$\OAB[#EW=Q#"BKD&0G:J
M<8_=M@*,<IC[Z;HY/A7XYBW[O#-\=F[.U0V=OF9Q@\_ZIL8ZY3&=Z;@#CZ]D
M_9OA9O'6IS@Q[$TQD(,BALM+&1A<Y(^4Y(&!QG&1GBT^%?CEY6C'AF^#+*82
M2H W!D4D$G!7+KAA\I 8@X5B/9_@!X5UWPW%K\FLZ9/8K=?9?)$P +X5V/'7
M@2+G/0Y'56  /:**** "BBB@ HHHH ^'/&.A+X9\8ZKHT;R/%:7#)$TBL&*=
M5SE5R=I'(&#U7(()PZ^@_CC\.M7UWQ5IVJ^']-DNY+FW\JZ6&(+M9755=WR
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M%% !1110 4444 %%%% 'S!^T-XD_M/QI;Z&D>V/2(OF<K@M)*%<X.>5"B/'
M.=W48KQ^N\U+X>^/]=UF[U2;PO=I/J%PUPZJFQ5:5D;'S'*@&9>IXP^?]6^V
MG'\*_',NS;X9OAOVXW*%QN\O&<GC_6KG/3#YQL?: <?76?#3P]-XE^(.CV26
MT<\$=PEQ=+*A:/R4(9P_!&"!M&>"6 /6I(_A7XYEV;?#-\-^W&Y0N-WEXSD\
M?ZU<YZ8?.-C[?7_@-\/]4\/WFIZ[K5K/97#Q+:V]O*-I*,$E9F!'_7,#!X(<
M, 1P >X4444 %%%% !1110 4444 %%%% 'G?QMT!M>^&5\T2R-/ISK?(JLJ@
MA 0Y;/4"-G.!@Y Z]#\B5]]SP0W5O+;W$4<T$J%)(Y%#*ZD8((/!!'&*^0+W
MX/\ C2'4KVWL]$N[JV@N#%%<%5C\Y3*T2N%+9 )7<>NU2&)VD,0#@Z*["3X5
M^.8M^[PS?'9NSM4-G;YF<8//^J;&.N4QG>FZ27X2^/(GG1O#5V3 CN^QD8$*
MJL=I#88X<8"Y)(8#)5@ #T3]F[7W74=6\.&#,<D7VY9O-;Y2I1"NPG;SN!R
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M6BA/)1,L>-Z[N@P,/DXPN<,H!\@45V$?PK\<R[-OAF^&_;C<H7&[R\9R>/\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>tern-20220811.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-08-16T13:14:41.6873+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.ternspharma.com/20220811" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:tern="http://www.ternspharma.com/20220811" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tern-20220811_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tern-20220811_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.ternspharma.com/20220811/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>tern-20220811_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-08-16T13:14:41.7434+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.ternspharma.com/20220811/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="tern-20220811.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.ternspharma.com/20220811/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10091.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10200.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName" order="10150.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>tern-20220811_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-08-16T13:14:41.7459+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Information, Former Legal or Registered Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInformationFormerLegalOrRegisteredName" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139650643926816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 11, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 11,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Terns Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001831363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1448275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1065 East Hillsdale Blvd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Foster City<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">525-5535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationFormerLegalOrRegisteredName', window );">Entity Information, Former Legal or Registered Name</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TERN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationFormerLegalOrRegisteredName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Former Legal or Registered Name of an entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationFormerLegalOrRegisteredName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>tern-20220811_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tern-20220811.xsd" xlink:type="simple"/>
    <context id="C_68019b1d-3c51-449a-83c6-7131b22f32f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831363</identifier>
        </entity>
        <period>
            <startDate>2022-08-11</startDate>
            <endDate>2022-08-11</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3"
      id="F_4f161d9e-09a7-4a9c-a234-ce2bf546dbf5">0001831363</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3"
      id="F_dcb8bccf-5cea-421b-8344-042291526633">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3"
      id="F_4becf423-9090-422a-89a9-f92b4790c9cd">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3"
      id="F_d4e5e682-e254-4061-afae-eab8da2cb54d">2022-08-11</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3"
      id="F_c7320e8d-b88e-49bb-a95f-effbe0d32faf">Terns Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3"
      id="F_54d5b0d3-97f4-457c-a068-2063e81d9b8e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3"
      id="F_4d5befba-3aaf-4ad3-bb5b-1a3342be99d4">001-39926</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3"
      id="F_86db0caa-1aae-4b08-8ded-a3a2e898e683">98-1448275</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3"
      id="F_0f0c0007-8b5f-477f-bdd9-72bed300e3d7">1065 East Hillsdale Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3"
      id="F_178c5f46-17e9-486a-bf15-9f4625c6c27c">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3"
      id="F_9876f716-0443-4f98-8f4f-42f5683d7bd6">Foster City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3"
      id="F_e18e396f-9cff-42f2-a123-8e1e0b09b5d5">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3"
      id="F_d773e056-3f29-4b13-8723-c68d5eaf58e6">94404</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3"
      id="F_62bc6b0e-9291-4b94-b52a-05d1a65d74f9">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3"
      id="F_091cf60c-23ab-4f59-8d18-ee8f93bd0b57">525-5535</dei:LocalPhoneNumber>
    <dei:EntityInformationFormerLegalOrRegisteredName
      contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3"
      id="F_fc378f46-343e-4361-9ad1-6e9bf8bd4847">N/A</dei:EntityInformationFormerLegalOrRegisteredName>
    <dei:WrittenCommunications
      contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3"
      id="F_70f47f6a-c773-4584-a883-a4ba0d0b1bfc">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3"
      id="F_924c73a6-dac1-487b-aaac-7da200c55289">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3"
      id="F_e70910f9-fb7f-4804-a4a0-e7d56e42a14b">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3"
      id="F_8bb03b9c-36bb-445a-bfe4-4784c9c75648">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3"
      id="F_b58799d0-0471-4eb4-9655-eabaec2cf76d">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3"
      id="F_1fae9fe8-57a4-47da-a761-832e58b20c71">TERN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3"
      id="F_48f0c865-d1b4-48db-bfbc-ab09246856c7">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3"
      id="F_899031a1-41e9-472d-9231-ca568cfbec3e">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_68019b1d-3c51-449a-83c6-7131b22f32f3"
      id="F_551e8403-0b87-495d-bf96-eb53c65ee6c3">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( $**$%4'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !"BA!52Q9IO.X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L,P#(9?9?B>R':A%)/FTK'3!H,5-G8SLMJ:Q8FQ-9*^_9*L31G; ^QHZ?>G
M3Z *H\$NT7/J(B7VE.^&T+398-R*$W,T !E/%&PNQT0[-@]="I;'9SI"M/AA
MCP1:RC4$8NLL6YB 15R(HJX<&DQDN4L7O,,%'S]3,\,< C44J.4,JE0@ZFEB
M/ ]-!3? !&-*(7\7R"W$N?HG=NZ N"2'[)=4W_=EOYISXPX*WIX>7^9U"]]F
MMBW2^"M[P^=(6W&=_+K:W>\?1*VEUH7<%&J]U\JHC9'J?7+]X7<3#IWS!_^/
MC:^"=06_[J+^ E!+ P04    " !"BA!5F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M $**$%4M5/7^M@0  (T2   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MI9CQ;^(V%,?_%2N;IDUJF\00"AT@44IWU?5ZK+"=M&D_F,2 U23.V0ZT__V>
M$YJPN_""M%\@@;QO/GY^_CXGP[U4+WK+N2&O29SJD;,U)KMQ71UN><+TE<QX
M"O^LI4J8@5.U<76F.(N*H"1VJ>?UW(2)U!D/B]_F:CR4N8E%RN>*Z#Q)F'J[
MY;'<CQS?>?_A66RVQO[@CH<9V_ %-W]D<P5G;J42B82G6LB4*+X>.1/_YI9>
MVX#BBC\%W^NC8V*'LI+RQ9X\1"/'LT0\YJ&Q$@R^=GS*X]@J <?7@ZA3W=,&
M'A^_J]\7@X?!K)CF4QE_$9'9CIR^0R*^9GELGN7^ S\,*+!ZH8QU\4GVY;4!
M=4B8:R.30S 0)"(MO]GK(1%' =U3 ?000 ON\D8%Y1TS;#Q4<D^4O1K4[$$Q
MU"(:X$1J9V5A%/PK(,Z,[V280Y(-F:01F:5&F#?RD):S#5D;N@9N8B]UPX/@
M;2E(3PA.\LT5\?T+0CU*_QON EL%2"M 6NAU3NA-Y8XK\O=DI8V"*?RGB:A4
MZ#8KV+J^T1D+^<B!PM5<[;@S_ND'O^?]BO!U*KX.IEXG</F6\28X/+Q_^1&!
MZ%80751E @1107$?LTT3!1Z_9K'F"$=0<03G)6/.E9"VH"("9=F8%URI*J.V
M.NI5:#U4\%#;SWPC;"4!XQ-+&L%PG257J2;S+8,5$O+<B!!R=P%K)KQ"**\K
MRNMS**>00\5B4(WX*_G(WYHX<27/\_Q^Q^_T.@A6O\+JGX,U2[C:B'1#?H-X
MLR53F60L;83#]8S*L7(;5%B#<[#N1<S)4YZLN&I"P34@39>=P8#V$![?J]W4
M.X<(JD&J3*K"0R_(PL :(%)!PG*86)A?&3667HOZW0R#/+)\_QS()7LE#Q%4
MFEA#$1<]\G026R0'_4N_V^W3ZP CK#W?1RW[G7 216#8L+H.!^01KB.?T^;<
MX9*^UPO(C&E#/H@XUA&#FKF-=Q&V:OVZ"?BXC:/ R[UL!,8E%[F HO$]#P.L
M&X2/._RW@%-[!A6YE/OF)H_+W4MMH"U;%0RO[AL^;O??XE4K9J[D3J1A\XSC
MFM,)AE;W#?^LQE&AS6'H8,U_B>ST,L85!]VNU\78ZF[AXR9?S.($=N.G47"!
M7H"65]T??-S0'R6T0>B*,L6<N$4DH,%E$'10"ZE;@W]6;SC:RUX0NX^'JGWD
M&X"%XBHW USQZ.1FH.4N3RY69+3N&Q1W]B]*&,-3VU&3/#W8L6[<Z^)";3LY
M6G<)BEOZ0L8B%,:V^T^P&)5@<2,/KM+*<_0<@!OX7/'+$-+#P0W*#3?L>6$V
M/Z_7S=76HM=*5IL_Q9WZ.[('K7,@:P7$95L!:_.G9YG_[)4L8>>K1='KRRUZ
M(]?_>UB@M>M3W*&7PD 7EFOBTY]7OY %#W/U74<Y,+5X/:0?QK0P,GRY(#]Z
M5W;[2S*FR([%.2<9S(.&/3O*7;<$VO(,H%ADU\7B+5G)YE71(C![?L)(Z@9
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MZ.#<@V#OX96,'<V/'W?W U!+ P04    " !"BA!5)!Z;HJT   #X 0  &@
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I0P5,
M75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LIDR^SO
M *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\./VR
M./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/
M3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ 0HH05660>9(9 0  SP,
M !,   !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +
M77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5
M!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP
M39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM
M2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>
M,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]
M#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4
M" !"BA!5!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( $**$%5+%FF\[@   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( $**$%697)PC
M$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ 0HH052U4]?ZV!   C1(  !@              ("!#0@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( $**$%6?H!OP
ML0(  .(,   -              "  ?D,  !X;"]S='EL97,N>&UL4$L! A0#
M%     @ 0HH059>*NQS     $P(   L              ( !U0\  %]R96QS
M+RYR96QS4$L! A0#%     @ 0HH053JJHN=  0  / (   \
M ( !OA   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( $**$%4D'INBK0
M /@!   :              "  2L2  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( $**$%5ED'F2&0$  ,\#   3              "
M 1 3  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  %H4
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>25</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="tern-20220811.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ternspharma.com/20220811/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tern-20220811.htm">tern-20220811.htm</File>
    <File>tern-20220811.xsd</File>
    <File>tern-20220811_lab.xml</File>
    <File>tern-20220811_pre.xml</File>
    <File>tern-ex1_1.htm</File>
    <File>tern-ex4_1.htm</File>
    <File>tern-ex5_1.htm</File>
    <File>tern-ex99_1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>20
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tern-20220811.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "tern-20220811.htm"
     ]
    },
    "labelLink": {
     "local": [
      "tern-20220811_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tern-20220811_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "tern-20220811.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 26,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 25,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "tern",
   "nsuri": "http://www.ternspharma.com/20220811",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tern-20220811.htm",
      "contextRef": "C_68019b1d-3c51-449a-83c6-7131b22f32f3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document And Entity Information",
     "role": "http://www.ternspharma.com/20220811/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tern-20220811.htm",
      "contextRef": "C_68019b1d-3c51-449a-83c6-7131b22f32f3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20220811/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20220811/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20220811/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20220811/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20220811/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20220811/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20220811/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20220811/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20220811/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20220811/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20220811/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20220811/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20220811/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20220811/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Legal or Registered Name of an entity",
        "label": "Entity Information, Former Legal or Registered Name"
       }
      }
     },
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20220811/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20220811/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20220811/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20220811/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20220811/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20220811/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20220811/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20220811/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20220811/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20220811/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20220811/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>21
<FILENAME>0000950170-22-017517-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-22-017517-xbrl.zip
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MXPQ_)I]9P4E'4S2-*@Y5K2M5[ZA&QU!;CJ/;_ZDH'469?I4.QUETW2_(OG]
M\",8.4EX'(_)ERAAB1^QF/2J(0]ACGZ+',<QN<2O<G+)<Y[=\*"%7?[E0[\
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ME-9$N9(*!M/]G!6P$A)0[#"E"1@R.&D0A,,TE_$U8<-/]]2%/R=?@!!!,(D
M*DZDW*'D92<XI(R&%7,KF40<)]U*")0AGUH .HX&4;E2V3B0SD8I^7")&9,6
MU@R48'Q^G9:53<6R&/&RB(<@1G,_BX;URJ4SL:GE0#HD00KSQB"2@$U6E!X5
MDREZO.!UY5!F "+%2ZRLQFJ-*%;M*)945O.=)'(Y#"SL1.$,>F,)1%@P[B8
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MK/6R@<@E&>$-+Z(_-BKZ:08K#N:/.#WS^(FJ**]W_L1J*8KVP-D20V^YKO-
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M*4FHBT;^N&T:I\?GAR?FR(WO3#4XZ>/&<?HXW/3X'.Q3#^E.SO9AXS!J^7A
M#%/OFGAB4=!0Z>,JPQMQQ1(J>=@XS#4)Q;7Q/(:"(/[#9QEJ:\B*8VO#[+P
MLU,QIKCI[]F(KL@NR*W(:A$?*%^N_7_PHF#>E@17"SH,^=2\9P^,/F'Q>-F!
MF@VO"+;/IRUS_ %_(*W_0IM"RFQ<17C7<\2F_/7L,Z.K<-:G\X5#BB'UT56A
MKD?,(0$6+TW1\ES,F0^M"/(&^^AN.1\C5@BW%5(1%']#I6Q!F7S?E/.@3Y?\
M=MN43O'R496A3RB;2X0;OH'8+9HZ_CU[1%,<A(@A[\Z9E]6PU_"*BHFR\CLS
M+(7.A%4$-W+6 X\O0GB"HP^3';=Q4;QQ7/'AY#_,*"F>:+D0XU /C,^..7]'
M<Y%X41L$P1*QD?@,8?>3B19RYY"JH5^$6RGH$+E+QN^Y=F<\$I]^&KQ<2&50
MUVMWYI I*IC3VC#S<-3'+G_^D>D7OG S[/@ZM'R0<3#^8!9VT' S'U,=4_JX
M<9R_^:4)$1%W]I+$"UF@P=+'I?%$M'!&^);PNQ"QO@[3S@1_#Z5+IGU737D%
MW_UQ<F[V\D:$3N-2:L"_2N6_C_9SEM<C3=D(!Y(F&B!$S'!N&PR'GE N 4(#
MA(@93*WC<"!O8I)&8L#5I/MIEERX$L<""PTSE(4.Q8'(D1[$2A_4AG"J$=R3
MBJOHF*ABM*(55/'L<+Q2#7*V4@9"L@+^E/?Q2B5$FL!%#:XX9;;(*]4A5<6U
M4+HF*\E8)\>5$(N!5 ,N9Y)<ZZ<<QZ\D(=*$6-1H%3FWY<@2UO L&#_*3/(_
M&S+'<0L=B(1,XI;Z,L=5D)+>FL5Q N-KTGYVS;$U)CD^0)0%9!I1Z',B$)E,
MUIIV>8ZKZ5G+.':![7,</Q>%M*K1>92UAPZ$ES(@=8SB[C**#L3GLI:[I0N1
M,$3*(*4K*<A *>9KR/I-!Y++L4 GT.Z<C-^#4C7+O&U%'<BMI$!I&5QX\C;5
MH=")$"@E,\0I$^O0.R/2@$C$#*?6U3J0-]:"M%@I=X^E#3V'N2HQW]R1.XZP
M7<HG_2*T(HQX^(31N:X'1Z6C1:9;WM&K E+;N:,@\WY;/9"Z?I[D1&:]MGH0
M2[M\%&NQX58O]';O3Y8UL=CJ0=S9$:1XR\VVMP7?V1>^\U;@\]U#6O2,L?8&
MP+4]15KVO*GV!O +.HVT!>C\M#I+*.@_2K/K'+0ZH4N[DM+HQ19:K044]BIE
MZ/7669WH^0ZF-'+&+:L3=:^^IC3];O.LWH)>TNV4K6QO[ZS.$O4]4.E2--98
MG<@[.J/2[&7^6#U%%/5+*6ZM&U8/ZKY=5 I]+V?L392R?Q%O [^HXTI!:^VO
M>E%U?5A9W)SS51-R87=6 JSWO.K!U?9L*=*\UU4/9&DGEX(M-KPD]+9;Q;_\
M?ER^4WMP]$]RE_\#4$L#!!0    ( $**$%5O"@NHSP0  +HI   5    =&5R
M;BTR,#(R,#@Q,5]P<F4N>&ULW5I=<^(V%'W/KU#=E]UIC6U(=Q,F9(>2I,.4
M? RPTYV^[!C[ IK*DD<RP?S[7AF,,=B0/.#6^Q(;ZT@Z1[I7'V=R\R4.&'D%
MJ:C@'<-IV 8![@F?\EG'^#HRNZ->OV]\N;VX^<DTR=U#_XD\P9)TO8B^PAU5
M'A-J(8%\&#U^)-]^'P[(@/)_)JX"<B>\10 \(B:91U'8MJSE<MGPIY0KP181
M=J@:G@@L8IJ;YGL27/V=W+D1D';3;C9-^\IT/HV=5MNY;%\ZC<^7K<M?;+MM
MVSO51+B2=#:/R ?O(]&UL&_.@;$5>:#<Y1YU&1FEG?Y*^MQKD"YC9*AK*3($
M!?(5_,:Z388*VBR5$2O:5MX< G<@O(1>Q]C1$T\D:P@YLYJVW;*VM4H1^I>9
MPDS]R72:9LMIQ,HW",X&5TG?;^@DA<<'^&4K03O7U]=64KJ%*EH$Q&8=Z]OC
M8)3H-'&&(APU,&XO"%D/AQ0,AC E^OEUV,\U$H'D*IR[,G"3"=4S8%\YCA6Y
ML> B6%FZEI7&0_KL<O^>1S1:]?E48%T]M,@SZ6XN8=HQ=,-FVIH>H)^'V-#W
M]S04K4+H&(H&(0/#RO2$$N><1PE61^P&KHF>6QM^UIWL,\@SAC@"[H.?3$%*
MF@DO!V(Z((7,#YHFKY!]$C,*O,9,O%H^T(2Z?DE&-!E-_/&])S#[NQ,52=>+
MTI:8.P'6,0[+K7/3Z>+H^7H$'Y@[*Z"3+S\[G1Y.81=7I9[PH6AP=HO/3B8-
MKA>05&!\^7J9+&!5C*N,WAA;/,(J*3X[F77V=7T?LTQM'IAEX!0P*\?^9S2;
M[Z#9K)BF#OIG.19+?HKD#K):BB\"-S#V-PU+\O8(N%JB(US_X5F^2/%*]89[
M@NH^O"*R/4Q;Z;(^;DCQG[ J9;F/JXC>?0!RA@?6/Z181O.>"$*7EY,L1E=%
M-1Y+ERNJ-_WU\ES.\Q!:$<D'RN!I$4Q EI+;@51$"L_L0H9")N>E) ]Z8H'A
MMCJ:XL=K549]>P9\P!>0 YBY[%D.8485'C#!?W*#8QK>5+TB,>M>,3*CHZ3W
M8!61&[MQW\=%B$[I^JIV(HS+\&>GJZ^2[&4N>'FB'4#.3NI%8G8$>$;S0!_4
M^DHM0([U-40^3Z>%)$]6J9KTN^A62G0$WD)BS#G-R5C?  OH'4 J(W4?>W.7
MSZ DIPMAYR<G&/5P_^.S1URX)759$;5#T-F)X<:L#;+1*IB((D[Y\K/3^0NG
M)@*N(WO!-PN9*J!5C,O1VS4ENC)/U95>VBB^'C@E>8]J@[!"5V)[IC>G;'O4
MF4H1%)D+:6^BZ*I/A,1<[1B.;3NVMBE#/!+IF.P8>%E:*"0C0DU[/P#^3Y+R
M=L)6D=.JK:(23R*;K&;MI:W]C$R175M%1TR13-[U#R>OF9/G_!#R=DV8;!WY
M04)SS[[)]-5W,3GN^F0*Z[NWE5A%6>9=UEQ:B<V4"?RM[@(+S*FMNF;=UY9=
M5RN;LT\U5W7"%LN$?JZ]T+>9:-E26O=TW'?:LKFL[W7AA$V72;RJK<1#:R\+
MR?IN@:>]P4QE?6\0Q\S$3%]]8_/0@\SV]_J>/(M-S*VR5GVSKL@!S>*POEOZ
MGH&:!6%]+W@E)FPV6V\[:=Y8!\H&^.'V8E.@_^C__;O]%U!+ P04    " !"
MBA!5DHV6^![B   CUP< #@   '1E<FXM97@Q7S$N:'1M[+UI<]M(EC;Z_?X*
MQ+SS3H@1D$;R6F7UG0B5[:IQC,OE:[N[>CZ"0))$"0186$2Q?_T]6VY82,HE
MVZ*)F.FR1('(S).99S_/^=NB7F;_]?\$?UNH*(%_@[_5:9VI_WK]S].+LXN_
M_2?_!G__3WG@;],BV="#JZ"J-YGZ?_^M5K?U:9HG*J]?G)^=_]_+69'7IU7Z
M+_7B GY?U9?+J)RG^6E=K%Y</*)/LC17IPN5SA?U"QCH*7]G%BW3;//B4[I4
M5?!.K8,/Q3+*]=>G15T7RQ?\2AHTRM)Y_J+$MUS^VW_]#=^A)S6-XNMY631Y
M<AH765&^*.?3Z.0\I/^;7'8^NYA<KA=IK4ZK512K%ZM2G:[+:,7S6O-$IT66
MN(OCI6R=.4Q[G2;UXL4LK6$B>0U$@JF^OEVDT[0.B,;X@O_ZVW^N1JKN255^
M&&?T(JUAMO$6.JNXJ=,B#_ZAR@K^?:C4CF%@57X-<N=%N8RR^SG&?YN6YG^?
M5)E7P?M%!*^/%1 ]CK(J#-[D\=E(]/LD^L6C\-%3&/C\//@(U(;O%+/@9;%<
MPBG_6!?Q=1B\C\K@'U'6J.#?8='GYP^6R1SF#D1Y,A+T/@GZ'@;X&6:GDN#W
MJ"RCO*Z"N@C>-V6\B"H57#P)GSW>=N3'[;C/[?@[$*Q<EVF=YO/@:EXJM80_
M/%0:?S5%Y3Y)?-7,FPKTOXLP>'3^Z-&]T/;\WDF;J=G!4?9EL59Y "P:&<0J
MRC=A\/;MRY' ]ZKT757!!P4C5?!15*<WS)'KA<(_5NI&E5$6&#8"JG>0I56M
M$OQS"CP[7JBDR8"Q!PM5JKHXH.T9IO5?)BP3X3_^S\6S\\M#(,5#/ZGQ?Q;!
MR Z^,)&?_OAC\%;=@JI0@S9V=:/R1HWDO3?RXA/_6Y1@U+W[W^#B_+!TA9%7
MCJ0XO"OW-DI2>!!EQB_P28;6SXOQUMWIJ#T[>_;L^1<FABSDP$_;%K]I&$3!
M*Y5%ZZA405R4JZ*,R)E] IIV\!__Y_;1^45\*7H-_YI<3L)@51:KHE+D0TFK
MJE%TEBN59?@)?E>KZ$U710_Z]'-_1%>Q=X:=%66P7A3+8%,T 4XYBLF#$%5!
MV3(6O->U+ GGC1%H;O-YJ>91K=# <%R?E?$#Q>P'JMCUN8K*X,9U?08K5?+3
MH=@H6A/T9\&.)3,XD0PW?\9^J;7CEUIIOU1G?M9/U3^_U@Q@A36^1-VJ,D[A
MA:LRC56@_FPBVJJ>)<#NX N UDOX<AWA3NE- D+KP-)/_N*T5\TL[RSX!'\6
M9QHNU?C=<./P?3!0J6:J+.']_&Z/6BINT$&DJC/]3GKC7LNF0QE-X7PUJ\)9
MO3QUQZG(X[*8SYD.O',*HS=U50,IZ,C.X&P'\_0&?U&SF8IK<W6BS,S4H1_^
MNG4A[@ID46V:XMST]/<*FHQ<=F\N6\@.X>_P8X3_4<BCX'\YG*DD29&U]KLM
M@J*')\+E!89*VZKRF+DMCM%VC.C3X;T7#J;^<O '>@+AR\ V0_,T/+7L.EGP
MKSWO62ID(BFNB,\H'-LF TX(''F5-<CIHTH?*'?;OOF^! >D5WV=,W[Q^8'!
M Z+E#AWU^?%80SLH\</]4F)1ZG%7T5R=3DL579^2M'L19>MH4\$7OR'%O@]A
M@RR8?KNM@<7_V:2HEP2^""KR; /_:8L+4(VTS(FFQ8WJ%3(@&CJ2P1$$[3?F
MODQ U?'L<(7!J//LK?,X*BZJ+-,-GLI9BHI%BEJICNP&:U =/+O0TS'@2S$8
MJ:@*XS..]9/XVK"Q"4)4;6=%EA7KJNTY2=*;O;;U?(\=1<TIG6WTFE_,,G5[
M"DI\6?=OJ*64#'?0.^RQYLLDK599M'F1YD0F),7=!ME&S#;=0-DP+,394'\.
M7Y&:1(I$Q>(@>4%^#9K#O=RD#VH./%F<+Q^!KWH)$8=S8O[MO\Z"P&,+<$]A
MS%6$ABG>YUF:H;-#\P-[I>FOKV_AYN=S^OX2C/@^7Y1\;ATIM!?MMUV!08T.
MDQ\?/R9F$0%!$Y58^Z<$4XL'+17*+21]Y1CN>GBRXGB($Z!N!I8Z"+UL$PZX
M*W!DU\.$K[=[6^F]18OO9_2Q?#Q]')S\#%0)WA5GP>/'CT\?/7O\^/GY!%TQ
M<=:PNP!=;M4*QFZ ]Y4*IXO<LN@CHN,9T#Z+(/C8Q(N!J;CT"=AN#6K8;N#A
MP53%\!?Q4*0WRIT4/I?F*.WIA?"G64 ^IP2Y?H)\O&IP$C#-#VC8/GE\?A7B
M?W]"NQ'^?3F\=^PR@7-3ZST9H*,[87@2Y8Z9;:ZJ*C@Q;D"90_#&3MK9J;3:
MPX72?U'U6RZ)_O"5IA*G69J'QMHV+WD/&YC"!8K*3?#>[*OQ*Z&.!8N(8,/L
MK@O=V7U:#6]F<$)3@*M'.XH?57R&ZV(")(65*Y] (3WMC-2ZHLY=Z.[HHR<G
MT98;J(_CP#K8F]%'T=W;2BZ68HE_Z-M8GVW\A.I$E]03WQWB;-# IN"3K7>)
M']?\6C6K5<9KV'%/_3OJ.5Y!AZIJ/D4G<%6640+:T$V49M:IB7J_JNAV:(4)
M5*G.#ET\?SRX/1,<$UAWCF2%5]*6BP;'1(27HP)6=34P8"EO?"<GLGH^.NBU
MGH+E=Y-&:&<,'-3N87KVZ&2ZY3#Y/GWYQL#Y<788OI73$3=&CK[;LBW>UF]_
MG5A!P)F$QV$ A \T7\H=TSH+KKR)T)X#XS%A$F+V1FT^H3_JJ9E$22OZC$>P
M;S"^V/W,!ADP?M/YI&=I[#Y$CWB>F'7BUY(B;IBUP*<2-X*O3-VUU4)E=Y_?
MP,R"BT=XG(SP&]IO$DMR[LS5#Q*)A&QA';(T_23MR[Y4"#7#C_&6+Z,-$(29
MA'^"8"UZ6XC/ZBT)_8^]LP.#Z3]:)F'^2I</^,#*"05\U7W%E]I]E9M,80JB
M()&S=Z^,TF9UKB=?0^=RQW6N!,H%=+K;Y4[5[F-Z%KR,5E3L\R_\$CG'B?].
MFSK(BQI>-P-U7TMUH>HBNN$+@>(![FZ%(1U%G(6(QN_9(>F$.';+;&@&3!_Y
M[^BN^.LIT<0:5F5:E/J"7<$U3&,2JO@64)XJL]%3E15KEA^.C$NL.</2&GT0
MR+535_=P#ZW5I##XVGZT4C6*?'@"D]M %-\&5_XQ?R_?>I56<594#1SM]T#I
M:*[,H7\QJ)B0%JG?- /Y<:JES*JKX[BK[TKG\Z=;% D;QI(U2 QK] ,>P<4R
M"HI_FUJZ\[,7H*&_/_OU+ QTSF'P,JTWI..'='3\FH7[*>L;0W<XV>\HJ7,,
MW7WCT-WH8/\N'.R/CLG!;BH].XZ,@W2R#Q@(X\W\+F[F231Y2%?SWF/%Y.#J
M31[V+8M6+K$7,Z:X4G&3&D]R6ME*XM#:/LZ72,?$%TZC*JUL6,$F,Q1Y%>I$
M7.VE-=ZXRK'5='  )]Y,_W!<-K!B3O3K/A[*PD.](K -\0WH7?BC2/.:'!QN
M]F]-@1_,V#4)NCCM?W]T]NCYDQ]ZTHMM13M:C=9 #&9EL?134FGI9 &B6RUO
MEE,8 EXNWFC'+EVMB@KHQQX-AY[\]A\OJR#'&%%?6K>X?OK79%;RG):GW>%]
M><7WL"Z3*WL_*QM9\/?-@J??-PLF]8JRT2N3K.PSV!2_1G=W&5TKO+3-%*Q[
MN$HS5:(#J2\IA]S)\ OQ-O@J/=QFZ\*%V3=J;Z-X28?=7:W4 O@P+]:92N8N
MIQY:#KKR>39&VOB2AASGL'OS!4=/9[,T2R6$$.7NR\:K_WU?_?C[N_KOHPW%
M&F9%YS::\! %F:?HKH8K5X.LK/"VP*U,ETN5X%5 ?<4$H;%LR:AH41S#XH$<
M('?36<HQEE8%3&_I M]4N)AIS%'F5]$-Z&;OB^PZ^(]HN;I$N9VL\;J^??L^
M#)X\/>\4@UM_HN-9O#@_OWB.[[\X?W%^'ER=_7K6XW9TO8[/V.L8(B> [Y%.
M4'#% SV)E0Y1K#3[JB+^T'D.0V0AJ7-95!/?BR2FG\Z P4V;*J74A23:<-B)
MG"LFY#A4UZ%IB"R,>!PG ,#.B"]?&"--$[_D13Y7PUN_5\;+2V#"Q(_AI:;V
M:0Q0?>5;*NE0H@4G^A"ZF].ZR=$\2O,*XY89G*9R\ KJP1RE66ZS,9%Z#;".
M^.<X%UUVS3SJZ!8^AQ-('*,GV<2M=Z/3ZKP.U.T-?#=M\Y(S+%GE)?E5<O[Z
MM3"G^Q?%(,Q9^9C177FE2/4OX"6?2KS^IF13G_M7GUZZ*889YQQUZ<>C$@-8
M8VD>$KULXIH+(*W58:/P-'F^<FZZLZ6I^=*)C51VF ,0"!AU7%M>VWJ$$@@Y
MGI?2MF+0,91L')J SB1#(Z<2Y4V"_2HO,+> #=D!_J1+S#@/R;*C/@[H<1&?
M,NO4/;56OA0H?/A,PG'I7Z.QZ%W6ZD5XO8''L-^](H<4-5YB4],JV6MJ7L!O
M?MQ<B[+^(Z2OS*[K(!9"VQ#1)DI;TIGO]3%+?3QD@E]*[V%WAW9>N'Z/)Q<_
M_NCZ/>BV9JEJ**-/EB)O\QCO3"L=>GUA1U-@L@JG\1\VJ2DNG7OHTV4=1J*X
M:H4W:V<*UH-2P&;-.=<!AAZ<4WN99YZMQPM:E?!K#;MQ@DDY,'!>!"":\JW<
M9H)3Q4+WBR=/+WY\0B1?;W,U>>"$:(7B#O>DW/DG^9X/T.&F33R0T.E##\@_
M/B!:C@'YAQV0'VMI_U+IE<?(0QM66A1K-'Q"ZU%L![#TYVUAH%5:^ 3;&^BJ
MFK0$G;V*2Z6E(3H_08T)7'6E7_X8X4L*4-M.)/O'IBFKVQAUX6A)WZ3)E&H9
MH4B7:)LVR7HD_UGPAC]DR;J?2F9TL1E(N8Y"UM*U<-ID,Y5>?<\V=2WLJD'L
M"=EC*%_5:,74--$-(HZ[$W[0Z=*<C+#G:+2/ #IK%.: AJ0:P*3AO*%EE,9M
MY3/DE.Q8H:9EBT&T5B6D@ED7I2G*:*M/?8:E1RZ=NNF&2=O$X!"B1XJ^J"*K
M9A:72,Z9C1UZ<#\#DVO3RV9\<](]$ 067L24L"TT=BZ/J0#PWP(*84L5W,\R
M#*60 P:MR*N7*/D9G^P$1XO24;X-OS!GP9*F\TV/-!3]3H*DH)G7=&_A]T?/
MPA]^()"GML$Z1AB^CPA#\OU%&.X4F1OR=+,;W6?S%N:M*C*TI$3DQ!$L#/WX
M')^+RJ6U.3.5S[F4#<RQN$9^1E)4E2AP-FTIT5=ZXX8Y':<D+7BYRH@M">;!
MB2V)[7%Q)@H#G:E!-^"PI_ O/<K$)()@V4P =G>4QRFB*B4W:564+ !F:=+
MI^3+Y3 %PL-1R=/,][?0WS9"3V#M59&?!<&5P:#"3)/<P7/J\E'W!<Z&8,R
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M\[B&H=0E%PBYG0#U]_/AK:=[J=!X9R.>0_%.RSPBB>GT>[)><+D#INX4QA\
M5AT#"("I5_+UTX03?+BTLG1OA?3W6ITPKH;@VJ@5I.E,B & :29-%+&2HE0<
M%D V"OLH-^P>)G&IZ[ ^D\X5"&P;R()+7O&R8$J:!9N^DZ;A\/V0CUD(OTEF
M3A;Z+$4@0;@JF.J$Y(-W)FJ9QB&ZNXK$]E>,HRQ:T@%NG0'M*YHB!P2^A8R:
M<;QP %II-!6&TI13YN/TZZJIE;[2?-I"25?2K9--/R8\6+2I43E-D8-R,],Y
MCIWCT>22,Z?SIU3(U9[SB@"2R'N%G+_6E7H)\]Q=I46?P:A'/?OH].P_CD'/
M_JV<1WGZ+XOV^ LRBX^B2!VHKOVIQ5:)6_0S<^W.3YH,)1 10X(,Z.:^ >(E
M\!>C(DH^W!RI9-1-6TN916LG(B$F/&J2;L-B5AD<PH<T%DW!EHPCH&)AQ8>>
M46=PS0W=$2B]3@>X_8D4ZQR4F46Z(D5320! E**-3C, :B9-7/<N14])&3QO
MR5&3N<=Z33!C;DF<H4ZU5B4O0O-S/Z"//@T8')6M[I!69V/67)@)NKH=!WJ<
MP#[22W #C/!8DQ5#8:HHS9#IBX^^<&A/TKQ%9YP<KD:*8-8LW>QJ6'6ELDY;
M/)MMY%WD09^#_C6G'&2F2U>%Y;J:H,@/3&DE]2+7H2?R53G0K\9HX"MHM;S*
M7!U09ZZL=AJ9"NJ.$^ U4<A%>,';[DU.ZK*!ZJ]O%RFH&<$C$*8M?<MVA[_*
M<RQS_J PB(2K^!F382[.3_^'#I!-[P0A2L<;6:$[WGX]HQ^RX_JAAT-^&,,A
M8SCDJX1#1HW]@#7VZV/0V%^RITU4QP/5T*] )23!ZCAMK4/8=R*W])&6SH[J
MB=;2/3"=1%>0:\UYUJ Z1DY-25(^C5!IK"C+1#^%GA GN85JIX$>:KEB]1FX
M3 J+C4 _1;J(7X<F9=SB-+%UE$H#B IVJN+,(E%"(]^IC _9JA:BTW*514XZ
MS#VZ\MF-STOUZ"_KL8ES(7FQ,*4(@45K4>M=:O!7PKO08!):_STJC>*41U+'
M9$R$&L>JM&GC-ZC[XBZ19Y.HQ<Y>VCI0-T-.!!HZ0=KW91S\Z">MC-OS#IYU
MW)PRB@F[90E$X6TPCM50%PI9HX$6.[=IS]K][I9-M6,C--*V2R"S(5O$S',3
MV@]=HK7I5=DD0/<]>C-[MN>R)[;3FI'DP&WIT2#KY(._$@PC*F/:%Q+H,\Z[
MY.G?A=T,'!9Z5(#9-<')FDZTKUH;>_JWL&W_W)5UA7OPK1/+4AP_J,M<[I=_
M3 RGI+4/++VU<C!4T0>,WXPS!;Q3SGB6*N H<#1+C-NH/&Z64_$[RR&U]"?;
MM2[%P0'_?U/4<L4HS#$3@]QT*XFS*%WJD<#"+!,@8EF/*1/'IQAFQZ 8<OS\
MMY4 _QTD!NCOK8)EKO!Q$P!.\"/M'?*6;/.G*>2/K6<<""#SIM-IA $BS*A7
M><4<D>/\^SB^O.'UDSR-]_@2,PG.F2!Y83(0HL"=, C:2@2!9?Z@DZ'BY^1,
M<+J(X]>T[R.QW7DEQN]0W"J4QNS<M' ]WOQ_H1<A*H*E'58J8P67\<V:)!,3
MVG,4Q':I *$O(L(IL_]I$0'7A9FR7$!TR!:13Y!E,Q5LZ['$=13_BS>+TL.5
MUA@F)OG;I%H[;L_./.QJ<I PBN3/#>6>>_"6A/-:V=01RA)QHN8<I23EH3'[
M>L( ^Q.[G>H69)=>A>V3!'.AXT!"2)>@A!SMMPU?^*7X+EV0W]=VBC>WBPW5
M/9%&_V&AZ#Q+L0INM6:"K9)K7WK%(Z$3+N^;*#NGN=H!4\0%?;-GZECFH%62
M.U?M]%;K="*^'??N+ 7V/J]Z"U\'J-LI:ARDWZA+')TNL3P&7>)5 X=?^.\A
M^YD^>=971;84&[IA;T@2T969>[O,NQV?DABD1+HZ,2WD[.0&L,:GY&"UZH(X
MBJ8+T9)&26(XLE,C_L3MPM/247K3:H^$/3/&[A0YD%LURZ5INIF:=$(G-ZSR
M?4Z<6>Z4 K6-59KW&.>Z_SC7CV.<:XQSC7&NAR];OJT*DA^#"F*PLM 8,(+M
M["#=&J"'>-*Y)5J=QN'#MN,>*2;CE?]NKWQQ#%<>M?6/');1^NOO$HPZ4'\F
M^@"=5;':[\2E*TQW;$>)M/G0B1=9AUCK*[:_M_-NRSW(JL#X$9H:[+ A(,Q
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MXF=8A@CP@SQ\&!A^JN)BJ5P3<B \=Q>SKRBUY"#T )U!1K'6W89#.@-:LL,
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MSQ[JV#A?2)QLE:VRR50F?BU%XF!$?$EA^C76G-\1^GQ!A2>2T.(GLY3JIK
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M'C-CE#HFJ6.1.I-T3K:I%)IP^4@).]-)VM5TT@F[^4V1W2C/(#2E(K:,WG1
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MO_PZU8>XK/O3Y9Q,AHX_TJ0VA#J!W':9)DZ).=_#=KL.P8("1_VZ!3:_<!W
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M9C"<D8CA*>8-Y(T$5<!6%-';W3N%ZU[&E87Z^FB)H#EGRJSJPR0N(H+(MKX
MY[H%DM#"[<,QEJN,FG/D^Z^[!E_ETR"97((1O40D4,-&)#[_)8YL1C#K$N>_
MA.\Q<D4D FX[)J=2GHUPO9,$8<T-T5U"A1J[A]2_=W86UTYHI1M4L9[IHVJ$
MNBX1S5H( F'ZGK%TLGVK?]MLR&KHD$'-+3%&OK9W0?J5 Z09XYG,[=Z3^42"
ME]RCMEJ-3>R;O=XDIU>9:7.F:_M]0T\C>*^\Q;\6C@!&\"=XC#G1?$&W2%L%
M 7MP7B"7^,#5]$8AOL/;][B'@[A.G31E^WN^V01Y0R5W[0&MI+$01HBKG,W4
MY7AL<LY^XZ$@1P,49(""/#X49' T>NQH]+@KV3I'@\W@>71K*9ET\MJQ&/)6
MH_;A=AS:#15;1Z*^ZPS1AHWB9/N[NF%5"^V2<C'APKSZ69NI!;([EHE^G; U
MBFB0WPR;14#Y,RS65-A!1\-[[WD<55%6'E-UJMJ\@#;&3C)'N"JQ>]8:9G;W
M%#0@O@_V!;UE7.:-WVOX*JV2AX4&^#(PY)V).[]_;$#N,-I O-K3>J 4HE"S
M^\1@<E?@-5^O)A@/APSNEFOX'G<^&C3\-VIX70^Q7K/;2HD':W9TQ=LH-_DT
MP;1C[JIXVY&WT8G7OGC=*99;FJRU(0&LT!CIDF?]6FM61"A6"YO>;W&;U[BW
M-HCUH)&8_+AN\J I<VWO32'^B!+FZ6U2VRZ#E<Y/FOJB>L&^+?WPF%Y=.#"K
M#ZT6"5D,H?S$+I^=;XL8%'%#2!_ML.&LV.ZSHL>D2VMZXB';@Q-*EW;U6L*Y
M44/W 3"K-6^H]6VHA4+Q/VL,6=S?NB1M&E!0<+)B?F3^P;##MGJ'[>\_I8S[
MA3W%3N44V^1T.U_\D,J#?M88#*IEFU7+-F(&/@E!$YR:9*)BL@Q\NYSKXSN8
MW1VH:<;\!>5BH=.VM2O@#XN.]9M6.E: 8X*3>-O$-4)& Z;NRXM&$YUI%#HI
MQ*7*B%XI84*L*IK!*<[S/=M@Q/H8FH? -]UE^)'UIP@Z\U]R,>)1 ^+D1Y2A
M+RG/H .;V^ B(PK_X M6(0EG0R2,$9:NP&E&TSXDYYDX@"@I-(DLMJ[0_=%;
MBM4M(G-=&_KV;O(1F6H/[RK_55#(2@\86'WUY2::P(+Z-HW,\V<3R3E#9(MT
M9.X7XDOIHON"?3"WITYK*P-'*FTXTO0W$(YY@A.CS#.1!WBR^6O;Y::MWY.
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M<\Q^P**2V9M71W:7EG%8_95%9:Q_1Z9E;!\_O6O'2\!($>OCFLEU*[C22(W
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M\N2BHO( #1 IZ;5 7*?\1Q*SG8<_P?IE0_VMNT)2 W@R*U';D/JH!)O)'Y%
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M0B^4*O*:G@M=<2IO22..\AS/3OR\:Y1"OE$NX3JE&0C@UH&.2IGC5TY4,!1
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MXHTCVUL;%9M3F^-DTK'C=L7OY..#"O[N(B0J"'155-4AA\?XU@0A3E%#0,9
M9U&\A(3G":YC<UQ32A_2_CTL:JRME\&*C$"MM9V7,\,H@B_P@CL1'0NC7>_C
M4@KCR/W-*HN?F9\A040"LWUG2=N6[1QLA/K/"[B(;7,IMELTWG3'/-2Y<;]I
M-?&*K:!D4U0!-]6>0Y>PYJD1$#17#-Y#_#'-JBN7*"4A&,^9I_JCP#\!*YQJ
M03L>BAY%]<%4=$P>WSTCH(H\76:)IE@PQ8"V=IT)IN(,31P!.WX#>C3/0?M-
M<>6!<Z^)"+;S2[W[Q4+%M9,:APF<>8&):X./M%2<FJL/AYP0!^IW$S1_8>>I
MQ3=ZH/H".5L2PRU-(I=@JSBZQ5A;T1Z, PL4+,RE2G)%NL0=MG;>HMQZG*!V
M0#_$7HCDQ_ "\&BCN++:^6-5$#QZ,"FWW(YZOM^CR1S*-X;RC<&WVWJ=Y 9L
MUL5IQ#B0\ Q'9?#TO.&OM57N1%&D:+$:P93B@X""KAR/Q"^?7I!ER%-Q:.%H
M6T(+AM4<!?^DW)+$U+ #MWX'$@?JV(G>!%G#X;).H<3:*>XB/F3SL)! #SPV
MH;(PW7/&:6:PO_<-W.@MV;E!0I^"A$Y&Y/&+>"V"54=-YV2EW7GAXZJ23=E?
ML<%A,FP4Q N*(IC>4$<K[PK_0>E:LGS@3CW/C)KCZ9S>O(^'D9,8I6BW*@3\
M  L%]B6E*#DRI#G1)#N*X:K:RF-:4R3%AM),/R2J*#:49L@.3( &&UVGK"S?
MB#JUY!3B8AN9VG"!K/5/1K1T&UGI:\>&70.\<+1&Q0$Q$%HB>>, (#DV^H1Q
M<A;49)F*CQDJXNH1DQ'?]6#6IIQK=J***XL\J>R_.OM\;HN*4/U,4=3BV,8)
MVX;&_#,6';4^]HR37$EM5"/2B6FJ7D>Z</SYSS/3'Q%/ZC +"CQ2@QU\\CQK
M$?)*RLGV0.0?SSE&CDT7)U@D'^1V:1P=H&^$C;CG\&HW?JUPW\P_K5@E$="
M71GIXGQ=UQIYP6T0Q622S;@- C_!_%R;6G,0R81-*T: >+'*J5B?C\%@@>P#
ML+B!U,@RZ^%4(RMV![/F$<V:Y]OB^IXXNJ[_#=X&CV+[MQ[YO(0.L(0B;3UC
MJL%+A&TNL1/%#K9] ,L@ 9O@%G-[R-2;:3V*!\7.X<AS:HYRQXFM6%<CWQ+<
MHDVB<I,>U5"U*9@I4<%6;#"'8PAQH\Y98%NQ5L *#IK/$J[8_K 5S&W50JY
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M50'XT^AP[>SO@=&$5%HF[D\GK26SEGIE1.'5:%X24S.MJP*XLD[Q:8K60IW
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M^QRF8IB*)S(5S/*I3TKJ2D$/AU/BU=YK^O99'*S2LH"[?5'A:[XS9^+E>E"
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M>F%"8KPX&%IF9<G1 ;UW7) ^K0@*H)K;.NXT:[4V[,#)_-I[^A1Q.!9E/*-
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MK*Q#WKM_5?CDW.9:(/F9X%&+8VL^J1L: RC8H)&;37*XR)[%US?4):8J<#4
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M2'#58[L0\)<2N L)ZTMCTE%(7&2S2A=5"V0%M(K.(0T<WI[C>=1]<1D1$8;
MN7*E:*OUMU].=7G6RIW2Q[UE^9\NRWN^\_SYCU\E [OE/.]X6C%F=YN^^9M^
M"70L#\Y!KEU ?R75M\G[H %,6BSEWF'W.]08'.S>[O-GP1"1E]Z RIB'J *]
MBJ_".V4#=*M\QU4>E=!9L+>[VZWJ/:[JZS1'N1#%OWYP"/, &28!*?/%TZ>[
M3[N5OL>5'F!8 &%.![_(1&8@JA[":',9=RQBXS?_4L9R.4\3>1#\Z_??&Q%X
MNK7]C+4=HA9V]W7M C_ON*Y_?:"KV05^/IK SX>Q%%\*H--%^%#4_ENLCH?O
MX8ZCO2S!&F%,&D-*H3+*5D<1.I[U#O,I5"Z%BL5! SF;H,=I^H$M?@S]7PVJ
M:K&.WWFR[NC).LLH!8J*'.DZ&..48D(P1'A"18]5$BC[59J/FDHZ@L,4+2/*
M%1)8X&0.W]NXW/%:*#$[23!)3)A.^$V#_#Q%Q\G6LSKD9^-8250D,!NJ*3RK
M.\";?X#WGFZ**U:'00PP#^XA3ZG9(7NYCAV<1 7'LJ$+C+(2=%PLY_O55;;G
M'#X7[5W'9U;2#^J2^3"P32R7:81=! F,VNN0O<:ZR@MY(A,'$'"M[M%: RJ?
M,EC(;"9-^2>W02"&9<Q)C)@&P3\G6)Q%E1_ZM/Z,4UDHLEC3Y:>UJ%,N*>X7
MR;S:(I5XBP*%+8-39&5.0<P4WL)1Q;EV:.;6@^D,$T@PYF78&E2->VU<[A1)
M5&;,829JEXB4-S6F0GM,F49")+ E!:@,#K^J A<K:Y!R(5E*BMT"KL2I'9-8
MP%SPZSZB*U':"15JC,)>M8!!41M '"/#<E@BEC!,M,BEIWTA9Q$:*#L.]0@X
MU+--X5!OHQSS/D0BT[*=(4/===OXZT8@/YM6?3.XX+*.6%^7TPB8$;?R$I*8
MJ$4W$(L0,4.G:W)8D^6F$P&#PA@NFKG*:5H#\6B$4Z)2@R ZZ$P'7;4SYU0+
M@]YH\Z5TWH8IBKD&_L)2E<H1P@PY#>=44\.#,BM\:#VJI925IK 20E^81,7/
M6!4W?6H==<K4-=1U0:=4.-J6!ZRO]DE/ZP7LDXK.13.+.55[Q$DH*<H514W1
MQ*WKN619#AN3:3832?0?%5+)]41PH57>G"2IBTLKJVQ"]9,G-_=9YD:L3CB,
M,Z$K3E&&VHK*;KOI<+V^V78K%BZD1,D\[]<?"54G=<ER/"V9GV/7]ZT/%-*>
M5!42O:AUV%ONAAK,<??(ZG&9,Q&6S0FLE:J3,,];#J"1TNTQA#,4+98<YH[;
M%4=B',4JF\@]EE3-TZT;ZZ0=;=U<&-S;%SID^8WG$*OS\@&BY7*'1"73\YP3
M4M<A9>";229A0=*U4JX=]W\,W'^\:=Q_H O#AJW.21IR%4+*T%&FVX_X(ZOF
M0/%"E8Z.C$5%+J\:K3P.QU]Q6=R)8BZWA/,O).->D)$#TZV)ZW#)8"Q4''/&
M)C3CF%<( UJ5U*IA: ;""KDKD"9D&@V<RRM)K1@A$#D,K5O+X[09];:DM9ZF
MN$HC6K!<R@_$AND+7*)TC,89S0Z7,J/BC GS/T<BP%32&D TA#:@%#',34>H
M8-IAX",SA/">"DH0 VZ=%SIO= *O4D@[+K;";V,L:NJ!DK_YR4)\4&7*S3,\
M(9)LE6$MD6BTP<GJ.LC <LD2E:*YI]"5FZU$HPTRKK>KROC$3*!+ UF=P#0#
MY)WOW0.BP_UG',3DE(2&!N4L72O83(N$J1L,1N) FBQ%II+)U(I7! 'VL#@I
MO$NQHI1^2M9'"9.XJ8=C=P,XI^D;YFRZUKD;"!5>6>R[K+7-.G; R(U]E8IF
MQYQ\$\N9A3$/IB7^C>8R@U*!-R)G"(/*.MR*S\&XJ9RD@>8]0E?/5'(TSCE-
MJ%TYQ4VGU,%TC)*/,V5%/3EE 8NARL72I 0I<I-;2ZW"MX,=+V,!0@0L4QJB
M$XO ?/Z ZYF'T43E5#.T0MURHCLKT7MJ\2]2?1^)_J30U4SE4M38P3=87-GL
M (@'N!0/73X(0'*;;)KD-M*N"V:" ^":LZ2EXMO((L0 %5Z"1H82!:>++^'C
MA(B=(\#$XCJO*58Z)NT-UJ$*_K+# !ONL\J@4WW>,F!FWR[:IS9,5- ^50EL
M@K>Q#J4[XU[PV#IZO/&QH2\>Z&IVL:%=;.BCD@?6[)7CB/7V5*&))65FK*Z,
MF514;=F5F@OJ8Y1IP#^TLN8^BV96DWOLCC0Z4X*/K!/ ^JRQ]0XF5FB%3.C*
M7*ZLOZS;4^KZC<->L8Y%$7=_EE%!G%:!S67HOR#MC0,@D(NQ=E(76+/&89&[
M+JA0%U<1=_ ,ZGFN/[@^6T9P31L6<H-Y9F=RU2;7<-,$]P'>"0)JQ+/\'JV3
M+76U:JMK[D Q&2A<6]=FG2PLTI #=M$PI$E$IH@AO)^3U4)90)3]UH J-DCC
M]42DHQ&/@4;(C:,1$[Q9J 6WDS)<*#R9FR&#69@A228J2G+PZVFS<1M8_2R3
M7 <$Q1M;N\5:_^%U]E#G:]"PW>5_#)=_NFF7_Q>&> (Q^41<OPS^[K@%VDD-
M!B<GP?^^&XXNC\].1\'AV>GA\.+T^/27X/+-$#^.+B_>'>*/_>#7P<GQT?'E
M;_U@>/KZ[.)P^'9X>AD,3H^"X]/+X<7YQ?!R@$\&9Z_A[>-1\'YP<3& 1T9O
ML)=7P^"7LU^A]>%1\.HW>D^U#U_@)]4J-A<,#@_/+HX&,)K@_?'E&QK-R>#]
MB-L>!B/H:H@?3H?O@]_.+OY!CYV]NPPNAK\,+HZ"RS-Z[OSB^/3P^/QD2&]"
M?Z]/C@\OZ0,TAX]<#,]>@[@T.'RCVSX\>WL^..41XN<W9R='PXL 'X5Q'U]<
M#'\].QR\.ODM&+U[]?886E.=#?]Y>/)N=/SK,/C[NXOCT='QH5T./61L]/40
MVAN<0$?O+N#MT?'E):XX3)NZAR5V9]8/7IU=G+W[A<;W=G#Z9G!Y.8#M@,6B
MYP='?W\'79FEQZ$?'8_.WT%O..9WISAZ>!C:AP4X'?*H\"=:6OB%_L7W+F&_
M1@-^ )Z]'+X]/X%1'^G)P[/0].&[T4A]!VUNP0J?P A@!M3.Q7!T#GV817'.
MBAJ=6A"WLZ.SPW?XR*C7IR6J6>SW UC9$?\\^.5B"%MZ>D;=#& X%Y=T;$YQ
M4XXOX2FU]A=P!,X.AT,<7Y]^/SP9'+^% 0S@#?A_;N5\>#$Z.X5C2IOZ=V?\
MU:WD+N"TT.Y][LGAR9AN YC K\>'=*)IO*.1N2"X*C@8_?VK(2XUOJ"NBAY0
M\\3QOKT=')_@GP-H]/PW??*#7X\'>&6.1W"#H3UX#0C Y?'K8_B K^ W=&N/
M?WES&1P-3V#<%[\%6[35PU^/CX:G/&S]4P_'2N/AR06PSGQ,CRYP^##BX>O7
MN,!X@&'M8=HTO^-+=VMI?WA::FF8BA#).+[$P_W+V1D3CM&[UZ^/#X_QA#6L
M(W=CKSM\?H.+@6=\<'QJ#[,A54=#.+)$1DZ.WQZ;P_5^\!O]>T'+@3/%?3!]
MJ:?@EI["OL,"P*N73.^ W'S*85$'!$=#?=$2#>#.',-I@=_A6/[6R5"/08::
M;9H,]482XF9+_:$8PSY7,S!E+C(*%N* Y"22I"0E\:JO:YZX>A0E\ZUI7Q9%
M5CD_=81ZRE%*9(ZQ!8>5JK5FD>E(0A<\\JBHXWS3J.-(@H;)4>^K=E+(XX3K
MSQ*=2B@8E0K)KM.L*A%TX+4ITA!?+1.9 &V=<.VC*%&!N.3(X[A,>I228A##
M6#\<N9&<MIR6-4[=.@Y5:XXB3I3+C @P&\0YGI1SB#(Y7ME2[PW^/!5;BS54
MBDI8+=K/T)BF<)]Y1OYT8F?A=$*)3;QNBH^D-&_F.SK$E,?)<::J6XIP-576
M3$J/RL(V+=C^*Y[/CNFT)D+F\Y?S8@CJ()L20+<:_#(DJ\\I*IND-I\,7U\&
MKTX&I__8Y./P,.)5=C=3!&EGZ-C>G0!\VW&RNMBQ+G:LTXRZI=@D)?'X%/T2
MIVB>?<_V7S^="V'J*(8N])4 !@H*RYAJHDU*E79,J(LV,S.=3J,)YZ I78/*
MQC"H$(8N3JA>(F5^=8)1=^VZI=B<I7#Q;I_26KB+ ]WN[>T]")/FER#1XS0.
M[V>1+X<7IZ/@_,W@XNW@</CN\OAP<#+J@WIYV%APY%&O_'T2_U>K@]]O^=]/
MX^SGP/G?J5C(@^J7EPAC\D K0SU4!O>P[4#\\%W0X48P&5%@6L8YHB:"W&01
M356$8&4'.KVPM?R7TD\Z>U5W+.[A6&SH6GP]NEZ5P3[_GHT.WPR/WIT,@[U[
MX^'W-[C[8>#W7]FQC1O]^NSB+7IPAO\<7AP>CX8J-*[;]0>XZ^MBV^>OYK\N
MR9SE6K(: /ZXFCU:LP[3Q2)-&';4I)4:,)]_?T%I_UN?FHW2#C]_,4]$2,B+
M28@E_D## UG^2RIYWWK;-ZGX[^>OY=9>CZ(<Z<:K;/"HBC>K5;S3="?X_???
M@RW\F8%J)R_5C_PQ?-ECC# B.C=4%NX'(CB2L;@F%%X'A<]K6YGM3=L[P2$#
M]I(YGL-[R)BO8S,)C:QPTF!#.742T1#A2ZH@(8,.L) BH0#/"JZ<_!HA+]_Z
M%G3$CZ_!D_5KP*%>!K8N)V^0P4PV+-2QGE6A[^ 91 XV !/=>7HTYVF_YP"@
M8_49 I\FG,6E6"V<?/FAAD4\SQ"^V@3Z+40H&4'94$.1SV,L.*)?T711R6LC
MR: @>[L5;.H[U?+NMO:.6_NT%YQ[%SNR.P(L$D'(ZV!L0QDCPD0%1+Q",4*)
M3$V#>HL)5NRS&&P50%?I8KZLX6Z:@Z0ZE@:2=YK&<7J- ;)'[P>'P0!Z07S2
MTW(QEEDG\FW\ 7[6"UYQ;(,Z&BL3%%U[CEVFF$D8'Z.IHK"ERBWE^F@9#%0D
M=!CW'!&B*M?OLY#0JA-)H/P3RVNK$=2<'H.X3RK<&:LL827#CQ-5"!#?2.C@
MFJ(.Z^KLEKCM9AG2N8\X-ZK=D<4Y''[D8H-P68AP[[W8?]HGZLRH*3V$?%T@
M'DJH8DE@I/!WA3#O8=F22MT IZH7;( J8I"!:%S(+XJL]#@N8RN\%=U2=$OQ
M2):"<>TTIR3T<>H<N,3![DOZ=3L6J[0LH+6/,GS)+7/<AWH>"& LEKD\R.52
M8/8*>Y"A<>-JQMP5S@HZT$^KA^"IT,R=VM[?W]E]\N)[&G$1-CRTN_/BQ=-;
MGGG^;.?%CS]Z#\$?F1[;VENW" K7,%MVEQ^PTQR_J*?T5UCC8")BM<^+* QC
MG'#CR=-;^@E^LMTV'[W:7?MBZ\^+T*W_MUK_[OPWKK]+D/0X]!2YOW4R^<7V
M"9;ZP6_20]?FCC#D_,"1R+\)J5.<V2SLC\]@/@'5Q@G\Q7GH^[VQ1!$O6[=-
M7XIV/MEY\NSK$L]/97(/<Y^^U&V"M89.D[_]Y<E?NIWX5CO1"1L;)FQ@.H"M
MQ=9)':UF9YW4T8IMZJ2.5O"Z3NIX*#O121T;)G6\6G621JM96"=IM&*;.DFC
M%?RMDS0>RDYTDL:&21H,=]#)&BUF8IVLT8IMZF2-5G"X3M9X*#O1R1H;)FOX
M*$J=L-%&+M8)&ZW8)DT[X5\,,'Y8.7#MA)C8LD!@BS*GHC=3:)YR:^)8IU=3
M7E#B.8TQ:09_4W6'.=%Z*B:RDA?3V^#4E[J;]B4.42O2'.Y_,=J"A?[3#^,T
M7/W\7S_],"\6\<__'U!+ P04    " !"BA!5D>_)/OH.  !O<   #@   '1E
M<FXM97@U7S$N:'1M[5WK<]LV$O_<^RLPZ;4CSU"R'GY%<C.3NNECZO8R=FYR
MWVY $I00DP0+@)9U?_WM+D")>CFVZR22HLF,8U$@L-C'#[N+!7P^LEGZZA_L
M?"1X#/^S<RMM*EZ]^4_SN-4Y/W2?X/M#W^ \5/&$&A;,V$DJ?GAAQ9UMRCP6
MN>VW6^WO!HG*;=/(_XE^!SX7=I!Q/91YTZJB[QZD,A?-D9##D>UW6IUC]TK"
M,YE.^N]D)@S[4XS9E<IX7KT=*FM5YCN@,7DJAWD_%8D=O'AUCEU4)(U'THJF
M*7@D^H46S;'FQ3)9]PX*(XYE;$?]1-IF!"UA>CC,(;[UZOMO.R?MP?EAX7C&
MPU148X=*QT+3X#(?]ML#^K:9\HDJ+?1V)^*!Z_FDB]SR[2.5IKPPHF]$P36W
M @:#OJ%S7?5\*XT,92KMI%^U]HV@53R=._7=:9,HD& ;NXX.K5[LT8O@N-TZ
M*NR*OD(>W0RU*O,8Z5.ZKX<A;[0#^G<P& /IS5 +?M.GGTU\,%C)_%NAK8QX
MZH4&JH"TK=.A2C@DK=,'Z%#GXP)]=BTZ71KSM98\?;CJ+(D&_D==V2CSTMC+
M(F<^HA=+SSH'J[6"Z!H[0D.5QL]CHV_N1F GEA&"$<\K0]T4IE;:)K,A,SKZ
MX07\<M+N@M&>G?ZWW?I0#%\PGMJ5S^?,O'M\6MP-/%6]8_C]Q0(V;<J4IWJT
M<LZ=-7/NK)ASY^59;<Z=[@9/>A6J? K;R97. 'EJD^L^V7I>E\/26-8Y"5BW
MW>UNN 4]9M5_.D]6KOI[5NQ9L5VLV'3H>2=T;MC;$8<N(U&2PV@"]EL>M;8(
MAC:=RYWVR3%[PP'C?Y5I:F(.L<N/Z6V\Y_'S\?AG9:S0[ )BM8!=P#P2I7/)
MV<NCH_;1L_#9$_>U,_J;*]'_IF+H9R*<6!:+2$&8+E7>AS&$1D$\SY2NQ% :
MZ_IFUY9;D<$7##[\#..SZV:/-?Y4+=;K]9K=DU[O%*;#.MW@N WS:+>9 ?R$
M@53"(I5E\)JQ*KH)V#]!X.UVAQ5<LUN>EH(5H*+4.F \CQG..<')Q&S,M>:Y
M-<PJ5I0Z&G$C6.<H..D]>8SG@9=/H/8?P-V5R63;-/^=8G8D&(]CD(01@AEA
M&<",'3$>JEO1?PB_3UHG)Z=[CC^,X^\%&_%;8'EDP42X8:80D>0IV$"9&Y&B
ML=SCPH"1L9]$RL&V!+RB"X\?K(%R_/[;NVZ[$PT^%Y8MIEL^SA;7&"GJ2PN"
MC-8RZD)E!<\GGQF6GT7&3@SQX"!@,@<IY;F(2$AC"8:%@BJT*I0!!9#&E#R/
M!*+@WX/?W=. :V+"EBO D]?$"R?X:Q0\:P@>C=#V=TF^;V' GQU;WCNV;+.L
MF=(,=U30U&]%"B[[KMGCLKRVVSA;[!U(R*$,V>F*"3)$5IE':8E/ <TYTW77
MVJQTK<F9)_E?BZC4TDH8X75D">5?]GH!+OP<7L-.=PZW8:);K1<!2V2*6%VM
MUC4AHIJ\N0/8SH>"(!H6\%UUO_S<MEJ6:)9_<%AGV9G;BF"-N=!X(09FC9EA
M[AZ KTX*;+=\T2 1HT,A\R'@:R(TF"ZX5NA76W2S. O1R0*7&T,M6QH6<XR]
MG%J [^7U8M>D_2/.^NUTUCL@YKH,35D4J5MYG3BK+<>.E^<"AM>PNJX<5V4J
MV%'WJ!$>U%9M7*H;5@T%?-"S/A8XNGL L2/:TF(/]>P<:AA@Z3QDK%STOO@$
MV19MKGQDQ_3L>3=,1]-JM((/A2LG:_+$"MWGZ9A/C*M+VV:.;4B]H:\)W(""
MP^YIJW>\U16'#S""S=AL6UAS'ENTN+X::,_*1[+R+< ;^T*NQF-IG1/T\Y>I
M'K=.CO\>+'?.'E53V5U37]A=55]XTIO5%W8ZSU9>N-](J[2+O/4QIF7 @^-#
M+>X+!D)AQT+D522 &TOD%UZH,3QUO]'3@%U>7E!Z3@N8@H$N.>9S,7.'+QL!
M2P)/V71TH0W+>>:2@]?12,08472PL1;@2NY<6/GO.M]?5WS?\GCAW4@:I@J9
M8WP(O[JX("EU+LW(R7;5-IX6?Y52$P-HS^8W*S)VTNY --DX/L G5V)8IC[A
MTOQ]/L1TFT.YJ@\L[@K:B8\9Z@_FFXT+2"8LXQ;+@0IP23BT!_JLV[WW,S*5
MCJZK_7 #U^-71?&M'7$:QX^=3EQ6>TH"31>^P;>J,7'?<FH4+M *5D59;H[^
M4Q6189(M%@E@6 R<3M7XH+6]\=:^^N$Q=>&8N(E&5;%#P,:^'$+<04>H#_2U
M4W52Z(2#TJ$._54*@QI-3U,^1HVMWH8!C(PI\\<+W%L'O\0*+&3!L!YWVKUQ
M@(6E OMNL?>HU1#>:'H;R)L1HT4JH:NR /N), )(( :P/I7@;(:#_FO<N*>.
M50(M/,&+2PRU-]Z.<38E+!_5!-&T(,+"8=&@4:4*07H%5@@K#8Q<\63A59B
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M>ML;;IL-)9W:\"=:9CYZK,AGIAU.])?C#&>'OOI8^ O%W,H%U ^5II6UD@*
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M_RNP_P-02P$"% ,4    " !"BA!5Q04ZYW8;  "U&@$ $0
M@ $     =&5R;BTR,#(R,#@Q,2YH=&U02P$"% ,4    " !"BA!5D0C+ @\#
M  "M"0  $0              @ &E&P  =&5R;BTR,#(R,#@Q,2YX<V102P$"
M% ,4    " !"BA!5,V(8Z0T&  #C.   %0              @ 'C'@  =&5R
M;BTR,#(R,#@Q,5]L86(N>&UL4$L! A0#%     @ 0HH056\*"ZC/!   NBD
M !4              ( !(R4  '1E<FXM,C R,C X,3%?<')E+GAM;%!+ 0(4
M Q0    ( $**$%62C9;X'N(  "/7!P .              "  24J  !T97)N
M+65X,5\Q+FAT;5!+ 0(4 Q0    ( $**$%7=PV.+"3T   <; @ .
M      "  6\, 0!T97)N+65X-%\Q+FAT;5!+ 0(4 Q0    ( $**$%61[\D^
M^@X  &]P   .              "  :1) 0!T97)N+65X-5\Q+FAT;5!+ 0(4
M Q0    ( $**$%6B'=KE  X   Q6   /              "  <I8 0!T97)N
A+65X.3E?,2YH=&U02P4&      @ " #U 0  ]V8!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
